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ABSTRACT
 
Serotype I feline infectious peritonitis virus (FIPV) is an alphacoronavirus of high 
veterinary importance due to the 99% mortality rate observed in cats. Since the 1980s, 
robust experimentation on these viruses has been limited by availability of culturable 
pathogenic strains, few permissive cell lines, and a lack of standardized methods to 
study their basic virology. These complications have resulted in variable and conflicting 
literature reports, have slowed study of clinical strains and hindered effective vaccine 
design. The goal of this dissertation was to develop a laboratory “toolbox” containing 
standardized methods, permissive cell lines and genetic techniques to alleviate some of 
the technical barriers to investigating type I feline coronavirus (FCoV). To this end, our 
group characterized the replication kinetics of serotype I FIPV Black in three feline cell 
lines. From this work, colleagues and I described a new macrophage-like cell line, 
termed Fcwf-4 Cornell University (CU), which rapidly grew FCoV to high titer. Using 
these cells, we established a standardized plaque assay to accurately determine type I 
FCoV titer. To facilitate study of live-attenuated and clinical isolate FCoVs, I used 
Crispr/Cas to disrupt IFNαR, the major antiviral signaling component, in two feline cell 
lines: AK-D and Fcwf-4 CU. Further, I isolated a clone, termed Fcwf-4 CU IRN, and 
demonstrated that expression of a feline protease enhanced FIPV infection in these 
cells. Finally, using a deep-sequenced laboratory strain of FIPV Black, we constructed 
an infectious clone (ic) reverse genetics system and successfully produced icFIPV.   
  24 
CHAPTER ONE 
 INTRODUCTION 
The Biology of Coronaviruses 
Overview and Classification.   
Coronaviridae are a family of enveloped, positive-sense RNA viruses that, along 
with the Arteriviridae, Mesoniviridae, and Roniviridae, make up the taxonomic order 
Nidovirales (Figure 1). Contained within the Coronaviridae are two subfamilies: the 
newly defined Letovirinae housing the Alphaletovirus genus, and the much larger 
Orthocoronavirinae subfamily composed of four monophyletic genus clusters: Alpha-, 
Beta-, Delta- and Gammacoronavirus. The Betacoronavirus genus is further divided into 
four lineages, A-D. Together, the Orthocoronavirinae represent the majority of known 
and studied coronavirus species and include important animal, human and zoonotic 
pathogens (International Committee on Taxonomy of Viruses (ICTV), 2018). 
Viruses in the order Nidovirales, including coronaviruses are organized into the 
above taxonomic groups based on phylogenetic similarity of the positive-sense RNA 
genomes. All Nidoviruses have large RNA genomes, with the Coronaviridae family 
boasting the largest known, containing between 27 and 32 kilobases (kb). A unique 
feature of Nidovirus genomes, and the one from which the name was derived, is the 
expression of genes via the synthesis of a 3’ nested set of 7-9 subgenomic RNAs 
(sgRNAs) (Masters, 2006) – nido meaning “nest” in Latin. Other features common to 
Nidoviruses include a highly conserved genome organization with a large 5’ replicase,
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arising from ribosomal frameshift translation, which precedes a set of structural and 
group-specific accessory genes, as well as a set of viral nonstructural proteins 
processed from the replicase polyprotein by replicase-encoded viral proteases. The 
major differences between members of the Nidovirus order are morphologic – wide 
variations in structural protein type, number and size results in unique virion and 
nucleocapsid constructions (Fehr and Perlman, 2015).  
Genome Organization.   
Coronaviruses (CoVs) carry single copy, non-segmented, single-stranded, 
positive-sense RNA genomes, which range in size between 27-32 kb (Figure 2). The 5’ 
end of the genome is capped with a guanine residue methylated at the N7 position while 
the 3’ end terminates with repeating adenosine monophosphate residues, termed the 
 
Figure 1: Phylogenetic Classification of Orthocoronavirinae Subfamily. The 
taxonomic tree depicted here is based on the 2018 report from the International 
Committee on Taxonomy of Viruses (ICTV). 
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poly (A) tail. These terminal features mimic host messenger (m) RNA thus the CoV 
genomic RNA can be directly translated on host ribosomes following membrane fusion.  
The 5’ terminal region of the CoV genome is highly structured and contains a 
large (210-530 bp) untranslated region (5’ UTR) comprising seven stem-loops (Brown et 
al., 2007; Guan et al., 2011; Liu et al., 2009; Yang and Leibowitz, 2015). These stem-
loops directly associate with host ribosomes as well as the virus-encoded RNA-
dependent RNA polymerase (RdRp) and are critical to virus replication. The 5’ UTR also 
includes a 70-100 nt leader (L) sequence (Lai et al., 1984, 1983), the 3’ end of which 
houses the 6-8 nucleotide transcription-regulating sequence (TRS-L [Leader]). Identical 
TRS segments are also present on the 5’ end of each of the 7-9 subgenomic mRNAs 
(TRS-B [Body]) acting as cis-regulatory elements (Budzilowicz et al., 1985; Masters, 
2006) critical for the hallmark discontinuous transcription (Sawicki et al., 2007) observed 
during Nidovirus replication (discussed in detail below).  
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Figure 2: Feline Coronavirus Genome Organization, Replicase Processing and 
Subgenomic mRNAs. The typical coronavirus genome organization is depicted using 
feline infectious peritonitis virus (FIPV) as a model. The replicase, comprising ORF1a 
and ORF1b separated by a ribosomal frameshift site (RFS), contain nonstructural 
proteins (nsps) 1-16. The two replicase polyproteins (pp1a and pp1ab) are depicted. 
Arrows indicate PLP1/2 or 3CLpro cleavage sites; numbers below indicate nsp number. 
Specific nsp components: nsp3, papain-like protease 1/2 (PLP1/2); nsp5, 3C-like 
protease (3CL); nsp12, RNA-dependent RNA polymerase (RdRp); nsp13, helicase 
(HEL); nsp14, exoribonuclease (ExN); nsp15, endoribonuclease (EnU); nsp16, 2-O-
methyltransferase (MT). The structural proteins spike (S), envelope (E), membrane (M), 
nucleocapsid (N) and accessory protein regions ORF3 (3a, 3bc) and ORF7 (7a, 7b) are 
shown. The 5’ leader (L) and body (B) transcription-regulating sequences (TRS-) are 
indicated on genomic and subgenomic mRNAs 1-7. Bottom arrow indicates direction of 
translation.  
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The first two thirds (~20 kb) of the CoV genome downstream of the 5’ UTR is 
dominated by the replicase polyprotein coding region. Translation of two open reading 
frames, ORF1a and ORF1b produce two replicase polyproteins (pp) 1a and 1ab (Lai et 
al., 1994). While pp1a is translated directly from ORF1a, the larger pp1ab is produced 
due to a -1 nt ribosomal frameshift (RFS) that occurs at a tandem pseudoknot-slippery 
sequence in ORF1 allowing continual translation through ORF1b. Together, the 
replicase polyproteins encode 16 nonstructural proteins (nsp1-16) that have wide-
ranging activities including formation of the replicase-transcriptase complex (RTC) and 
modulation of innate immune signaling. Downstream of the replicase, the final third (~10 
kb) of the CoV genome encodes the structural and accessory genes. CoV structural 
proteins include spike (S), envelope (E), membrane (M), and nucleocapsid (N) (de Haan 
and Rottier, 2005; Masters, 2006). Several members of the Betacoronavirus genus, 
including murine hepatitis virus and bovine coronavirus, also encode a fifth structural 
gene, hemagglutinin-esterase (HE) (Cornelissen et al., 1997; Kazi et al., 2005; 
Klausegger et al., 1999). Interspersed within the structural proteins are the accessory 
genes, which are unique to different CoV subfamilies. Accessory proteins are largely 
dispensable for replication but often provide a selective pathogenic advantage (Zhong 
et al., 2016) such as antagonism of innate immunity. The genome of the feline 
alphacoronavirus FIPV, the focus of this dissertation, contains five such accessory 
proteins encoded on two polycistronic gene regions, ORF3 (3a, 3b, 3c) and ORF7 (7a, 
7b) (Kipar and Meli, 2014). FIPV 7a, and ORF3, have been implicated in antagonism of 
host innate response during infection, however the mechanisms of this activity are not 
fully understood (Dedeurwaerder, 2014; Dedeurwaerder et al., 2014, 2013).  
 
 
 
29 
 
The 3’ terminal end of the CoV genome contains a 270-500 bp untranslated 
region (3’ UTR) that directly precedes the poly (A) tail. Like the 5’ end, the 3’ UTR is 
also highly structured (Goebel et al., 2004; Yang and Leibowitz, 2015) and contains 
several cis-acting elements essential for coronavirus replication [reviewed in (Yang and 
Leibowitz, 2015)] as well as a putative molecular switch predicted to be involved in a 
transition event during RNA synthesis (Goebel et al., 2004).  
Virion Structure.   
The coronavirus virion. Coronaviruses are such named due to the solar halo or 
corona-like, Latin for crown, pattern of the virion when observed using EM microscopy. 
This crown-like appearance is due to the large, trimeric, club-like spike (S) structures, 
which jut out from the host membrane-derived lipidic envelope that forms the outside of 
the roughly spherical virion (Benjamin W Neuman et al., 2006). Two to three other viral 
proteins are also anchored in the envelope: the abundant membrane (M) and the more 
sparse envelope (E) proteins are present on all coronaviruses, while the hemagglutinin-
esterase (HE) protein is found on only a subset of Betacoronviruses (de Haan and 
Rottier, 2005; Masters, 2006). Coronavirus virions are approximately 100-125 nm in 
diameter as determined by studies using cryo-electron microscopy (Benjamin W 
Neuman et al., 2006) and cryo-electron tomography (Bárcenaa et al., 2009). Contained 
within the virion is the ribonucleoprotein (RNP) core composed of the ~ 30 kb genomic 
RNA encased in an oligomer of nucleocapsid (N) protein oriented with helical symmetry. 
A typical coronavirus virion is shown in Figure 3.   
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Spike protein. The spike (S) protein is the main determinant of coronavirus host-
range and tissue tropism as it functions to both engage host receptors as well as 
mediate the membrane fusion events that deliver the viral RNP to the cell cytoplasm. 
For example, small sequence variations of the feline coronavirus spike protein can lead 
to drastic changes in cell tropism and virulence (Chang et al., 2012; Licitra et al., 2013; 
Rottier et al., 2005). The mature spike is a trimeric type I glycoprotein of approximately 
150 kDa. During protein synthesis, the S homotrimer is heavily glycosylated on 21-35 N-
glycosylation sites and tethered to the virus envelope outer leaflet via a membrane-
anchoring sequence and a short hydrophilic CTD tail (de Haan and Rottier, 2005). The 
 
Figure 3: The Coronavirus Virion. A schematic of a typical coronavirus virion is 
depicted. Trimeric spike (S), dimeric membrane (M) and envelope (E) proteins extend 
out from a host-derived membrane and form the outer envelope. The 
ribonucleoprotein (RNP), composed of genomic (g) RNA surrounded by nucleocapsid 
(N) proteins, forms helical symmetry and associates with M protein dimers. The 
approximate virion size in nanometers (nm), measured between opposed spike 
exodomains, is indicated below. Hemagglutinin-esterase (HE) membrane proteins are 
not shown.  
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ectodomain makes up the majority of the S molecule and, for most CoVs, is cleaved into 
two polypeptide regions, S1 and S2 by host proteases (Abraham et al., 1990; Luytjes et 
al., 1987). The amino-terminal S1 “head” region contains the receptor-binding domain 
(RBD), while the carboxy-terminal S2 “stalk” houses the components of a class I fusion 
protein (Bosch et al., 2003; Collins et al., 1982; de Haan and Rottier, 2005; Walls et al., 
2019). Many coronaviruses engage host peptidases as entry receptors, although this is 
not universally true. A partial list of entry receptors used by alpha- and 
betacoronaviruses is provided in Table 1.  
Envelope protein. The envelope (E) is a small, 8-12 kDa integral membrane 
protein and a minor component of the coronaviral envelope (Raamsman et al., 2000; 
Siddell, 1995). The protein has a short hydrophilic amino-terminal end followed by a 
hydrophobic membrane domain and a hydrophilic carboxy-terminal domain. The E 
protein functions in assembly and release of the virus through potential interaction with, 
or modulation of the M protein, or by influencing the curvature of the virion envelope 
(Boscarino et al., 2008; Corse and Machamer, 2000; Fischer et al., 1998; Ye and 
Hogue, 2007). A portion of the CTD has also been shown to have ion-channel activity, 
which has importance in determining SARS-CoV virulence (Nieto-Torres et al., 2014; 
Verdiá-Báguena et al., 2012).  
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Membrane protein. The membrane (M) protein is a small (25-30 kDa), highly 
abundant component of the coronaviral envelope and directs the complete assembly of 
mature virion (de Haan and Rottier, 2005; Fehr and Perlman, 2015; Masters, 2006). 
Owing to its description as the virion “building block”, the M protein has been shown to 
interact with all other structural components via its five, largely hydrophobic domains 
[reviewed in (de Haan and Rottier, 2005)]. The amino-terminal ectodomain is 
glycosylated and is followed by three hydrophobic transmembrane domains and a large 
GENUS  SPECIES RECEPTOR REFERENCES 
Alpha- 
Coronavirus 
HCoV-NL63 ACE2 (Hofmann et al., 2005) 
FCoV Serotype I Unknown (Dye et al., 2007) 
FCoV Serotype II Feline APN (Tresnan and Holmes, 1998) (Tresnan et al., 1996) 
CCoV Serotype II Canine APN (Benbacer et al., 1997) 
TGEV Porcine APN (Delmas et al., 1992) 
PEDV Porcine APN (Li et al., 2007) 
HCoV-229E Human APN (Yeager et al., 1992) 
Beta- 
Coronavirus 
SARS-CoV ACE2 (Li et al., 2003) 
MERS-CoV DPP4 (Raj et al., 2013) 
MHV mCEACAM (Nedellec et al., 1994) (Williams et al., 1991) 
BCoV Neu 5,9 Ac2 (Schultze and Herrler, 1992) 
HCoV-OC43 Neu 5,9 Ac2 (Qian et al., 2015) (Vlasak et al., 1988) 
 
Table 1: Coronavirus Entry Receptors. Adapted from (Masters, 2006); (Fehr and 
Perlman, 2015) 
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carboxy-terminal endodomain (Armstrong et al., 1984; Nal et al., 2005). On the 
envelope, the M protein dimer has been shown by cryo-EM and tomography to adopt 
two conformations, which influence membrane curvature and interactions with other 
virion components including the nucleocapsid (N) protein (Neuman et al., 2011).     
Nucleocapsid protein. The nucleocapsid (N) phosphoprotein is the most 
abundant viral protein expressed during infection and, together with the CoV RNA 
genome, forms the protective and stable ribonucleoprotein (RNP) core (Laude and 
Masters, 1995; Narayanan et al., 2003). The N protein ranges in size between 43 and 
50 kDa and amino acid identity varies between coronavirus subfamilies. The highly-
basic amino-terminal and carboxy-terminal domains of the nucleocapsid associate with 
RNA by different mechanisms, possibly utilizing both ends for optimal binding (Chang et 
al., 2006; Hurst et al., 2009) and the N protein has been shown to bind specifically to 
the TRS and packaging signal of the CoV genome (Molenkamp and Spaan, 1997; 
Stohlman et al., 1988). Additionally, phosphorylation of the N protein has been 
suggested to impose structural changes that increase affinity for viral, rather than host 
RNAs (Stohlman and Lai, 1979). When in complex, the N protein and RNA form a 
compact structure with helical symmetry referred to as the ribonucleoprotein (RNP) core 
or complex. Other interacting partners include nsp3 (Hurst et al., 2013, 2009), a major 
component of the replicase-transcriptase complex (RTC), and the M protein (Sturman et 
al., 1980) highlighting potential roles for the N protein in promoting transcription and 
packaging newly-synthesized genomic RNAs into virions.  
Hemagglutinin-esterase. Several members of the Betacoronavirus genus 
cluster encode a fifth structural protein: the hemagglutinin-esterase (HE) (Brian et al., 
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1995). The HE protein is a 60-65 kDa type I transmembrane protein of 424-439 amino 
acids that contains an amino-terminal signal peptide ectodomain, a transmembrane 
domain and a small, cytoplasmic, carboxy-terminal tail (de Haan and Rottier, 2005; 
Hogue et al., 1989). The mature protein is a glycosylated homodimer linked by disulfide 
bonds that juts out from the viral envelope, resembling the spike protein (Kienzle et al., 
1990). Much like the hemagglutinin of influenza C virus, the CoV HE protein dimer binds 
and cleaves sialic acid residues found on surface glycoproteins (Cornelissen et al., 
1997). HE proteins from specific coronavirus species have also been shown to have 
acetyl-esterase activity, a function not present in the HE of influenza C or other CoVs 
(Klausegger et al., 1999). Although the exact role of HE during CoV infection and 
replication is not fully understood, it has been suggested that HE may enhance S-
mediated virus entry and/or spread through mucosal tissue, thereby contributing to 
pathogenesis (Cornelissen et al., 1997). 
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Figure 4: The Coronavirus Replication Cycle. A typical coronavirus replication cycle 
is shown in 6 steps: 1) CoV spike engages the host receptor at the cell surface and 
membrane fusion, mediated by host proteases at the surface or within endosomes, 
allows uncoating and insertion of the RNP into the cytoplasm. 2) gRNA associates with 
host ribosomes and translation of the replicase pp1a and 1ab occurs. 3) Pp1a/1ab are 
processed by viral proteases (PLP1/2 and 3CLpro) releasing 16 nsps, which form the 
RTC on host-derived DMVs. 4) The RTC produces subgenomic RNAs by discontinuous 
transcription that are translated into structural and accessory proteins, and replicates 
gRNA, which becomes engulfed by N protein to form RNP cores. The structural proteins 
traffic from the ER to the ERGIC. 5) RNP cores bud into the ERGIC and are surrounded 
by the viral envelope containing the structural proteins to form the mature virion. 6) 
Mature virions are released due to vesicle fusion at the cell surface.     
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Replication Cycle.   
Overview. Replication of CoVs (Figure 4) is initiated through engagement of the 
CoV spike protein with the corresponding target cell receptor. The virus is then taken 
into intracellular vesicles through receptor-mediated endocytosis (Gallagher and 
Buchmeier, 2001), and following a membrane fusion event (Bosch et al., 2003), the 
single-stranded RNA genome is released into the cell cytoplasm (Fehr and Perlman, 
2015). In some cases, CoV virions fuse directly at the cell plasma membrane and 
immediately release genomic RNP into the cytoplasm (Millet and Whittaker, 2015). 
Fusion at the cell surface or within vesicles may be linked to the overall stability of the 
virus spike protein, the density or presence of host proteases and/or specific entry co-
factors such as tetraspanins involved in promoting membrane fusion (Belouzard et al., 
2012; Earnest et al., 2017; Millet and Whittaker, 2015). In either case, the positive-
sense genomic RNA enters the cytoplasm and is directly translated on host ribosomes 
(Lai et al., 1994), which initiate production of the CoV replicase polyproteins pp1a and 
pp1ab (Lai et al., 1994). The large replicase polyproteins are processed through 
catalytic cleavage by viral  proteases encoded on the replicase (Baker et al., 1993; 
Kanjanahaluethai et al., 2003; Masters, 2006) into 16 nonstructural proteins (nsp1-16) 
(de Haan and Rottier, 2005). Each nsp has a distinct function that is conserved among 
CoV orthologues (Gorbalenya et al., 1989; Su et al., 2014). Of note here are nsp12, 
encoding the RNA-dependent RNA polymerase (RdRp), and nsps 3,4 and 6, which 
modify host membranes to form the double-membrane vesicles (DMV) that house the 
replicase-transcriptase complex (RTC). The RTC has two primary functions: copy the 
full-length RNA genome (replication) and transcribe the structural and accessory genes 
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(discontinuous transcription) generating a nested set of subgenomic mRNAs. The 
structural gene products S, E and M (and HE, if present) are inserted into the 
endoplasmic reticulum (ER) and traffic to the endoplasmic reticulum-Golgi intermediate 
compartment (ERGIC). In the cytoplasm, the nucleocapsid protein surrounds newly-
synthesized genomic RNA then buds into the ERGIC where it becomes enveloped by 
the other structural proteins thus forming complete virions. Finally, virions are 
transported in smooth-walled vesicles to the cell surface where they fuse with the 
plasma membrane and release infectious CoV particles.  
Attachment and entry. The coronavirus spike protein is the main determinant of 
virus attachment and entry as it possesses both a receptor binding domain (S1) and is a 
type I fusion protein via the S2 domain. The interaction between the coronavirus spike 
protein and cognate host cell receptor is the first step in initiating the replication cycle. 
CoV host range, tissue tropism and zoonotic emergence are largely dependent on the 
specificity of the S to a particular receptor, however, may also be determined by the 
presence and density of host proteases involved in promoting membrane fusion. These 
interactions are highly species specific, but are also mutable as has been shown both 
experimentally (Saif, 2004) and naturally with the zoonotic emergence of both SARS- 
and MERS-CoV. The specific location of the receptor binding domain (RBD) varies 
along the S1 domain and different CoV species utilize one or both for this function. The 
galectin-like amino-terminal domain of S1 binds sialic-acid moieties as observed in 
mouse hepatitis virus (MHV) (mCEACAM) (Nedellec et al., 1994) and HCoV-OC43 
(Qian et al., 2015). The carboxy-terminal domain of S1 is more commonly utilized and 
engages peptidases as identified for HKU1 (Qian et al., 2015), feline CoV (APN) 
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(Tresnan et al., 1996; Tresnan and Holmes, 1998), SARS-CoV (ACE2) (Li et al., 2003) 
and MERS-CoV (Raj et al., 2013). Interestingly, a neurotropic strain of murine 
coronavirus (MHV-JHM) has also been shown to enter cells without specific receptor 
engagement (Gallagher et al., 1992) possibly owing to a highly fusogenic, metastable 
spike protein.  
In all cases, following engagement of the host receptor, the S2 region of S 
catalyzes a membrane fusion event, which allows transit of the genomic RNA from 
virion to the cytoplasm. This fusion process requires significant structural changes to 
spike and has been recently visualized by cryo-EM (Walls et al., 2017). The S 
conformational changes are triggered following cleavage by host proteases (in some 
cases pH-dependent) and drives the rapid release and insertion of the fusion peptide, 
which is located in the center of the pre-fusion spike trimer, into the host membrane. For 
most CoV spike proteins, cleavage of S occurs at a defined junction between S1 and 
S2; however, certain S proteins have been shown to have alternative or additional 
cleavage sites along S1, which can impact cell tropism and pathogenesis (Belouzard et 
al., 2012, 2009; Licitra et al., 2013; Millet and Whittaker, 2015). Proteolytic processing of 
the spike protein occurs in several locations depending on the CoV, including at the cell 
surface (Earnest et al., 2017; Glowacka et al., 2011; Park et al., 2016), within early 
endosomes (Millet and Whittaker, 2014) and in complex with lysosomes (Bosch et al., 
2008). This process allows spatiotemporal control of viral entry (Rottier and Bosch, 
2008) and has implications in cell tropism, entry efficiency and pathogenicity 
(Matsuyama et al., 2005; Park et al., 2016). The membrane fusion event mediated by 
the S2 region of the spike is typical of other type I fusion proteins (Harrison, 2015) and 
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includes a three step process: i) insertion of fusion peptide into the outer leaflet of the 
host membrane; ii) a fold-back event brining the outer leaflets of the host and viral 
membranes into close proximity; iii) a hemi-fusion event in which the lipid bilayers of the 
host and viral membrane fuse. The end result of this fusion event is the release of the 
genomic RNP core into the cytoplasm. 
Replicase protein translation, processing and formation of the replicase-
transcription complex (RTC). Once within the cytoplasm, translation of the CoV 
genomic RNA occurs on host ribosomes (Lai et al., 1994). The 5’ end of the genome is 
capped with a methylated guanine residue that precedes a highly-structured 
untranslated region containing seven stem-loops (Yang and Leibowitz, 2015). The 5’ 
structure of the RNA engages host translation machinery components eIF4 and the 
ribosomal 40 S subunit to form the pre-initiation complex. The 60 S ribosomal subunit 
then associates with this complex and begins translation of the first set of open reading 
frames encoding the coronavirus replicase [reviewed in (Nakagawa et al., 2016)].  
The replicase region comprises the first two-thirds of the genome and houses all 
the components necessary to drive formation of the replicase-transcriptase complex 
(RTC), a structure that functions to replicate the full-length genome and transcribe the 
downstream structural and accessory genes. The replicase is translated from two open 
reading frames, ORF1a and ORF1b that produce two co-terminal polyproteins (pp) 1a 
and 1ab (Lai et al., 1994). A large pseudoknot, preceded by a 5’-UUUAAAC-3’ “slippery” 
sequence, is present at the junction between ORF1a and ORF1b and directs production 
of either pp1a (75%) or pp1b (25%). For production of pp1a, the ribosome translates the 
entire ORF1a by unwinding and continuing through the pseudoknot before terminating 
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at a downstream stop codon. To produce pp1ab, the pseudoknot causes the ribosome 
to temporarily pause at the “slippery” sequence leading to a -1 nt ribosomal frameshift 
and subsequent continuation of translation through ORF1b.  
The functional components of the ~ 20 kb replicase are a set of 16 nonstructural 
proteins, which are released from the co-terminal polyproteins 1a and 1ab through 
catalytic cleavage by a set of 2-3 replicase-encoded viral proteases. Contained on nsp3 
are one or two papain-like proteases (PLP1; PLP2) (Baker et al., 1993; 
Kanjanahaluethai et al., 2003) that process the nsp1/2, 2/3, and 3/4 junctions in trans 
through recognition of a conserved LXGG motif. Nsp5 encodes the 3C-like protease 
(3CLpro; also termed Main protease or Mpro), a serine protease, which is released by 
autocatalytic cleavage and recognizes a conserved LQS motif to release nsps 5-16. 
Each nonstructural protein has a distinct function that is conserved among CoV 
orthologues (Gorbalenya et al., 1989; Su et al., 2014) and summarized Table 2. 
Together, these components mediate the assembly of the cytoplasmic replicase-
transcriptase complex (RTC), the site of de novo RNA synthesis and transcription of 
subgenomic RNAs. Within hours of infection, nsp3, 4 and 6 (Angelini et al., 2013) 
induce large alterations of the cellular reticulovesicular membrane network forming 
perinuclear convoluted membranes from which the double-membrane vesicles (DMVs), 
the scaffolds of the RTC, are derived (Gosert et al., 2002; Knoops et al., 2008; Prentice 
et al., 2004; Shi et al., 1999; van der Meer et al., 1999). Other notable components of 
the RTC include nsp12 and 13 that encode the RdRp and helicase, respectively.   
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PROTEIN FUNCTION(S) REFERENCE 
nsp1 
Cellular mRNA degradation 
Blocks host translation 
Innate immune antagonism 
(Tanaka et al., 2012) 
(Huang et al., 2011) 
(Kamitani et al., 2009) 
(Kamitani et al., 2006) 
nsp2 Not required for replication Binds prohibitin proteins 
(Cornillez-Ty et al., 2009) 
(Graham et al., 2005) 
nsp3 
Multi-domain transmembrane protein; DMV formation 
(Ubl1 / Ac) Associate with N protein 
(Macrodomain) IFN antagonism, PLP2 interaction 
(PLP1/2) LXGG-specific protease (nsp1/2, 2/3, 3/4 junctions) 
               Deubiquitinase-mediated IFN antagonism 
               DeISGylase: deconjugates ISG15 
(DPUP, Ubl2, NAB, G2M, SUD, Y) unknown functions 
(Chen et al., 2015) 
(Chatterjee et al., 2009) 
(Frieman et al., 2009) 
(Serrano et al., 2009) 
(Eriksson et al., 2008) 
(Neuman et al., 2008) 
(Serrano et al., 2007) 
(Egloff et al., 2006) 
(Ziebuhr et al., 2001) 
(Deng et al., 2019a) 
nsp4 DMV formation (Gadlage et al., 2010) (Clementz et al., 2008) 
nsp5 (3CL pro / M pro) RLG-specific protease (nsp4-16 junctions) (Lu et al., 1995) 
nsp6 DMV formation (Oostra et al., 2008) 
nsp7 Forms hexadecameric complex with nsp8 Potential processivity clamp for RNA polymerase (nsp12) (Zhai et al., 2005) 
nsp8 
Forms hexadecameric complex with nsp7 
Potential processivity clamp for RNA polymerase (nsp12) 
Potential primase  
(Imbert et al., 2006) 
(Zhai et al., 2005) 
nsp9 RNA binding protein (Egloff et al., 2004) 
nsp10 Cofactor for nsp14 and nsp16 Promotes 2-O-MT and ExoN activities of nsp14 and nsp16, rsp. 
(Decroly et al., 2011) 
(Bouvet et al., 2010) 
nsp11 Small peptide formed at end of pp1a (de Haan and Rottier, 2005) 
nsp12 (RdRp) RNA-dependent RNA polymerase (Xu et al., 2003) 
nsp13 DNA/RNA helicase; unwinds with 5’ to 3’ polarity 5’ triphosphatase 
(Ivanov et al., 2004b) 
(Ivanov and Ziebuhr, 2004)  
nsp14 (N7 MTase) Addition of 5’ cap to viral mRNAs (ExoN) exoribonuclease; RNA proofreading activity 
(Eckerle et al., 2010) 
(Chen et al., 2009) 
(Eckerle et al., 2007) 
(Minskaia et al., 2006) 
nsp15 (EndoU) Endoribonuclease of ss/dsRNAs at uridylate residues                Prevents dsRNA accumulation; strong IFN antagonist 
(Deng et al., 2019b) 
(Deng et al., 2017) 
(Kindler et al., 2017) 
(Bhardwaj et al., 2006) 
(Bhardwaj et al., 2004) 
(Ivanov et al., 2004a) 
nsp16 (2’-O-Methyltrasferase); Prevents RNA detection by MDA5  (Züst et al., 2011) (Decroly et al., 2008) 
   
 
 
 
 
 
42 
 
 
Interestingly, several of the nonstructural proteins, including the papain-like 
protease (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009; Li et al., 
2011; Mielech et al., 2014; Rose and Weiss, 2009; Sun et al., 2012), and the EndoU 
encoded on nsp15 (Deng et al., 2019b, 2017; Deng and Baker, 2018; Kindler et al., 
2017) have been demonstrated to have additional functions and antagonize innate 
immunity.  
RNA replication and transcription. Within the RTC, replication of the full-length 
gRNA occurs and is used as a template to generate of a set of subgenomic (sg) 
messenger (m) RNAs that encode the structural proteins, spike (S), envelope (E), 
membrane (M), nucleocapsid (N) and hemagglutinin-esterase (HE), if present (de Haan 
and Rottier, 2005; Masters, 2006), as well as the group-specific accessory proteins. 
Together, the structural and accessory genes comprise the final third of the genome, 
downstream of the replicase. The number of sgRNAs differs between coronaviruses but 
is typically between 7 and 9. The positive sense (+) sg mRNAs are 5’ capped 
(Nakagawa et al., 2016) and contain a 70-100 nt leader (L) sequence downstream of 
the cap, which includes a 6-9 nt section called the transcription-regulating sequence 
(TRS-B [Body]). The TRS-B is identical to the TRS at the 5’ end of the gRNA (termed 
TRS-L [Leader]) and the exact composition of the TRS is highly conserved within each 
Table 2: Coronavirus Nonstructural Proteins and Associated Functions. Included 
abbreviations: nsp3, ubiquitin-like domain (Ubl); acidic domain (Ac), papain-like 
protease 1/2 (PLP1/2), domain preceding Ubl2 and PLP2 (DPUP), nucleic acid-
binding (NAB) domain, coronavirus group 2 marker (G2M) domain, SARS-CoV unique 
domain (SUD), coronavirus highly conserved (Y) domain; nsp5, 3C-like protease 
(3CLpro), Main protease (M pro); nsp14, methyltransferase (MTase). Adapted from 
(Fehr and Perlman, 2015). 
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CoV subfamily. Additionally, the sgRNAs are 3’ co-terminal with genomic RNA and thus 
form the nested-set of subgenomic mRNAs that partly define the Nidovirus order.     
The “discontinuous transcription” model (Figure 5) proposed by Sawicki et al. 
(Sawicki and Sawicki, 1995) is widely accepted as the mechanism through which sg 
mRNAs are produced. In this model, the full-length genomic RNA acts as a template for 
the generation of negative-sense (-) sgRNAs, which in turn become templates for 
transcription of the positive-sense sg mRNAs. To produce the (-) sgRNAs, the viral 
RdRp binds the gRNA at the 3’ poly (A) tail and extension occurs 3’ to 5’ until a TRS-B 
is reached. A looping event brings the TRS-B in proximity to the TRS-L located at the 5’ 
end of the gRNA and here the polymerase strand-switches to produce a complimentary 
replicate of the 5’ gRNA leader. When extension terminates, the negative-sense RNAs 
possess an anti-sense leader sequence and a poly (U) tail (Sethna et al., 1991). From 
the limited population of negative-sense sgRNA templates, the viral RdRp produces 
one-hundred times more positive-sense sgRNAs, which are 5’-capped and exit the RTC 
to be translated on host ribosomes into S, E, M, N and accessory proteins (de Haan and 
Rottier, 2005; Fehr and Perlman, 2015; Masters, 2006; Sawicki et al., 2007).  
Owing to the co-terminal nature of the 3’ ends of the sgRNA, the identical TRS 
compositions and the strand-jumping tendency of the viral RdRp, CoV genomic 
recombination events can occur. Recombination helps drive viral adaptation, evolution, 
zoonotic emergence and the generation of quasispecies during an infection. The strain 
variation and difficulty in investigating feline coronaviruses, as will be discussed below, 
is likely due in large part to recombination.  
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Figure 5: Model for Discontinuous Negative-strand Transcription. The viral 
RNA-dependent RNA polymerase binds the 3’ end of the positive-strand (solid 
black line) RNA and initiates elongation of the negative-strand (red dotted line) 
RNAs until a body transcription-regulating sequence (TRS-B) is encountered. 
Strand-switching occurs, which pairs the TRS-B with the leader-containing TRS 
(TRS-L) on the positive strand. Transcription of the negative strand re-initiates 
creating a complement to the TRS-L on the 3’ end and forming a dsRNA 
intermediate. The complete negative-strand is used as a template to produce 
100-1000 times more positive-sense subgenomic mRNAs. Adapted from 
(Masters, 2006). 
 
 
 
 
45 
 
As a final note, the formation of double-stranded RNA intermediates in the RTC 
during replication presents a unique challenge to coronaviruses as dsRNAs are highly 
potent pathogen-associated molecular patterns (PAMP). As mentioned above and will 
be discussed below, the activity of at least one nonstructural protein, the EndoU 
encoded on nsp15, has been shown to maintain association of dsRNA with RTC 
thereby preventing detection of this viral PAMP by cytoplasmic pathogen recognition 
receptors.   
Virion assembly and release. In addition to the nonstructural proteins, the 
structural nucleocapsid (N) protein has also been shown to localize to the replicase-
transcriptase complex (Bost et al., 2000; van der Meer et al., 1999). Here, the N protein 
binds newly-synthesized, full-length coronavirus genomic RNA through associations 
with the 5’ leader, TRS and 3’ UTR to form a ribonucleoprotein (RNP) core (Molenkamp 
and Spaan, 1997; Shi and Lai, 2005; Stohlman et al., 1988). The stable RNP core is 
maintained by the large number of N-N interactions, which together form a structure 
with helical symmetry (de Haan and Rottier, 2005).    
Following translation on host ribosomes, the other structural proteins S, E, M and 
HE localize to the endoplasmic reticulum (ER) via encoded signal peptides (Fehr and 
Perlman, 2015). The proteins are inserted in the ER and oriented such that the protein 
ectodomains extend into the ER lumen, then transported via the host secretory pathway 
to the ER-Golgi intermediate compartment (ERGIC), the site of mature virion assembly 
(Krijnse-Locker et al., 1994; Tooze et al., 1984). Cytoplasmic RNP cores bud into the 
ERGIC and become surrounded by host membranes with embedded structural proteins, 
thus giving rise to the mature coronavirus virion. The M protein, often referred to as the 
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virion “building block” directs the majority of the protein-protein interactions that 
necessitate the formation of the mature virion including the accumulation/incorporation 
of S into the envelope and directing the RNP core to bud into the ERGIC (de Haan and 
Rottier, 2005). However, several groups have shown that M protein alone is not 
sufficient to form virions and requires the E protein to form basic virus-like particles 
(VLPs), a process that is made more efficient by the N protein (Bos et al., 1996; Siu et 
al., 2008). Although the role of E is not fully defined, it may play a role in inducing proper 
membrane curvature (Corse and Machamer, 2000; Fischer et al., 1998; Raamsman et 
al., 2000), preventing M protein aggregation (Boscarino et al., 2008), altering the host 
secretory pathway (Ye and Hogue, 2007), or as is observed with other coronavirus 
proteins, may have pleiotropic effects in virion assembly and release. Assembled virions 
are transported in smooth-walled exocytic vesicles to the cell plasma membrane where 
the vesicles fuse and release the mature, infectious coronavirus particle (de Haan and 
Rottier, 2005; Masters, 2006).  
Innate Immune Responses to RNA Virus Infection 
Overview.   
During virus infection, host cells detect extracellular and intracellular products of 
virus replication and mount an antiviral response. The so called “antiviral state” limits 
virus replication through production of directly-acting antiviral factors, blocking new 
infections, stimulation of cellular apoptosis and recruitment of innate and adaptive 
immune cells. Interferons (IFNs), host antiviral signaling molecules, are the master 
regulators of this antiviral state and are produced in response to detection of viral 
pathogen-associated molecular patterns (PAMPs), mainly viral RNAs, by host pattern 
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recognition receptors (PRRs). Autocrine and paracrine IFN signaling propagates 
through IFN receptors and stimulates expression of hundreds of IFN-stimulated genes 
(ISGs) that establish the rapid, pro-inflammatory antiviral state. In addition to interferon, 
other PRRs direct the synthesis and release of pro-inflammatory cytokines including 
tumor necrosis factor alpha (TNF-α), numerous interleukins (IL’s) and chemotactic 
cytokines resulting in an influx of neutrophils, macrophages, natural killer cells, 
lymphocytes and plasmacytoid dendritic cells (pDCs) to the sites of infection. Immune-
activated macrophages and pDCs secrete high amounts of type I IFN that significantly 
enhance ISG production in surrounding tissue as well as collect viral antigens 
necessary to develop long-term immune memory. Together, the pro-inflammatory 
antiviral state is intended to limit the spread of the virus and prevent new infections 
during an intense yet brief window of time, while recruiting the cells necessary to 
generate long-lasting immunologic memory. As prolonged inflammation can lead to 
pathology, cells also encode a set of negative regulators to return tissues to 
homeostasis.  
Detection of RNA Viruses by Host Sensors.   
 Cells distinguish self from non-self by detecting microbial- and viral-specific 
signatures collectively known as pathogen-associated molecular patterns (PAMPs), 
which are detected by a set of pattern-recognition receptors (PRRs). Host cells encode 
three major classes of PRRs: the cytoplasmic-resident retinoic acid-inducible gene I-like 
receptors (RLRs), the surface- and endosomal-resident toll-like receptors (TLRs) and 
the cytoplasmic-resident nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs). Together, these PRRs detect virus components and trigger a signal 
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cascade to induce production type I and type III interferons and pro-inflammatory 
cytokines, which act in concert to orchestrate the “antiviral state” [reviewed in (Koyama 
et al., 2008; Loo and Gale, 2011; Takeuchi and Akira, 2009)].  
Retinoic-acid inducible gene-like receptors (RLRs). The RLR class of pattern 
recognition receptors is the most well-studied and includes three members: retinoic 
acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), and 
laboratory of genetics and physiology 2 (LGP2). RIG-I and MDA5 are highly expressed 
in conventional dendritic cells (cDCs), macrophages and fibroblasts, but are also 
present in most tissues at a low basal level (Yoneyama et al., 2004). RLR expression is 
also tied to IFN signaling as cytoplasmic levels rapidly increase with IFN stimulation 
(Kang et al., 2004; Yoneyama et al., 2004; Yount et al., 2007). These two RLRs are 
individually or dually responsible for response to numerous RNA viruses [reviewed in 
(Loo and Gale, 2011)]. While RIG-I directs responses to Influenza, Japanese-
Encephalitis virus and VSV, MDA5 is required for detection of Picornaviruses and, 
importantly, Coronaviruses (Deng et al., 2017; Kato et al., 2006; Kindler et al., 2017; 
Zalinger et al., 2015). A combined RIG-I and MDA5 response occurs following West 
Nile virus, Dengue and Reovirus infections (Fredericksen et al., 2008; Loo et al., 2008).    
RIG-I and MDA5 proteins comprise two N-terminal caspase activation and 
recruitment domains (CARDs) followed by a DExD/H RNA helicase domain and a C-
terminal repressor domain (RD) (Yoneyama et al., 2004). LGP2 does not contain a 
CARD domain and is thought to act as a negative regulator of RIG-I and MDA5 through 
associations with the RD (Saito et al., 2008). Both RIG-I and MDA5 bind viral RNAs via 
the RNA helicase and RD domains, which form a set of RNA-binding loops (Takahasi et 
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al., 2009). RIG-I binds short (19-1000 nt), cytoplasmic single-stranded (ss) and double-
stranded (ds) RNA species, which are distinguished from host RNAs due to the lack of a 
5’ CAP exposing a 5’ triphosphate group (Hornung et al., 2006; Kato et al., 2008; 
Pichlmair et al., 2006; Takahasi et al., 2008). MDA5 also binds cytoplasmic RNAs, 
however associations are only made with dsRNA species longer than 2 kilobases (Kato 
et al., 2008). Additionally, both RIG-I and MDA5 bind the products of the 2’5’-
oligoadenylate synthase (OAS)-RNaseL system (Malathi et al., 2007), a set of 
interferon-stimulated genes that sense cytoplasmic dsRNAs and cleave host and viral 
RNA indiscriminately, thus creating a positive-feedback loop to potentiate RLR 
signaling. The N-terminal CARDs are held in an inactive “closed” conformation by the 
RD and released into an active, “open” conformation following RNA binding allowing 
signal propagation (Cui et al., 2008; Saito et al., 2008). Active RIG-I and MDA5 signal 
via homotypic CARD-CARD interactions with the mitochondrial antiviral signaling 
protein (MAVS) (Seth et al., 2005), also termed IPS-1 (Kawai et al., 2005), VISA (Xu et 
al., 2005) or Cardif (Meylan et al., 2005). MAVS is a membrane-associated, CARD-
containing protein essential for RLR-dependent IFN production and resides on 
mitochondrial (Seth et al., 2005) and peroxisome (Dixit et al., 2010) membranes. Once 
associated, the RLR-MAVS complexes aggregate on host membranes to form the 
MAVS “signalome”, an intricate signaling platform modulated by a number of positive- 
and negative-regulators that functions to activate transcription of interferons and pro-
inflammatory cytokines (Hiscott et al., 2006). Specifically, the MAVS signalome leads to 
downstream phosphorylation of interferon regulatory factor (IRF) 3 and IRF7, which 
form homodimers that translocate into the nucleus, bind target sequences and drive 
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expression of IFN. Interestingly, mitochondrial-associated and peroxisomal-associated 
MAVS signalome complexes are thought to differentially stimulate production of type I 
and type III interferons, respectively, seemingly by similar activation pathways (Coccia 
et al., 2004; Kotenko et al., 2003; Loo and Gale, 2011; Odendall et al., 2014; Onoguchi 
et al., 2007; Seth et al., 2005). In parallel, the MAVS signalome also results in the 
phosphorylation and subsequent ubiquitin-dependent proteasomal degradation of I𝜅Bα, 
releasing active NF𝜅B into the nucleus leading to transcription of pro-inflammatory 
cytokines and interferons. 
Toll-like receptors (TLRs). Mammalian cells express between 10 and 13 unique 
toll-like receptors (TLRs), which specifically associate with a broad range of viral, 
bacterial and fungal PAMPs. TLRs are single-span type I transmembrane proteins 
containing an N-terminal, leucine-rich ectodomain responsible for binding to PAMPs, a 
transmembrane domain, and a C-terminal, cytoplasmic toll/interleukin-1 receptor (TIL) 
domain, which allows homo- and heterodimer formation. The endosomal TLRs 3, 7, 8 
and 9 are responsible for detection of phagocytosed viral materials or viruses that gain 
access to cells via the endosomal network. TLR7 and 9 are highly expressed in 
plasmacytoid dendritic cells (pDCs), a specialized innate-immune cell type responsible 
for the majority of type I interferon production in mammalian cells and the major 
modulator of cell-mediated immunity to coronavirus infection (Cervantes-Barragan et al., 
2006). Within the endosome, TLR7 detects ssRNA species, while TLR9 binds non-
methylated, CpG-containing DNA. TLR3 is more broadly expressed in mammalian 
tissues and detects endosomal dsRNA species [reviewed in (Iwasaki, 2012; Iwasaki 
and Medzhitov, 2004)]; it has also been shown to be important for appropriate innate 
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responses to coronaviruses including the human pathogen SARS-CoV (Totura et al., 
2015).  
Following binding to their respective ligands, TLR3 or TLR7 form homodimers 
through interactions between the cytosolic TIR domains. For TLR3, the TIR-TIR 
interactions form a complex with TIR domain-containing adaptor inducing IFN beta 
(TRIF), tumor necrosis factor receptor-associated factor (TRAF) 3, TRAF6, and receptor 
interacting protein 1 (RIP1) (Meylan et al., 2004; Oshiumi et al., 2003; Sato et al., 2003; 
Yamamoto et al., 2002). NF𝜅B and AP-1 activation occurs via TRAF6/RIP1 resulting in 
pro-inflammatory cytokine production, while TRAF3 mediates IRF3 activation through 
the kinase activity of TBK1, resulting in type I IFN synthesis. The TLR7 TIR-TIR 
interaction forms a more traditional TLR signaling pathway mediated by interaction with 
myeloid differentiation factor 88 (MyD88). MyD88 proteins form a signaling complex with 
interleukin 1 receptor associated kinase (IRAK) 1, IRAK4, TRAFs 3 and 6 and I𝜅𝜅α to 
promote NF𝜅B-mediated cytokine production and IRF-7 mediated IFN synthesis 
(Häcker et al., 2006; Kawai et al., 2004; Uematsu et al., 2005). 
NOD-like receptors (NLRs). NLRs are a third class of RLRs that detect both 
PAMPs and danger-associated molecular patterns (DAMPs), host-derived biomolecules 
that propagate pro-inflammatory signals following substantial tissue damage. The NLRs 
have a number of functions including the activation of the NLRP3 inflammasome and 
production of the pro-inflammatory cytokine IL-1𝛽 (Martinon et al., 2002), regulation of 
apoptosis, activation of NF𝜅B and IFN synthesis, and as negative regulators of other 
RLRs (discussed below) [reviewed in (Carneiro et al., 2007; Lupfer and Kanneganti, 
2013)]. Many of the antiviral NLRs, particularly the NLRP3 inflammasome components, 
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are interferon-stimulated geneses and thus are coordinated through the upstream 
activation of RLR and TLR signaling. Once formed, the NLRP3 inflammasome can be 
activated by a number of cell stresses to produce IL-1𝛽, a highly pro-inflammatory 
cytokine with pleiotropic effects. This system is becoming increasingly appreciated in 
the antiviral response to RNA and DNA viruses including Orthomyxo-, Paramyxo-, 
Picrona-, Flavi-, Pox-, Herpes- and Adenoviridae [reviewed in (Lupfer and Kanneganti, 
2013)]. The NLRP3 inflammasome had also been recently shown to be activated by 
SARS-CoV (Chen et al., 2019). 
Interferons and the Antiviral Effects of Interferon-stimulated Genes.   
Pro-inflammatory cytokines and interferons (IFNs) play an integral role in the 
innate immune system (de Weerd and Nguyen, 2012; Ivashkiv and Donlin, 2013; 
Pestka et al., 2004; Trinchieri, 2010) and are produced through the activity of the 
pattern recognition receptors discussed in detail above (Goubau et al., 2013; Iwasaki, 
2012; Sen, 2002). These molecules have pleiotropic effects on various cell types and 
can direct both local and systemic responses. In most cases, the composition, intensity 
and duration of the IFN/cytokine response to viral infection determines if the virus is 
cleared, if immune memory is developed and if the host experiences immunopathologic 
side-effects. Thus, synthesis and signaling is tightly regulated.    
Interferons. Interferons fall into three classes: type I comprising predominantly 
IFN-alpha (α) and -beta (𝛽), type II or IFN-gamma (𝛾), and type III or IFN-lambda (𝜆). 
These different classes are structurally distinct, and as such, signal through different cell 
surface receptors, specific to each class. Type II (gamma) IFN is synthesized by 
specialized immune cells such as NK cells, CD4+ Th1 cells and CD8+ T cells and is 
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important for immune cell activation and adaptive immunity. Type I and III IFN, the focus 
of this discussion, play dominant roles as master regulators of the innate immune 
antiviral state. The effects of type I and type III IFN are largely cell-type specific and are 
determined both by the level and type of IFN transcription as well as the expression of 
the corresponding receptor. Type III IFNs are produced in greater amounts at barrier 
tissue sites (pulmonary and intestinal epithelia) and tend to stimulate a mild, localized 
response rather than the large, often systemic pro-inflammatory response observed with 
type I IFN. It should be noted that tissue-resident macrophages are largely insensitive to 
IFN-𝜆 (Zanoni et al., 2017) and therefore, function in an IFN-stimulation paradigm that is 
not dependent directly on type III. As a result, IFN-𝜆 is often triggered first in epithelial 
cells in an attempt to clear the infection. If the IFN-𝜆 response is insufficient and the 
infection persists, then type I IFN, produced predominantly by recruited macrophages 
and dendritic cells, takes over. A great example is the relationship between type I and III 
interferons in response to influenza infection, which recapitulates the above model 
(Galani et al., 2017). Thus, it can be generally stated that IFN-𝜆 is important for antiviral 
response at barrier sites, while type I IFN is broadly utilized in antiviral response 
[reviewed in (Donnelly and Kotenko, 2010; Lazear et al., 2015)]. 
The signaling pathways required to trigger synthesis of type I and III IFN 
discussed above, converge on the activation of a family of transcription factors termed 
interferon regulatory factors (IRFs) (Ito et al., 1999) with IRF3 and IRF7 being of 
particular importance to RLR-mediated synthesis of type I / III interferons (Marié et al., 
1998). IRF3 is expressed in a broad range of cell types and low basal levels are present 
in the cytoplasm. Activation of IRF3 via the RLR signaling pathways leads to 
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homodimerization and translocation into the nucleus where it stimulates production of 
mainly IFN-𝛽 (or IFN-𝜆) and several IFN-α	subtypes. Following downstream IFN 
signaling, IRF7, which is not constitutively expressed and acts as a positive feedback 
mechanism for IFN production, is activated by a similar pathway as IRF3 and promotes 
transcription of a different set of IFNs than IRF3 [reviewed in (Sen, 2002)]. Together, 
active IRF3 and IRF7 promote the synthesis of all type I / III IFNs, which are secreted 
from cells and stimulate autocrine (producer cell) and paracrine (surrounding cells) 
signal transduction pathways. 
Type I and III IFNs signal through distinct receptors, IFNαR and IFNLR1, 
respectively, which activate a Janus Kinase / Signal Transducer Activator of 
Transcription (Jak/STAT) signal cascade resulting in the transcription of hundreds of 
interferon-stimulated genes (ISGs) (Randall and Goodbourn, 2008; Takeuchi and Akira, 
2010; Wilkins et al., 2010; Yoneyama and Fujita, 2010). The type I IFN signal cascade 
is well defined. Association with type I IFNs causes dimerization of the two IFNαR 
component subunits, IFNαR1 and IFNαR2, leading to cross-phosphorylation of two 
JAKs associated with the cytoplasmic tail. The Janus Kinases allow association of 
STAT1 and STAT2, which are phosphorylated, dimerize and are released to bind 
cytoplasmic IRF9 (Meyer, 2009; Samuel, 2001; Yoneyama and Fujita, 2010). This 
complex, termed interferon-stimulated transcription factor 3 (ISGF3), enters the nucleus 
and binds consensus cis-acting DNA elements (interferon-stimulated response 
elements; ISRE) present on several hundred ISG promoters, which enhance 
transcription (Liu et al., 2012; Schoggins et al., 2014, 2011). The result is the production 
of hundreds of ISGs with a broad-range of antiviral activities.  
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Antiviral activity of interferon-stimulated genes (ISGs). The end result of the 
intricate interferon signaling cascade is the transcription of hundreds of interferon-
stimulated genes (ISGs) in both infected and uninfected neighboring cells. These ISGs 
range in function from direct antiviral activity, immune cell regulation, negative and 
positive- IFN signaling feedback and many more detailed in Table 3. Together, these  
responses produce a host antiviral response against a multitude of RNA and DNA 
viruses and determine the outcome of infection, degree of associated sequelae and 
initiation of immune memory development. Several are discussed here, but please note 
that this is by no means an exhaustive list. 
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Multiple ISGs play roles in virus surveillance and inducing drastic cellular 
responses including shutdown of protein synthesis and/or programmed cell death 
(apoptosis). The importance of pattern recognition receptors cannot be understated as 
these allow host cells to determine if a virus is present in the tissue and ultimately 
ACTIVITY 
TYPE SPECIFIC ISG(S) FUNCTION(S) LITERATURE REVIEW 
PRRs 
RLRs  
(RIG-I, MDA5) 
Binding cytoplasmic viral nucleic acids; 
IFN I / III stimulation (Loo and Gale, 2011) 
TLRs  
(TLR3,7-9) 
Binding endosomal viral nucleic acids; 
IFN I / III stimulation (Iwasaki and Medzhitov, 2004) 
Translation 
Inhibition / 
Apoptosis 
PKR (via eIF2a) Translation inhibition (via FADD and Caspase 8) Apoptosis (Dauber and Wolff, 2009) 
OAS / RNaseL Binds dsRNA to induce total RNA degradation; Substrates for RLRs (Chakrabarti et al., 2010) 
IFIT Family 
Pleiotropic: Reduce cap-dependent 
translation; 5’ppp RNA binding; cell-intrinsic 
and cell-extrinsic immune responses 
(Diamond and Farzan, 2013) 
RNA Mutation APOBEC Cytidine deamination (Stavrou and Ross, 2015) 
Host or Viral  
Protein 
Modulation 
ISG15 Pleiotropic regulation of cell processes:  IFN signaling, translation, motility (Perng and Lenschow, 2018) 
Mx Direct interaction with viral proteins (e.g. nucleocapsid and polymerase) (Verhelst et al., 2013) 
Virus entry 
and release 
IFITM Family Inhibit entry of enveloped viruses (Diamond and Farzan, 2013) 
Tethrin Binds to virions and prevents virus release from membranes (Sauter, 2014) 
Viperin Disruption of lipid rafts and lipid homeostasis (Fitzgerald, 2010) 
Inflammasome RIG-I-mediated; NLRp3-mediated 
Non-canonical Production of IL-1𝛽; 
Modulation of NLRP3 inflammasome 
(Kopitar-Jerala, 2017; Poeck et 
al., 2010) 
T Cell and 
Cytolytic Cell 
Responses 
IL-12 CD4+ Th1 differentiation; NK cell production of IFN-𝛾 (Biron et al., 1999) 
IL-21 CD8+ / NK cell cytolytic activity (Strengell et al., 2004) 
Perforin and 
Granzyme B CD8+ / NK cell cytolytic activity (Curtsinger et al., 2014) 
IL-15 Proliferation of memory T cells and NK cells (Verbist and Klonowski, 2012) 
IFN-𝛾 Activation of CD8+ T cells and Macrophages (Samuel, 2001) 
CCL3; CCL5; 
CXCL10 T cell chemoattractants (Meager, 2006) 
Antigen 
Processing / 
Presentation 
Multiple 
Upregulates MHC-I, antigen processing 
machinery and co-stimulatory molecules; 
dendritic cell expansion, others 
(Gessani et al., 2014) 
 
Table 3: Type I Interferon Stimulated Genes and Antiviral Activities. 
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trigger the interferon signaling cascade. It is not surprising then, that these PRRs, 
including the RLRs, TLRs and NLRs, are significantly upregulated in response to 
interferon signaling and therefore provide enhanced virus surveillance in infected and 
uninfected cells. Additional cytoplasmic RNA binding proteins are also induced by 
interferon and include both protein kinase R (PKR) and 2’5’-oligoadenylate synthase 
(OAS). Following binding to cytoplasmic dsRNA, PKR has multiple roles in antiviral 
response including phosphorylation of eukaryotic initiation factor (eIF) 2a leading to host 
translation shutdown and promoting cellular apoptosis via the FADD/caspase8 pathway. 
2’5’-OAS also binds cytoplasmic dsRNAs and produces the small signaling molecule 
2’5’-oligoadenylate. This activates a second ISG, RNaseL, which non-specifically 
degrades host and viral RNAs resulting in a shutdown of protein synthesis and 
apoptosis. The products of RNaseL activity are also recognized by RIG-I and MDA5 and 
thus represent a positive IFN-signaling feedback loop. Other ISGs including the large 
family of cytoplasmic IFN-induced proteins with tetratricopeptide repeats (IFITs) and 
ISG15 have been shown to have pleiotropic effects on virus surveillance and 
fundamental cell processes. IFIT1 for example, is known to bind 5’-triphosphate-
containing RNAs similar to RIG-I, sequestering viral mRNAs and preventing uncapped 
protein translation. IFIT1 has also been shown to inhibit cap-dependent translation 
through interaction with eIF3 thereby stalling the translation initiation complex or by 
directly preventing association of non-methylated, capped viral mRNAs. ISG15, which is 
one of the first and most abundant ISGs produced, is a ubiquitin-like polypeptide and is 
post-translationally conjugated to both host and viral proteins. As a result, ISG15 can 
caused proteasome-dependent protein degradation, impact the RLR/IFN signaling 
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cascades and cell processes such as translation, glycolysis and motility. The full 
spectrum of ISG15 activities and the mechanisms through which it acts are not fully 
understood, however it can be appreciated as a significant antiviral response mediator.  
Another set of ISGs act to inhibit virion entry, maturation and release from cells. 
IFN-induced transmembrane proteins (IFITMs), are small host transmembrane proteins 
that broadly inhibit the entry of enveloped viruses such as coronaviruses, flaviviruses, 
influenza and others. While IFITMs are produced in cells at low basal levels, their 
expression increases significantly with IFN stimulation. These proteins appear to more 
potently inhibit viruses that fuse in late endosomes and although the exact antiviral 
mechanism is not known, they have been predicted to affect the curvature of 
endosomes to prevent fusion, alter the composition of lipids and host proteases and 
recently, disrupt the vesicular trafficking network completely. Another ISG, Viperin 
disrupts lipid homeostasis and lipid raft formation, critical sites for the budding and 
release of several host lipid membrane-derived enveloped viruses. Finally, the activity of 
an ISG called tetherin, physically binds to budding virions and significantly reduces the 
efficiency to release from the cell surface. The activity of these ISGs acts to slow virion 
production and help prevent entry of viruses into uninfected cells.  
An early and robust interferon response is also important for modulating the 
“quality, quantity and balance” of host adaptive responses, a notion our group has 
utilized in the design of live-attenuated coronavirus vaccines. Type I interferon 
stimulation has been shown to increase surface levels of MHC-I, the machinery required 
to process and load antigens on MHC-I as well as and production of co-stimulatory 
molecules in, and specific expansion of, antigen presenting cells. Several ISGs have 
 
 
 
59 
 
also been shown to regulate T lymphocytes, which provide a critical adaptive response 
to viral infection and are involved in activating phagocytic cells, antigen-specific killing of 
virus-infected cells and cross-talk with B cells to establish humoral immunity. Among the 
T cell modulating ISGs are IFN- 𝛾, IL’s -12, -15, -21 and several chemoattractant 
cytokines that recruit CD4+ and CD8+ T cells to sites of infection. B cell differentiation 
and isotype switching has also been observed, however the relationship between IFN 
and these processes is complex and not fully understood. Thus, type I and III 
interferons are critical modulators of innate antiviral immunity but are also important 
regulators in CMI, humoral and long-term adaptive immunity.  
Negative Regulators of Interferon Synthesis and Signaling.   
Prolonged inflammation resulting from sustained IFN signaling and ISG activity 
can lead to extensive tissue damage and sequelae long after viral clearance. These 
immune-mediated complications are collectively referred to as “immune pathologies” or 
“interferonopathies” and are observed following infection of multiple viruses including 
influenza, West Nile virus and SARS-CoV (Channappanavar et al., 2016; Garcia-Sastre 
and Biron, 2006; Le Goffic et al., 2006; Wang et al., 2004). As a result, cells encode a 
number of negative regulators that act to suppress IFN signaling at the transcription and 
post-transcriptional level [reviewed in (Arimoto et al., 2018)]. IRF2, for example, is a 
member of the interferon regulatory factor (IRF) protein family that has been shown to 
attenuate type I IFN gene synthesis by preventing transcription in the nucleus (Hida et 
al., 2000). Several other ISGs are known to suppress IFN through post-translational 
modification or direct interaction with components of RLR signaling pathways. NLRC5, a 
NOD-like receptor (NLR) family protein, disrupts RLR-induced antiviral responses 
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through direct CARD-CARD sequestration of RIG-I and MDA5, preventing association 
with MAVS, while another NLR, NLXR1, disrupts the RLR signaling through competitive 
binding to MAVS (Moore et al., 2008). Other proteins affect IFN signaling through 
ubiquitin modifications that target RLRs. RNF125 is a K48 ubiquitin ligase that targets 
RIG-I and MDA5 causing degradation by the proteasome (Arimoto et al., 2007). CYLD, 
a deubiquitinase, removes poly-ubiquitin chains from activated RLRs, preventing 
downstream binding to MAVS (Zhang et al., 2008). 
Coronavirus-encoded Antagonists of Type I Interferon 
 
Overview.  
 
Establishing successful viral infection is a complex interplay between host and 
viral factors. While the host attempts to detect and respond to unique virus signatures, 
viruses utilize encoded factors to antagonize these host pathways and establish an 
intracellular environment amenable to production of progeny virions [reviewed in (Katze 
et al., 2002)]. This competition is often referred to as the “Red Queen Hypothesis”, a 
literary allusion to continuous movement without progress, and is the driving force 
behind both virus and innate response evolution (Duggal and Emerman, 2012).  The 
major obstacle to virus replication is the host master antiviral signaling molecule, 
interferon. Indeed, all successful viral pathogens, including the coronaviruses discussed 
in this dissertation, encode viral proteins that antagonize the synthesis, signaling and/or 
effector functions of the host interferon pathway. Importantly, virus strains encoding 
mutations in these interferon antagonists, creating so called hyper interferon-inducing 
(HII) or hyper interferon-sensitive (HIS) strains, have been shown to attenuate virus 
replication and are useful platforms for live-attenuated vaccine design (Deng et al., 
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2017; Du et al., 2018; Kindler et al., 2017). Coronaviruses carry a large, single-stranded 
RNA genome, which is replicated in the cell cytoplasm and forms double-stranded RNA 
intermediates during the process of discontinuous transcription. These single and 
double-stranded viral RNAs are known to be potent triggers of type I / III interferon 
synthesis and are detected by cytoplasmic and endosomal PRRs. Interestingly, 
coronavirus infection does not result in an early or robust type I IFN response and these 
viruses appear to replicate seemingly without innate immune detection by the host. In 
fact, this has become a hallmark of coronavirus infection kinetics and is observed in 
both human and animal cases (Channappanavar et al., 2016; Kint et al., 2014; Lau et 
al., 2013; Menachery et al., 2014). This subversion of the IFN signaling cascade is due 
to a complex and coordinated set of CoV-encoded interferon antagonists as well as 
several fundamental aspects of coronavirus replication biology. Indeed, over fifteen 
unique components of human and animal CoVs have been demonstrated to antagonize 
distinct elements of the IFN synthesis and signaling pathways or affect ISG function 
(Table 4). From these studies, several key conclusions can be drawn: First, all CoV 
have multiple antagonists to delay the IFN response, the majority of which are group-
specific accessory genes, but several, such as the papain-like protease encoded on 
nsp3 and the EndoU encoded on nsp15, are highly conserved across all CoVs. Second, 
some antagonists are inherent aspects of CoV replication biology and may or may not 
have evolved specifically to prevent immune activation. Finally, the ability of CoV 
proteins to antagonize IFN may be cell-type specific as observed with MHV ns2 (Zhao 
et al., 2012). Together, these mechanisms allow productive replication of coronaviruses 
in various mammalian tissues without triggering an early innate immune response.  
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Antagonism of the Interferon Pathway: Synthesis, Signaling and ISG Activity.  
Synthesis. A number of coronavirus factors prevent the synthesis of type I 
interferons by preventing detection of cytoplasmic RNAs or by directly targeting 
components of the RLR or TLR signaling cascades. One aspect of coronavirus 
ANTAGONIST 
TARGET VIRUS ANTAGONIST ACTIVITY / TARGET REFERENCE 
 IFN Synthesis 
SARS-CoV 
PLpro Binds STING and blocks IRF3 translocation  (Sun et al., 2012) 
nsp14 and nsp16 RNA capping (Totura and Baric, 2012) 
ORF3b Binds and blocks IRF3 translocation (Freundt et al., 2009) 
ORF6 Blocks NF-κB signaling 
(Hussain and Gallagher, 
2010; Kopecky-Bromberg 
et al., 2007) 
MERS-CoV 
ORF4a Binds dsRNA; blocks PKR (Niemeyer et al., 2013; Rabouw et al., 2016) 
ORF4b Prevents MAVS signaling by binding TBK1 (Yang et al., 2015) 
PLpro DUB activity prevents IRF3 signaling 
(Mielech et al., 2014; 
Yang et al., 2014) 
MHV 
Nsp15 Prevents MDA5, OAS and PKR detection of dsRNAs 
(Deng et al., 2017; 
Kindler et al., 2017) 
PLP2 DUB activity (Mielech et al., 2015; Rose and Weiss, 2009) 
HCoV 229E Nsp15 Prevents MDA5, OAS and PKR detection of dsRNAs 
(Deng et al., 2017; 
Kindler et al., 2017) 
IFN  
Signaling SARS-CoV 
nsp1  Decreases STAT phosphorylation (Wathelet et al., 2007) 
PLpro Interaction with several cell signaling components 
(Clementz et al., 2010; 
Devaraj et al., 2007; 
Frieman et al., 2009; Li et 
al., 2011) 
ORF3a Degradation of IFNαR (Minakshi et al., 2009) 
ORF6 Blocks STAT1 translocation (Frieman et al., 2007) 
ISG Activity 
MHV  
ns2 Cleaves 2-5A and prevents RNase-L activation (Zhao et al., 2012) 
ORF5a Uncharacterized phenotype (Koetzner et al., 2010) 
Nsp15 Binds dsRNAs and prevents OAS and PKR activation 
(Deng et al., 2017; 
Kindler et al., 2017) 
MERS-CoV ORF4a Binds dsRNA; blocks PKR (Niemeyer et al., 2013; Rabouw et al., 2016) 
IBV  nsp2 Overexpress GADD34 to block PKR (Wang et al., 2009) 
TGEV ORF7 Activates PP1c-mediated inactivation of PKR and OAS (Cruz et al., 2013, 2011) 
FIPV ORF7 Prevents phosphorylation of eIF2α (Dedeurwaerder et al., 2014) 
 
Table 4:  Coronaviruses and Encoded Antagonists of the Type I IFN System. 
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replication biology, the formation of host-derived double-membrane vesicles (DMVs), is 
an important and well-conserved method to prevent RLR activation. These DMVs, 
which are the sites of genomic RNA replication and mRNA transcription, act to 
physically separate viral dsRNA replication intermediates from detection by MDA5 
(Gosert et al., 2002; Knoops et al., 2008; Prentice et al., 2004; Shi et al., 1999; van der 
Meer et al., 1999). Once viral mRNAs are produced within the DMVs, they must enter 
the cytoplasm for translation. This is problematic as these viral RNAs contain a 5’ 
triphosphate, a potent activator of RIG-I. However, the conserved activity of 
nonstructural protein (nsp) 13 removes the 5’ triphosphate and further processing by 
nsps 10, 14 and 16 adds a methylated guanidine 5’ cap thus preventing the detection of 
this viral mRNA by RIG-I and allowing translation (Bouvet et al., 2010; Chen et al., 
2009; Decroly et al., 2008; Ivanov and Ziebuhr, 2004; Züst et al., 2011). Our group and 
others have also demonstrated that other highly conserved components of the DMV-
associated replicase-transcriptase complex (RTC), the papain-like protease and the 
EndoU, are important interferon antagonists. My contributions to determining the IFN 
antagonism functions of these proteins will discussed further below. 
In many cases, however, DMV formation and viral mRNA capping are not 
sufficient to prevent detection of viral PAMPs, thus coronaviruses encode compensatory 
mechanisms to directly antagonize components of the RLR or TLR signaling cascades. 
The well-studied human coronaviruses, SARS- and MERS-CoV, for example, utilize 
several unique accessory proteins for this role. In SARS-CoV, ORF3b binds directly to 
IRF3 preventing nuclear translocation (Freundt et al., 2009), while ORF6 blocks NF𝜅B 
and downstream STAT1 signaling by impeding protein import into the nucleus (Frieman 
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et al., 2007; Hussain and Gallagher, 2010; Kopecky-Bromberg et al., 2007). The MERS-
CoV accessory protein ORF4a has been shown to bind cytoplasmic dsRNA species 
preventing RLR binding as well as PKR-mediated shutdown of host protein synthesis 
(Niemeyer et al., 2013; Rabouw et al., 2016). ORF4b, another MERS accessory protein 
prevents MAVS signaling by binding to TBK1 and preventing kinase activity (Yang et al., 
2015). Together, these IFN synthesis antagonists represent a small number of studied 
viral factors and it is likely that other coronavirus species, including the large number of 
SARS-related bat CoVs, encode unique accessory proteins to prevent IFN synthesis.    
Signaling and activity of interferon-stimulated genes (ISGs). Following 
synthesis, interferons are released and propagate the antiviral signal back to the 
producer cell (autocrine) and neighboring cells (paracrine) through engagement of the 
IFN alpha-receptor (IFNαR). This triggers the Jak/STAT signal cascade and results in 
ISG production. Not surprisingly, coronavirus IFN antagonists also target components of 
this signal pathway as well as specific activities of the ISGs produced. To prevent 
signaling, SARS-CoV reduces the cell-surface abundance of IFNαR, through the activity 
of the accessory protein, ORF3a (Minakshi et al., 2009). Further, SARS-CoV nsp1 and 
ORF6 antagonize the host protein STAT by decreasing the phosphorylation required for 
STAT activity and blocking STAT1 translocation, respectively (Frieman et al., 2007; 
Wathelet et al., 2007). 
Further downstream, multiple coronaviruses encode ISG antagonists many of 
which target PKR and the 2’5’-OAS / RNaseL system. These two cytoplasmic systems 
bind dsRNAs and lead to shutdown of host protein synthesis and apoptosis by 
phosphorylation of eIF2α (PKR) or non-specific digestion of host and viral RNAs 
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(OAS/RNaseL), thus blocking the activity of these ISGs is critical for virus production. 
Several factors including the highly conserved EndoU encoded on nsp15 (Deng et al., 
2019b, 2017; Kindler et al., 2017), and the MERS-CoV accessory protein ORF4a 
(Niemeyer et al., 2013; Rabouw et al., 2016) prevent ISG activation by binding and 
sequestering cytoplasmic dsRNAs. The MHV hepatocyte-specific accessory protein ns2 
cleaves the small signaling molecule 2’5’-oligoadenylate preventing activation of 
RNaseL (Zhao et al., 2012). Others, such as MHV ORF5a, are known ISG antagonists 
however but their functions have not been fully described (Koetzner et al., 2010). 
Generally speaking, coronaviruses that encode these downstream signaling and 
ISG antagonists are much more resistant to IFN treatment and are more likely to 
prevent de novo interferon activation of infected cells. FIPV, for example, remains highly 
resistant to serum IFN as is evident by the inability to treat feline peritonitis with 
intravenous IFN after infection is established (Weiss et al., 1990). Several studies 
investigating TGEV (Cruz et al., 2013, 2011) and FIPV (Dedeurwaerder et al., 2014, 
2013) have determined that 7a, an accessory protein only encoded in several 
alphacoronaviruses, antagonizes the activity of ISGs and correspondingly causes 
insensitivity to IFN. In TGEV, 7a enhances the specificity of protein phosphatase 1c 
(PP1c) for eukaryotic initiation factor (eIF) 2a. This interaction causes increased 
dephosphorylation of eIF2a and results in prevention of host translation shutdown. In 
FIPV, the activity of 7a is associated with a second unique accessory region, ORF3. 
From clinical studies, it was determined that deletion of 7a or ORF3 from WT FIPV 
resulted in a significant reduction of FIP severity. Wild-type FIPV and FIPV-∆7a viruses 
stimulated similar, increased levels of type I IFN in feline macrophages and serum 
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during cat infection. Interestingly, when 7a is expressed alone it not sufficient to 
establish IFN resistance during VSV infection, suggesting that 7a requires additional 
FIPV components, presumably ORF3 to function. The mechanism of ORF3 activity and 
the characterization of other conserved or unique viral components responsible for IFN 
antagonism have yet to be evaluated 
Experimental Examples of Highly Conserved Coronavirus Interferon Antagonists.  
The Baker Lab is interested in understanding how highly conserved nonstructural 
proteins contribute to antagonism of interferon. We predict that mutagenesis of these 
nsps, leading to a hyper-interferon-inducing (HII) virus phenotype, is a strategy that 
could be employed to attenuate most all coronavirus strains and provide a platform on 
which to construct live-attenuated vaccines. To test this hypothesis, colleagues and I 
studied two CoV factors, the PLP2 encoded on nsp3 and the EndoU encoded on nsp15 
and determined if these conserved proteins antagonized interferon. This work laid the 
groundwork my dissertation research and formed the long-term goal of developing an 
effective vaccine for feline coronavirus.  
The feline coronavirus papain-like protease is an IFN antagonist. CoVs 
encode one or two multifunctional papain-like protease(s) (PLP1 and/or PLP2), which 
catalyze three reactions within the host cell: processing of the nonstructural CoV 
replicase polyprotein (protease), cleavage of the host signaling molecule ubiquitin 
(DUB), and deconjugation of the antiviral signaling molecule interferon-stimulated gene 
(ISG) 15 (deISGylase). While protease activity is required for viral replication, it is 
unclear what role DUB or deISGylation play during infection. We and others 
hypothesize that PLP2 is an IFN antagonist acting through disruption of ub-dependent 
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signaling in the IFN synthesis pathway, and therefore DUB function is an interesting 
mutagenesis target for generating live-attenuated vaccine strains. The DUB activity of 
MERS-CoV (Bailey-Elkin et al., 2014) and Equine Arteritis Virus (EAV) (van Kasteren et 
al., 2013) PLPs have been shown to suppress innate immune responses by targeted 
disruption of critical ubiquitination marks of IFN synthesis pathways (Bibeau-Poirier and 
Servant, 2008). DUB activity, however, is not the only means by which PLP can 
antagonize innate immune responses. Several groups have experimentally determined 
that PLPs can indirectly antagonize IFN production through association with different 
cell signaling components (Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 
2009; Li et al., 2011; Mielech et al., 2014; Rose and Weiss, 2009; Sun et al., 2012). 
SARS-CoV PLpro stabilizes the NF-𝜅B inhibitor I𝜅Bα, preventing NF-𝜅B nuclear 
translocation and subsequent IFN production (Frieman et al., 2009). By a similar 
mechanism, the PLPs of HCoV-NL63 and SARS-CoV were shown to associate with and 
destabilize stimulator of interferon genes (STING) dimers (Sun et al., 2012). The end 
result is disruption of IRF-3 nuclear translocation, a key element of the MAVS-mediated 
IFN synthesis pathway. Additionally, SARS-CoV PLpro has been shown to decrease 
STAT phosphorylation through proteasome-mediated degradation of ERK1 (Li et al., 
2011), a component of the auto- and paracrine signaling pathways leading to ISG 
expression. These studies have largely been done on PLPs from the Betacoronavirus 
genus, and I was interested to understand how conserved these functions were in the 
alphacoronavirus feline infectious peritonitis virus (FIPV). Therefore, I characterized the 
activity of recombinant FIPV PLP2, and demonstrated that it functions as a robust 
protease (Figure 6A), deISGylase (Figure 6B) and DUB enzyme (Figure 6C) and is 
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able to antagonize MDA5-driven IFN transcription (Figure 6D). Thus, the PLP2 from the 
alphacoronavirus FIPV has the same conserved functions as other CoV PLPs, and 
therefore generating an FIPV PLP mutant virus may lead to increased IFN stimulation 
and virus attenuation. 
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Nonstructural protein 15 is a potent antagonist of type I interferon. Another 
effective method used by CoVs to prevent IFN synthesis and ISG activity is to avoid 
detection by PRRs entirely. Recently, our group and others demonstrated that the 
 
Figure 6: FIPV PLP2 is a Multifunctional Enzyme and IFN Antagonist. (A) Ability of 
FIPV PLP to recognize and cleave at the predicted LXGG motif shown by trans 
cleavage assay. Full-length nsp2/3(GFP) constructs co-transfected with empty vector 
(mock), wild-type or catalytic mutant PLP2 in 293T cells. Processed nsp2/3 indicated 
by nsp3-GFP cleavage product by western blot. (B-C) Western blot indicates removal 
of myc-tagged ISG15 conjugates (B) and flag-tagged ubiquitin (Ub) marks (C) 
compared to mock (M) and catalytic (CA) mutant. Cell protein expression (𝛽-actin) and 
recFIPV-PLP2(V5) indicated. (D) WT recFIPV-PLP2 at 100 and 200 ng antagonizes 
MDA5-mediated IFN promotion from ifn/luc reporter. Values presented as percent total 
MDA5-induced ifn/luc promotion. Mean values ±SD from technical triplicate values. 
 
A. 
D. 
Flag-Ub 
 
C. 
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endoribonuclease (EndoU) encoded on the highly conserved nonstructural protein 15 
acts as a dominant interferon antagonist by preventing detection of dsRNA replication 
intermediates (Deng et al., 2019b, 2017; Kindler et al., 2017). In our 2017 study, mutant 
mouse hepatitis viruses (MHV) encoding a hexamer-destabilizing mutation (N15m1) or 
a catalytic site-inactivating mutation (N15m3) in EndoU stimulated high amounts of type 
I IFN during replication in bone marrow-derived macrophages (Figure 7A). The nsp15-
mutant also promoted rapid macrophage apoptosis (Figure 7B-C) and prevented the 
activation of both PKR and the 2’5-OAS / RNaseL systems (data not shown). We 
determined that this virus was attenuated in tissue culture and did not cause pathology 
in mice (data not shown). Further, vaccination with the N15m1 virus was sufficient to 
protect mice from a lethal intracranial challenge of wild-type MHV (Figure 7D) 
demonstrating that nsp15 is a valuable target for generation of live-attenuated vaccine 
strains of other coronaviruses, such as FIPV.   
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A. 
C. 
B. 
D. 
 
Figure 7. EndoU Mutant MHV Stimulates IFN and Protective Immunity in Mice.  (A) 
MHV expressing mutations in EndoU (N15m1 and N15m3) induce early production of 
type I IFN in bone marrow-derived macrophages (BMDMs). BMDMs were infected with 
WT or mutant MHV at an MOI of 0.1. At indicated time points, total RNA was extracted 
and analyzed for mRNA levels of IFN-α11 by qPCR. The levels of mRNA relative to β-
actin mRNA were expressed as 2^-ΔCT [ΔCT= CT(gene of interest) −CT(β-actin)]. Values were 
analyzed using a two-way ANOVA test by time. (B) Representative electron micrograph 
images depicting induction of BMDM cell apoptosis following infection with mutant MHV 
or staurosporine positive control. No apoptosis is observed in mock or WT MHV-
infected BMDMs. Arrows indicate nuclear chromatin condensation, a hallmark of 
apoptosis. (C) B6 BMDMs were infected with WT or mutant MHV at a MOI of 0.1. At 
indicated time points, cell lysates were collected for the detection of cleaved–caspase-3 
(active form), N protein, and β-actin by Western blotting. (D) Primary challenge of 
C57/BL6 mice by N15m1 is protective against secondary challenge with WT virus. For 
the primary infection, mice were challenged intracranially (IC) with WT or N15m1 MHV. 
Primary WT infection was lethal by 10 days post-infection (DPI), whereas all mice 
survived N15m1 infection (data not shown). Surviving mice (N15m1 immunized) were 
challenged 7 weeks later with WT virus IC. All N15m1 immunized mice survived 
whereas all naïve mice succumbed to infection.   
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Final section remarks. From this preliminary work on the IFN antagonism 
functions of a highly conserved coronavirus endoribonuclease, EndoU, and defining the 
multifunctional activities of FIPV PLP2, it was clear that further investigation of IFN 
antagonists encoded by feline coronavirus would positively benefit the field. Feline 
coronaviruses (FCoVs) are arguably the most important veterinary infection in young 
cats and infections can be highly lethal. However, vaccine design and implementation 
has been a perennial challenge and no effective vaccine exists. The long-term goal of 
the FCoV research program in the Baker Lab is to develop an effective, live-attenuated 
vaccine against feline coronavirus through mutations of encoded interferon antagonists 
such as the EndoU and PLP2. The scope of my dissertation, which will be discussed in 
detail below, was to establish basic virology techniques to investigate FCoV in the lab 
and to design genetic, tissue culture and technical tools to facilitate further study of 
these important pathogens.   
Feline Coronaviruses  
Classification and Categorization.  
Feline coronaviruses (FCoV) are members of the Alphacoronavirus genus 
(Nidovirales order; Coronaviridae family; Orthocoronavirinae subfamily) (Figure 1) and 
are closely related to other important veterinary pathogens, such as canine coronavirus 
(CCoV) and transmissible gastroenteritis virus (TGEV), which share relatively high 
genetic similarity. The FCoV genome (Figure 2) is single-stranded, non-segmented, 
positive-sense RNA comprising approximately 29 kilobases. The genome organization 
and predicted RNA structures of a clinical FIPV isolate is described by Dye et al. (Dye 
and Siddell, 2007). Contained on the genome are 11 open reading frames, which 
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encode the two replicase polyproteins pp1a and pp1ab, four structural protein S, E, M 
and N (HE is not present), and two accessory protein regions, ORF3abc and ORF7ab. 
Individual strains of feline coronavirus are further defined by two criteria: serotype, 
based on antigenicity and sequence of the spike protein, and biotype (often referred to 
as “pathotype”) related to cell tropism and the disease characteristics resulting from 
infection (Table 5). The two FCoV biotypes include feline enteric coronavirus (FECV), 
which causes a mild, often sub-clinical enteritis, and feline infectious peritonitis virus 
(FIPV), the etiologic agent of the severe, systemic, immune-mediated disease known as 
feline infectious peritonitis (FIP). Both biotypes can encode either serotype I or serotype 
II (often referred to simply as “type I” or “type II”) spike proteins. The serotype 
designation was initially made on the basis of antibody binding specificity but has 
recently been updated to include sequence- and protease-cleavage site-specific 
designations (Whittaker et al., 2018).  
BIOTYPES SEROTYPE RECEPTOR CELL TROPISM DISEASE 
Feline enteric 
CoV (FECV) 
I Unknown receptor; DC-SIGN co-factor Intestinal, lung 
and kidney 
epithelia 
Subclinical 
enteritis; self-
limiting; 
persistent and 
recurrent II Feline aminopeptidase N; DC-SIGN co-factor 
Feline infectious 
peritonitis virus 
(FIPV) 
I Unknown receptor; DC-SIGN co-factor Myeloid lineage cells: 
monocytes, 
dendritic cells, 
macrophages 
Feline infectious 
peritonitis (FIP): 
high mortality; 
systemic;  
immune-
mediated 
II Feline aminopeptidase N;  DC-SIGN co-factor 
 
Table 5: Feline Coronavirus Biology. 
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Historical Significance.  
Feline coronaviruses are the most common pathogen identified in the feces of 
domestic cats and are widespread with upwards of 90% seropositivity in certain 
domestic feline populations (Hohdatsu et al., 1992; Pedersen, 2009). As a result, feline 
coronaviruses, more specifically FIPV, are considered some of the most significant 
causative agents of communicable disease in feline medicine. The connection between 
a coronavirus and FIP was first suggested by Ward et al. in 1970 (Ward, 1970), and the 
first strains were cultured in autochthonous macrophage tissue derived from an infected 
cat in 1976-1980 (Black, 1980; N C Pedersen, 1976). A permissive cell type, the 
macrophage-like Fcwf-4 cell line, was also described during this time and was used to 
isolate several FCoV strains including the serotype I Black strain, the progenitor to the 
stain used in this dissertation (Black, 1980; Jacobse-Geels and Horzinek, 1983).  
The emergence of FCoV-mediated disease occurred suddenly in the United 
States in the 1950-60s as cases of feline infectious peritonitis (FIP), then termed an 
“important disorder of cats” (Holzworth, 1963), were increasingly diagnosed by 
veterinarians at Angell Memorial Animal Hospital in Boston, MA. Investigators often 
speculate on the conditions that led to the emergence of FCoVs during this time and 
suggest three, possibly connected factors that may have facilitated the widespread 
infection of cats (Pedersen et al., 2009). First is the potential for a speciation event in 
which a related coronavirus, such as CCoV or TGEV, which became widespread in the 
United States just 10 years prior, jumped into the feline population (Haelterman, 1962). 
Indeed, recombination between these related alphacoronaviruses is observed (Benetka 
et al., 2006; Herrewegh et al., 1998; Pedersen, 2009; Wesley, 1999). A prime example 
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of natural recombination is the serotype II FCoV spike protein, which contains 
sequences of both FCoV and CCoV (Herrewegh et al., 1998). Additionally, at least one 
CCoV strain has been demonstrated to not only infect cats, but also enhance FIPV 
infection (McArdle et al., 1992). A second possibility for emergence of highly pathogenic 
FCoVs could stem from an FECV strain variant that is more easily mutable (lower 
“mutagenic barrier”) to FIPV that could have arisen during that time. A final theory 
involves the changes in feline husbandry in the years following WWII. As purebred cats 
became more desirable, the density of mixed-breed cats in animal shelters increased 
along with the number of feral cats. The cohousing of large numbers of cats (and dogs 
for that matter) increases the chance of virus transmission and recombination between 
FCoV strains. Feline leukemia virus (FeLV), another prominent pathogen of cats, also 
emerged during this time and may have acted as a cofactor for FIPV: FeLV infection 
leads to states of immune suppression, a scenario likely to allow development of a 
large, genetically diverse FECV/FIPV quasispecies (Pedersen et al., 2009). It is likely 
that multiple factors, possibly all three introduced here, led to the widespread 
prevalence of feline coronaviruses within the domestic cat population – a dominance 
still observed today. 
Biotypes.  
Feline coronaviruses are broadly grouped into two biotypes (often referred to as 
“pathotypes”), feline enteric coronavirus (FECV) and feline infectious peritonitis virus 
(FIPV). Traditionally, the biotype designation is based on several factors including cell 
tropism, disease progression or severity, and a collection of genetic markers in the S 
and 3c accessory gene (reviewed in Kipar and Meli, 2014; Pedersen, 2014, 2009), 
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although the range of disease signs and clinical outcomes are likely to extend beyond 
these two basic biotype definitions. Intriguingly, FIPV is not transmissible but rather, 
arises directly from FECV during persistent infection of intestinal epithelia. 
FECV is endemic in most healthy domestic cat populations. The virus is shed in 
the feces and urine of infected cats beginning 1 week after introduction. Shedding can 
be transient, recurrent or chronic for months or years. Due to the nature of the 
shedding, the virus is transmitted via the fecal-oral route and is carried into the gut 
where it replicates in mature apical epithelial cells in the intestine. FECV infection of 
cats causes mild enteritis associated with loose stool and diarrhea and commonly leads 
to an asymptomatic, persistent infection (Addie, 2011; Addie et al., 2003; Pedersen et 
al., 2008). Immunity to FECV is tenuous and felines that clear the virus are often re-
infected with the same FECV or a strain with high genetic similarity. Additionally, 
antibody titers to FECV positively correlate with increased virus shedding in the feces, 
and it thought that cell-mediated rather than antibody-mediated immunity is important to 
clear FECV infection. A subset of FECV infections (3-10%) result in progression to 
lethal feline infectious peritonitis (FIP) (Kipar and Meli, 2014; Pedersen, 2014a, 2009), a 
systemic, immune-mediated disease with high mortality rates (Addie and Jarrett, 1992; 
Niels C. Pedersen, 1976). This rapid-onset disease is due to genotypic and phenotypic 
changes in a subpopulation of FECV virions resulting in infection of myeloid-lineage 
cells. The infection of myeloid cells and the onset of FIP defines the second FCoV 
biotype, FIPV. 
FIPV is the second FCoV biotype and is not horizontally transmitted despite 
being highly infectious if isolated and artificially introduced. The lack of transmission is 
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likely due to the shift in tropism away from intestinal epithelia resulting in little to no 
detectable FIPV shed in the feces. Rather, FIPV specifically infects myeloid lineage 
cells including monocytes, macrophages and dendritic cells leading to systemic, 
immune-mediated disease pathology and mortality rates close to 99% (Pedersen, 
2014a).         
The Internal Mutation Theory.  
Characterizing the genotypic and phenotypic requirements for FECV to FIPV 
progression is one of the more well-studied aspects of feline coronavirus biology as it 
has such dramatic effects on disease and mortality. To date, the most widely-accepted 
model is known as the “internal mutation theory” (Poland et al., 1996; Vennema et al., 
1998), which proposes that, within an individual animal, FIPV arises directly from FECV 
due to non-synonymous mutations in spike (S) and the group-specific protein 3C. These 
mutations accumulate and arise independently, not as a “set” and therefore, the 
phenotype resulting from these mutations is critical – mainly productive infection of 
myeloid-lineage cells.   
Numerous factors can contribute to the accumulation of mutations in the FCoV 
genome during infection. All coronaviruses encode both an RNA-dependent RNA 
polymerase (nsp12), which has an error rate of 1 per 10,000 nucleotides, and an ExoN 
(nsp14) with proofreading activity to ensure sequence fidelity. Despite this, when one 
group compared 11 genomes each of FECV and FIPV obtained during natural 
infections, they found that approximately 10% of the FIPV nucleotide identity was 
unique, and did not occur across the FECV genomes tested (Chang et al., 2012; 
Pedersen, 2014a). Further, over half of these mutations occurred in spike while others 
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accumulated in ORF1ab and the accessory genes. The high rate of substitution 
suggests that advantageous mutations accumulate over the course of multiple 
replication cycles and, therefore, both acute and persistent FECV infection can increase 
the density of mutations. A second factor is immune suppression, which can allow 
mutations to arise that would normally be selected against due to a loss of fitness. FIP 
rates are higher in kittens and likely result during the primary FECV infection when virus 
titers are higher, and mutations are tolerated due to a less developed immune system. 
In adult cats with recurrent or persistent FECV infection, perturbations of the host feline 
immune state leading to immune deficiency can allow virus replication to flare up 
(Pedersen, 2009; Poland et al., 1996; Tekes and Thiel, 2016), resulting in the formation 
of a quasispecies and the genetic sampling required for progression to FIPV. Genetic 
recombination amongst co-infecting FECV is the final component that leads to 
accumulation of mutations. This can occur between members of a quasispecies or if a 
cat becomes infected with a different strain of FECV.    
Mutations that accumulate specifically within spike and accessory protein 3c are 
thought to be the determinants of myeloid cell infection and progression to FIPV (Bank-
Wolf et al., 2014; Cham et al., 2017; Chang et al., 2012; Licitra et al., 2014, 2013; 
Regan et al., 2008). The spike protein is the major determinant of cell tropism and 
critical for infection of myeloid cells. This was first demonstrated using FCoV 
recombinants where investigators determined that regions of the FIPV spike were 
absolutely required for macrophage replication (Rottier et al., 2005). Further studies 
done using serotype I laboratory strains determined that spike cleavage can be variable 
between biotypes. FECV-UCD strain recovered from experimentally-infected cats 
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maintained the S1/S2 furin cleavage site, while an FIPV strain, UCD1, lost this furin 
cleavage site exposing a heparan sulfate binding motif allowing spike interaction with 
polysaccharide residues (de Haan et al., 2008), which may impact cell tropism. In 
parallel using serotype II FCoVs, Regan et al. identified differential roles for pH and 
cathepsin cleavage during entry of FECV compared to FIPV (Regan et al., 2008). This 
study demonstrated that specific S cleavage site sequences and, by extension, specific 
host proteases are necessary to FCoV tropism. In an important study, another group 
compared the genomic sequences of 11 FECV-FIPV pairs as well as 100s of individual 
strains and found two mutations in the fusion peptide of spike S2, which were present in 
96% of FIPV and none of the FECV strains (Chang et al., 2012). The following year, 
Licitra et al. identified that 66% of FIPV strains evaluated carried unique mutations in 
the S1/S2 cleavage site, which altered the efficiency of cleavage by host furin (Licitra et 
al., 2013). Interestingly, several of these mutations at or around the S1/S2 cleavage site 
were also observed in non-pathogenic strains of FECV suggesting that this may be an 
early step in acquiring myeloid tropism. Together, these reports demonstrate that 
mutations to S that alter either spike cleavage or fusion are associated with or directly 
lead to myeloid cell tropism.    
 In approximately 20% of FECV primary infections, FECV replication in 
macrophages is observed without severe disease progression (Pedersen, 2009; Poland 
et al., 1996). This indicates that other mutations need to occur in order to cause FIP and 
simple infection of macrophages is not sufficient. The accessory protein 3C, produced 
from the polycistronic ORF3 region, is the second component that contributes to FCoV 
biotype transition, although the exact function of 3c is unknown. Across several studies 
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investigators determined that approximately two-thirds of sequenced FIPV strains have 
mutations resulting in a truncated 3C protein, with the other one-third carrying extensive 
mutations at the 3’ end (Bálint et al., 2012; Chang et al., 2012, 2010, Pedersen et al., 
2012, 2009). The authors collectively suggested that truncation of the 3C protein (or 
significant mutation) is critical for macrophage tropism as truncated 3c coding 
sequences were only observed in myeloid cell-isolated strains and not in strains derived 
from fecal or intestinal materials. Further, Hsieh et al. demonstrated that expression of 
full-length 3C in feline macrophage-like Fcwf-4 cells significantly reduced the titers of 
FIPV strains encoding truncated 3c genes (Hsieh et al., 2013). Interestingly, FECV 
intestinal isolates have been identified with collections of mutations at the 3’ end of the 
full-length 3C protein coding sequence and may represent a transition-state virus 
population. 
Collectively, the comparative studies of FCoV spike and 3C support the original 
proposal of the “internal mutation theory” in which FIPV arises directly from FECV: i) 
perturbations of feline immune competency lead to bursts of FECV quasispecies 
replication allowing new mutations to be sampled without negative selection; ii) spike 
mutations accumulate in a subset of FECV virions, allowing attachment and entry into 
myeloid cells; iii) truncations of the 3C protein enhance replication within these myeloid 
cells providing a competitive advantage; iv) infected myeloid cells traffic to various 
tissue sites leading to systemic infection and progression to FIP.    
Interestingly, following transition, the FIPV genome is relatively stable with an 
observed mutation rate of 5-6x10-6 over 50 passages (Phillips et al., 2013). This 
demonstrates that not only are large numbers of mutations tolerated (relative to the 
 
 
 
81 
 
parental FECV), but also illustrates the large degree of genetic disruption that can occur 
to the FCoV genome before significant disruptions to virus fitness occur. Finally, this 
observation underscores the high degree of genetic plasticity and variability observed 
between FCoV isolates and the various states of transition isolates may exist in.  
Serotypes.  
The feline coronavirus spike (S) glycoprotein is largely responsible for 
determining host range and cell tropism as it mediates both receptor binding and 
membrane fusion. These large, trimeric structures have extensive ectodomains, which 
represent the main surface antigen and binding target of FCoV-specific antibody 
responses. As a result, characterizing FCoVs based on antigenicity of the spike protein 
was an early method used to group new strains, and has revealed the existence of two 
such serotypes: serotype I and serotype II (Hohdatsu et al., 1991a; Pedersen et al., 
1984). Thus, FECV and FIPV strains can be defined as either serotype I or serotype II. 
Serotype I FCoVs, which utilize an unknown host receptor for entry, are widespread and 
are responsible for the majority (70-90%) of natural infections. Serotype II FCoV strains, 
which round out the other 10-30% of infections, express a naturally-occurring 
recombinant of feline and canine coronavirus type I S proteins (Addie et al., 2003; 
Benetka et al., 2004; Herrewegh et al., 1998; Hohdatsu et al., 1992; Kennedy et al., 
2002). Serotype II viruses use feline aminopeptidase N (fAPN), a cell-surface 
metalloprotease distributed in intestinal, lung and kidney epithelia, as an entry receptor. 
Both serotypes are known to use dendritic cell (DC)–specific intercellular adhesion 
molecule (ICAM) grabbing nonintegrin (DC-SIGN), a C-type lectin, as an entry co-factor 
enabling entry into macrophages, however this factor is not sufficient for entry (Regan et 
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al., 2010).  A commendable number of studies focus on type II FCoV as these viruses 
are much more easily propagated in cell culture than serotype I FCoVs. However, it is 
difficult to know how accurately type II laboratory strains reflect natural infections with 
type I viruses given that the bulk of what is known about type I is extrapolated from 
studies using a type II virus.  
With the advent of inexpensive high-throughput sequencing and FCoV strain 
isolation it has become increasingly clear that the traditional serotype designation is not 
sufficient to describe the large amount of FCoV strain variation. Recently, a new method 
to classify FCoV strains has been proposed to update the serotype designations and 
improve the taxonomy of alphacoronaviruses (Whittaker et al., 2018). Whittaker et al. 
argue that grouping FCoV based on spike antigenicity alone inappropriately implies that 
only minor biologic differences separate these viruses. However, it is now widely 
appreciated that major biologic differences do exist between serotypes including 
severity of associated pathogenesis (Pedersen, 2014a) and usage of cellular 
components, such as cholesterol, for replication (Takano et al., 2016). Additionally, 
serotype I and II FCoV spike proteins engage different host cell entry receptors (Dye et 
al., 2007; Tresnan et al., 1996), contain unique cleavage sites on S that require different 
host proteases for cleavage, and can even differ in the site of virus membrane fusion: 
surface versus endosomal. (Licitra et al., 2013; Whittaker et al., 2018). Therefore, rather 
than defining FCoV simply on antigenicity of S, Whittaker et al. propose to further 
categorize FCoVs into two clades by combining function-based data (e.g. receptor 
binding; protease cleavage) with S-protein sequencing (Whittaker et al., 2018). Although 
this method of categorizing FCoV strains is objectively more accurate, for the sake of 
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continuity, this dissertation will refer to strains based on their original serotype 
designations.   
FIPV Pathogenesis and FIP Clinical Features.  
FIPV primarily infects myeloid cells such as monocytes, macrophages and 
dendritic cells. During artificial infection, FIPV replication in macrophages progresses 
slowly over 2 weeks and is critical for determining disease progression. In rare cases, 
the feline mounts a strong, rapid cell-mediated immune (CMI) response, containing the 
virus within the mesenteric lymph nodes and eventually clearing it. However, in the 
majority of cases the CMI is not strong enough and the virus titer, distribution and naïve 
macrophage infection rate increase dramatically. Coincident with the rise in FIPV viral 
load is the onset of detectable viruses-specific antibody titers in the blood between 10-
21 days post-infection. Although antibodies have been shown to neutralize virus in vitro, 
during natural infection, antibody-dependent enhancement (ADE) of disease is 
observed. In this case, antibodies specific to S (and commonly the E protein) prevent 
engagement of the virus receptor; however, these large antibody-virus complexes are 
endocytosed via FcR-mediated uptake and accumulate in the late endosome and virus 
replication proceeds. 
 FIP can present in two forms depending on the dominant immune response to 
infection. The more common “wet” disease occurs when humoral immunity is strong and 
CMI is absent. This wet disease is effusive and results in inflammation of the visceral 
serosa and omentum with exudation into the abdomen. This is visualized by significant 
enlargement of the body cavity due to intestinal distension and ascites fluid buildup. The 
wet systemic disease results from the development of so-called pyogranulomas, a 
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collection of protein-rich edema fluid containing T and B lymphocytes and neutrophils 
that surround a large number of FIPV-infected macrophages, around different organ 
venules. In response to pyogranuloma formation, additional macrophages are recruited, 
which exacerbate inflammation with the release of cytokines and the activation of the 
classical complement cascade. Prolonged inflammation and complement activation 
cause microhemorrhages and red blood cell lysis. Infected cats usually succumb to FIP 
several days after the development of pyogranulomas.  
 The rarer form of FIP, known as “dry” disease occurs when humoral immunity is 
strong and CMI is present, but weak. In this case, the initial infection is more contained, 
but not completely eliminated thus the disease progresses more slowly over weeks to 
years. The dry disease presents with more traditional granuloma formation and 
involvement of parenchymatous organs such as the kidneys, mesenteric lymph node, 
bowel wall, liver and most commonly the eyes and central nervous system. Granulomas 
form when B and T lymphocytes surround around a small number of macrophages with 
little to no replicating virus. Unlike the wet disease, the inflammation is low-intensity and 
chronic rather than massive and acute. Complications due to prolonged inflammation 
occur in multiple organ systems and usually involve paralysis and seizure. Although the 
dry form progresses more slowly, the mortality rate is the same as the wet form – nearly 
99% fatal.  
 Due to the degree of immune suppression during FIPV infection, co-infections 
are common and lead to additional complications, accelerated disease and enhanced 
transmission of FECV. Feline leukemia virus (FeLV) infection is observed in one-half to 
one-third of FIPV cases and other coinfections include opportunistic bacterial pathogens 
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and parasites such as Toxoplasma gondii. Several groups have suggested that these 
co-infections, specifically of FeLV, which can induce immune suppression, can enhance 
progression to FIPV in co-housed cats.   
T and B Cell Responses and Effects on FIP Progression.   
FIP is defined as an “immune-mediated” disease meaning that the degree of 
associated pathology is largely due to differences in the timing strength and type of the 
immune response. Significant imbalances between intrinsic, T and B cell immune 
responses is the most widely accepted reason for the inability of cats to resist FIPV 
infection and the resulting > 90% mortality rate (de Groot-Mijnes et al., 2005; Kipar and 
Meli, 2014; Pedersen, 2014a, 2009).  
Although rare, positive FIP outcomes are associated with rapid cell-mediated 
immunity (CMI) involving cytotoxic T lymphocytes and natural killer (NK) cells. A strong 
CMI-response limits virus growth through direct killing of virus-infected cells, mostly 
macrophages, in the mesenteric lymph node and prevents the massive upregulation of 
pro-inflammatory cytokines and granuloma formation that mediate disease (Pedersen, 
2014a). Increased IFN-𝛾 production, a major product of activated CD8+ T cells and NK 
cells, is associated with protection in cats with natural FIPV infection and was observed 
in peripheral blood mononuclear cells (PBMCs) taken from experimentally-infected cats 
that survived FIPV challenge (Satoh et al., 2011). Surviving cats were also found to 
have high levels of IL-10, an important immune-suppressing cytokine produced by T 
regulatory cells. Additional evidence supporting the importance of CMI comes from 
examination of cats that succumb to FIPV infection. In these cases, CD4+ and CD8+ T 
cells and NK cells were found to be depleted in peripheral blood of moribund cats with 
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natural FIPV infections (Vermeulen et al., 2013). T regulatory cells, which produce IL-10 
and function to regulate the degree of inflammation in response to infection, were also 
found to be depleted suggesting that elimination of these cells may significantly 
contribute to unregulated inflammation associated with severe pathology (Vermeulen et 
al., 2013). Finally, transcriptional profiling of PBMs recovered from FIPV-infected 
animals demonstrated enrichment of the PD-1 / PD-L1 factor pair (Harun et al., 2013), 
which is involved in repression of cytotoxic T cell responses, further highlighting the 
importance of cell-mediated immune responses in controlling FIPV.  
The majority of FIPV infections result in death of the infected animal and are 
associated with depletion of T cells resulting in inefficient CMI, systemic virus replication 
and unrestricted inflammation (Kipar et al., 2006; Pedersen, 2014a). Indeed, moribund 
cats naturally infected with FIPV were found to have a higher proportion of activated 
macrophages and neutrophils (Kipar et al., 2006; Takano et al., 2009b), increased 
serum levels of macrophage differentiation / stimulation factors including IL-6, GM-CSF, 
M-CSF and IL-1𝛽, and reduced immune regulatory factors such as IL-10 and IL-12 
(Kipar et al., 2006). Macrophages from moribund FIPV-infected animals also expressed 
high levels of B-cell activation markers including IL-6, CD40 and B cell activating factor 
(BAFF), suggesting that B cells are somehow involved in FIP progression (Takano et 
al., 2009a). Indeed, activation of B cells and production of FIPV-specific antibodies 
(humoral immunity) is strongly associated with rapid disease progression though a 
process called antibody-dependent enhancement (ADE) (Pedersen and Boyle, 1980; 
Takano et al., 2008; Weiss and Scott, 1981). FCoV-specific antibodies are observed 
during both FECV and FIPV infections (Pedersen, 2009) and are directed against 
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surface epitopes on the FCoV S and E proteins. In tissue culture, these antibodies lead 
to virus neutralization; however, these same neutralizing sites were also responsible for 
directing ADE in animals – a fact that has complicated vaccine design for decades 
(Takano et al., 2011).  One group demonstrated the negative impact of these antibodies 
experimentally by injecting subclinically-infected cats with serum obtained from cats fully 
infected with either FECV or FIPV (Takano et al., 2008). This passive immunization led 
to serotype-matched-specific ADE and rapid disease progression compared to control.  
Several groups have proposed models of how ADE of FIP occurs. Studies by 
Dewerchin and colleagues determined that macrophages infected with FIPV expressed 
viral antigens on the cell surface (Dewerchin et al., 2008). When antibodies bound these 
antigens, the antigens were rapidly internalized (Dewerchin et al., 2008, 2006). The 
internalization of these cell surface antibody-antigen complexes reduces to chance of 
virus-infected macrophages to undergo antibody-dependent cell-mediated cytotoxicity 
(ADCC), a process in which infected cells are actively killed by surveying NK cells 
through interactions between NK cell Fc receptors (FcR) and a cell-bound antibody. 
Thus, FIPV-infected macrophages survive and continue to produce virus. A second, 
more traditional model of ADE was also proposed by this group (Dewerchin et al., 
2008). During in vivo infection, it was observed that large antibody-virus complexes 
were endocytosed by macrophages, accumulated in mature endosomes and led to 
productive infection. This internalization process was dependent on FcR-𝛾 on the 
surface of the macrophage, which allows internalization of viruses by CoV-receptor 
independent process. This provides some clarity on how the same virus epitope could 
lead to virus neutralization in tissue culture, but ADE in vivo – likely these “neutralized” 
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viruses do not require surface-level spike-receptor engagement, but rather gain entry 
through endocytosis of the entire complex. By either method, FIPV is able to enhance 
access to macrophages and maintain productive infection without triggering targeted 
cell death.  
The complex relationship between innate and adaptive responses and the 
immune-consequences that lead to FIP development need to be strongly considered 
during vaccine design. For this reason, vaccine development had been slow and viewed 
more as a pipedream, and much more emphasis has been placed on development of 
therapeutics (see below). However, new studies from our group on generating live-
attenuated CoV vaccines through generation of hyper-interferon inducing (HII) strains, 
and the research presented in this dissertation may overcome some of the previous 
challenges to designing an effective FIPV vaccine.   
Current Therapeutic Options.   
A large number of studies have looked at the efficacy of various therapeutic 
compounds in treating FIP. These compounds fall into three main categories: i) immune 
modulatory compounds targeting the rapid systemic inflammation arising during FIPV 
infection; ii) compounds targeting cellular pathways usurped by the virus during 
replication; iii) direct-acting antiviral inhibitors that specifically block virus replication.  
 As pathology associated with FIPV infections is mediated by an overactive 
inflammatory response, it is reasonable to predict that targeting these immune 
responses may decrease disease severity. Reduced levels of TNF-alpha, a 
proinflammatory host factor, were shown to be associated with positive outcomes in 
cats with natural FIPV infections (Kipar et al., 2006), however, treatment with the anti-
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TNF-alpha inhibitor Pentoxifylline failed to reduce FIP-associated mortality (Fischer et 
al., 2011). Another group pre-treated cats with type I IFN, which has pleiotropic antiviral 
effects, in an attempt to prime antiviral innate immune responses. This prophylactic 
administration of type I IFN was also ineffective at reducing mortality rates following 
FIPV infection (Weiss et al., 1990), an observation consistent with the presence of IFN 
signaling and ISG antagonists present in FCoVs (Dedeurwaerder et al., 2014, 2013). 
Interestingly, combining IFN treatment with peptides mimicking the FIPV spike heptad 
repeat (HR)-domain (predicted entry inhibitors) had a synergistic antiviral effect on 
reducing serotype II FIPV infection (Liu et al., 2013) suggesting that type I may be 
effective as a treatment supplement. These experiments, however, were performed in 
tissue culture and it is unclear if the tandem IFN/HR-peptide treatment would be 
effective in vivo.  
 Several groups have demonstrated effective FIPV treatment by employing 
compounds that target cellular processes. Takano and colleagues observed that type I, 
but not type II FIPV replication requires the presence of plasma-membrane cholesterol 
(Takano et al., 2016) and predicted that this may be a cellular target of antiviral 
treatment. Indeed, a follow-up study demonstrated that pre-treatment of cells with 
U1866A, an inhibitor of cholesterol transport, caused intracellular cholesterol 
accumulation and strong inhibition of type I FIPV replication (Takano et al., 2017). This 
study also reported that the antiviral activity of U1866A was reversed by the HDAC 
inhibitor Vorinostat, which reverses the negative effects of U18666A on the host protein 
Niemann-Pick C1 (NPC1) suggesting a possible role of NPC1 in type I FCoV 
replication. Further evidence for the role of NPC1 was recently demonstrated (Takano 
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et al., 2019). This study determined that therapeutic treatment of infected cats with the 
antifungal drug Itraconazole, which blocks NPC1, had significant antiviral activity 
against serotype I, but not serotype II FIPV. These studies represent exciting new 
avenues of drug development and treatment of cats with FIPV; however, as they target 
cell-intrinsic properties, further investigation will be needed to determine the long-term 
safety of these drugs.  
 The most promising anti-FIPV therapeutics are the class of small-molecule 
inhibitors with direct-acting antiviral activities. Several of these compounds have been 
developed and specifically inhibit the FIPV 3C-like protease (3CLpro), a viral enzyme 
absolutely required for CoV replication. St. John et al. investigated the inhibitory 
potential of several peptidomimetic compounds, which impersonate the natural peptide 
cleavage target and non-covalently associate with the active site of 3CLpro (St. John et 
al., 2015). Two such compounds were found to inhibit purified recombinant FIPV 
3CLpro with 50% inhibitory concentration (IC50) values in the sub-micromolar range. An 
exciting study was recently published by Kim et al., which demonstrated near-full 
reversal of FIP upon treatment with another 3CLpro inhibitor, GC376 (Kim et al., 2016). 
Investigators experimentally infected cats with serotype I FIPV (m3c-2 strain) and 
administered doses of GC376 after development of clinical signs of FIP and observed 
recovery of treated cats after several weeks. It should be noted that GC376 is a small, 
dipeptidyl compound containing a catalytic warhead, which covalently binds the catalytic 
cysteine reside in the active site of 3CLpro and may have unintended off-target effects 
on cellular proteases. Additionally, the compound has reduced access to the CNS due 
to the blood-brain barrier and therefore may be ineffective at treating the dry form of 
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disease. Although exciting, further investigation of this inhibitor will be needed before 
wide-spread use is adopted by veterinary professionals.  
 Much progress has been made in developing effective therapeutics to treat cats 
infected with FIPV. However, realistic and effective treatment of sick cats would likely 
require near-immediate recognition of FIP-like disease symptoms, multiple injections 
and a substantial investment by drug companies to synthesize large quantities of 
compounds, all factors that drive up the total cost of treatment. Additionally, these 
methods do not address the high seroprevalence of FECV in domestic cat populations 
and cannot prevent new infections with subclinical strains. The gold standard in the field 
remains the development of an effective vaccine against serotype I FCoV allowing long-
term and widespread immunity. Such a vaccination would be effective at preventing the 
spread of the virus, decrease global seroprevalence and allow maintenance of isolated 
FCoV disease using the more expensive antivirals. Over the decades, however, 
developing a vaccine for serotype I FIPV has been a significant challenge to the field 
and as a result of numerous factors, discussed in the following section, no such vaccine 
exists…yet.     
The Challenges and Value to Investigating Serotype I Feline Coronavirus  
Overview.   
Serotype I viruses account for the bulk (80-90%) of naturally occurring FCoV 
infections in domestic cats and are considered one of the most important veterinary 
animal pathogens. Investigating type I FCoV in a controlled laboratory setting is 
required to understand the basic virology of natural infection, characterize clinical 
isolates, test novel therapeutics, and develop effective feline vaccines. Additionally, 
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serotype I FCoVs provide an important model system in which to study the 
pathogenesis, immune regulation, and basic virology of the Alphacoronavirus genus, 
which comprises several under-studied yet economically-important animal 
coronaviruses such as TGEV and PEDV. However, a number of challenges to studying 
serotype I FCoVs have burdened the field for decades and include inefficient methods 
of virus isolation and growth in tissue culture, limited permissive cell types, the lack of a 
known receptor and significant variation between clinical and lab-adapted virus strains. 
As a result, many groups have focused on the less prevalent (<10%) type II FCoV as 
these viruses are much more easily propagated. However, despite the utility of the type 
II FCoVs it is difficult to know how accurately type II laboratory strains reflect natural 
infections with type I viruses given that the bulk of what is known about type I is 
extrapolated from studies using a type II virus. Thus, more needs to be done to facilitate 
research of serotype I feline coronavirus in order to overcome the challenges described 
in this section.    
Virus Isolation and Strain Variation.   
 Since the early 1980’s, a number of groups have isolated feline coronavirus 
strains representing both bio- and serotypes (Table 6). As mentioned, most groups 
study serotype II strains due to their rapid growth in tissue culture (TC). For example, 
the widely used FECV 79-1683 and FIPV 79-1146 viruses have been TC-adapted and 
readily propagate in cell lines expressing feline APN, such as Crandell Rees Feline 
Kidney (CRFK) cells (Miguel et al., 2002). Although there is debate on how “natural” 
these strains are, TC-adaptation does not appear to effect the patho-biology of the 
serotype II viruses as strains lead to the same illness in cats from which they were 
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derived (Pedersen, 2014a, 2009). In addition, several serotype II FCoV including the 
C1Je and NTU156 strains, have been maintained as primary clinical isolates (CI) by 
passage in felines (Dye and Siddell, 2007; Lin et al., 2013). This technique preserves 
the natural “clinical” virus phenotype, avoids any tissue-culture adaptations and allows 
experimental control of natural serotype II infection.  
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BIOTYPE TYPE STRAIN VIRULENCE SPECIMEN ACC # REFERENCE(S) 
FECV 
I 
UCD Avirulent CI - (Pedersen et al., 1981b) 
RM Avirulent CI - (Hickman et al., 1995) 
Felix Avirulent Rev Gen MG893511.1 (Ehmann et al., 2018) 
II 79-1683 Avirulent TC Adapt JN634064.1 (McKeirnan et al., 1981) 
FIPV 
I 
TN406-LP High CI - (Black, 1980) 
TN406-HP Avirulent TC Adapt  (Pedersen and Black, 1983) 
Black 
(TN406) Avirulent Rev Gen EU186072 (Tekes et al., 2008) 
UCD1 High Cat Tissue - (Pedersen et al., 1981a) 
UCD2 Avirulent TC Adapt - (Pedersen and Floyd, 1985) 
UCD3 - TC Adapt - (Pedersen and Floyd, 1985) 
UCD5 - CI - (Herrewegh et al., 1995) 
UCD8 FIP (+) CI - (Hickman et al., 1995) 
UCD9 FIP (+) CI; FECV-
RM infected 
cat with FIP 
- 
(Poland et al., 1996) 
UCD10 FIP (+) - 
Wellcome - TC Adapt - (O’Reilly et al., 1979) 
KU-2 - - D32044 (Hohdatsu et al., 1991b; Motokawa et al., 1995) 
m3c-2 FIP (+) Cat Passed - (Kim et al., 2016) 
II 
79-1146 High TC Adapt. DQ010921.1; NC002306 (Dye and Siddell, 2005) 
79-1146 High Rev Gen - (Tekes et al., 2012) 
UCD4 Moderate TC Adapt - (Pedersen and Floyd, 1985) 
UCD6 - CI - (Herrewegh et al., 1995) 
NOR15 High TC Adapt - (Evermann et al., 1981) 
DF2 - Rev Gen JQ408981 
(Bálint et al., 2012; 
Christianson et al., 1989; 
Evermann et al., 1981) 
DF2 (ts) Avirulent Vaccine  DQ286389.1 (Taboni et al., 2007) unpub 
C1Je FIP (+) CI DQ848678.1 (Dye and Siddell, 2007) 
NTU156 FIP (+) CI GQ152141 (Lin et al., 2013) 
 
Table 6: Feline Coronavirus Strains. Abbreviations: GenBank accession number (Acc 
#); TN406-Low Passage (LP), TN406-High Passage (HP), DF2-temperature- sensitive 
strain (ts); Causes FIP without indicated severity [FIP (+)]; Clinical isolate (CI), Reverse 
genetics strain (Rev Gen), Tissue culture adapted strain (TC Adapt); Unpublished 
sequence submitted to GenBank [(Taboni et al., 2007) unpub]. 
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The same cannot be said of serotype I FCoV strains, however. Serotype I FCoVs 
do not readily adapt to growth in cell culture and the few strains that have been 
successful isolated, required either numerous rounds of passage before cytopathic 
effects were observable [e.g.(Amer et al., 2012; Black, 1980)] or use of entry-
enhancement techniques such as spinoculation (Hohdatsu et al., 1995) or addition of 
DEAE-dextran or trypsin during virus adsorption (Jacobse-Geels and Horzinek, 1983). 
As a result of forcing virus growth in an atypical environment, TC-adapted type I FIPV 
strains lose in vivo pathogenicity and do not cause FIP in experimentally-infected cats 
(Pedersen and Black, 1983; Thiel et al., 2014). This suggests two things: first– that the 
current isolation techniques used to obtain serotype I viruses likely select for a subset of 
virus genotypes that do not represent the majority; and second– significant genomic 
mutations must be obtained in order for serotype I FCoVs to adapt to growth in the 
currently available feline cell lines. Both of these factors distance the lab-adapted 
strains from the parental clinical isolates and therefore complicate controlled 
investigations of virus attenuation, vaccination and evaluation of therapeutics. At least 
one type I FIPV strain, mc3-2, has maintained a virulent phenotype by continuous 
passage in cats (Kim et al., 2016) suggesting that preserving the genotype of FIPV is 
achievable of cultured appropriately. 
The issues surrounding type I FCoV isolation are exemplified by the prototypic 
serotype I FIPV strain Black, also referred to as TN406– one of the first type I FIPV 
isolated (Black, 1980). As this virus was derived from a cat with FIP, the low-passage 
(LP) Black strain remains highly pathogenic when introduced back into an animal 
(Black, 1980). However, as is observed with all TC-adapted type I FIPV strains, the 
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high-passage (HP) Black virus lost all pathogenicity following TC-adaptation (Pedersen 
and Black, 1983). More recent studies using variants of FIPV Black produced by 
reverse genetics further demonstrated that this virus was avirulent and had acquired 
numerous mutations in the spike and accessory genes (Thiel et al., 2014). Interestingly, 
all known serotype I FCoVs that replicate in TC lose in vivo virulence and accumulate 
significant mutations in spike and the ORF7 accessory protein region (Kipar and Meli, 
2014; Pedersen, 2014a, 2009). While mutations in the spike likely affect receptor or 
host-protease usage, it is unclear how these and the ORF7 mutations affect 
pathogenesis. At least one group has suggested that ORF7 is an antagonist of type I 
interferon (Dedeurwaerder et al., 2014), indicating that TC-adaptation may result in 
viruses that are less resilient to innate immune responses.   
 As a final note, it is well known that natural FIPV infection produces a viral 
quasispecies in feline tissues comprising numerous genetic variations and stages of 
progression from FECV to FIPV. As a result, virus isolation offers only a fraction of the 
total FIPV strain diversity and, further, results in large strain-to-strain variation between 
isolates. This, paired with the mutations required for TC-adaptation, make investigating 
type I FCoV complicated and ultimately inconsistent. Thus, better isolation techniques 
and permissive cell types need to be identified in order to replicate clinical serotype I 
FIPV isolates without the requirements of TC adaptation.   
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Permissive Cell Types.   
 The cell types available to study serotype I FCoV are limited and this has been 
one of the biggest hurdles to studying these viruses in the lab (Table 7). Unlike serotype 
II FCoV, which replicate in cells that naturally or ectopically express feline APN, the 
receptor for type I FCoVs is not known, thus permissive cell types are difficult to identify, 
and the receptor cannot be simply expressed in common cell lines such as BHK or HEK  
293Ts. Several TC-adapted strains of type I FIPV, particularly the Black strain, replicate 
in two continuous cell lines, the feline airway epithelial cell line, AK-D, and the feline 
macrophage-like cell line felis catus whole fetus 4 (Fcwf-4). As epithelial cells are an 
unnatural replication site for FIPVs, the immediate issue with AK-D cells is that they do 
CELL NAME CELL TYPE TYPE I FIPV 
TYPE II 
FIPV REFERENCES 
Crandell Rees 
Feline Kidney 
(CRFK) 
Immortalized feline 
kidney No Yes 
(Miguel et al., 2002) 
AK-D Feline airway epithelia Yes;  Low titer -  
(Millet and Whittaker, 
2015; Benjamin W. 
Neuman et al., 2006; 
Pedersen, 2009) 
Fcwf-4  Feline macrophage-like  Yes;  Low titer Yes 
(Alazawy et al., 2011; 
Jacobse-Geels and 
Horzinek, 1983) 
Peripheral blood 
mononuclear 
cells (PBMCs) 
Feline Primary cells; 
monocytes, lymphocytes, 
macrophages, others 
Yes Yes (Harun et al., 2013) 
Macrophages 
Feline Primary; 
Bone-marrow isolated or 
stem cell-derived 
Yes Yes 
(Gow et al., 2013; 
O’Brien et al., 2018; 
Rottier et al., 2005; 
Sprague et al., 2005) 
Dendritic Cells 
Feline Primary; 
Bone-marrow isolated or 
stem cell-derived 
Yes Yes (Bienzle et al., 2003; van Berne, 2008) 
 
Table 7: Cell Types Permissive to FIPV Infection. 
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not reflect a normal infection route and it is likely that TC-adaptations that allow type I 
viruses to replicate in these cells have adverse effects on virus pathology and shift 
viruses away from a clinically-important phenotype. Fcwf-4, another other permissive 
cell line, was originally isolated from the peritoneal cavity of a cat infected with FCoV. 
This continuous cell line was further characterized as “macrophage-like” due to active 
phagocytic activity, and the presence of Fc receptors and non-specific esterases 
(Jacobse-Geels and Horzinek, 1983). Compared to AK-Ds, Fcwf-4 cells represent a 
more biologically-relevant cell type in which to study serotype I FCoVs. Indeed, many 
groups have used these cells to study both type I and type II FCoVs and they have 
been an important tool for recovering type I FIPV strains and modeling feline 
coronavirus infection in macrophages. The type I FIPV Black strain, for example, was 
originally isolated using Fcwf-4 cells (Black, 1980), and others, such as strain DF2, 
replicate in Fcwf-4 cells as well. However, these cells have been used to study type I 
FCoVs more out of necessity than utility and have a number of associated issues. First, 
previous studies report that type I FIPV grows to low titers (104 - 105 pfu/mL) in these 
cells relative to type II (>106 pfu/mL) (Tekes et al., 2012) and can be measured by 
determining either the 50% tissue culture infectious dose (TCID50) (Ramakrishnan, 
2016; Reed and Muench, 1938) or by plaque assay (Takano et al., 2017; Tekes et al., 
2012, 2010). Second, type I virus growth kinetics are variable in Fcwf-4 cells, requiring 
between 15-96 h to achieve maximum titer (Jacobse-Geels and Horzinek, 1983; O’Brien 
et al., 2018; Tekes et al., 2012, 2008)). Third, some reports suggest that type I viruses 
produced in Fcwf-4 cells are highly cell-associated (Jacobse-Geels and Horzinek, 1983; 
Pedersen et al., 1984) and multiple freeze-thaw cycles may be required to recover virus, 
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which further reduces the overall titer. Finally, Fcwf-4 cell doubling time is slow (>31 h) 
(American Type Culture Collection, 2013), cells do not grow to high density and begin to 
die after several passages. These growth issues make advanced genetic techniques 
such as Crispr/Cas gene editing, which will be critical to evaluating attenuated FCoV 
strains, unrealistic. Thus, although serotype I FCoVs grow in Fcwf-4 cells, additional cell 
types are needed that grow viruses to high titer and are amenable to genetic 
manipulation.  
 Feline primary cells including total PBMCs, macrophages, and dendritic cells are 
the most natural cell types in which to grow and isolate serotype I FIPV strains. As 
these are a natural cell type, limited TC adaptations are required for sustained virus 
replication and the high virulence FIPV genotype is maintained. Certain type I strains 
such as UCD1, -2, and -3 have been successfully cultured in these ex vivo feline tissues 
and re-introduced into cats to cause FIP (Pedersen et al., 1981a; Pedersen and Floyd, 
1985). However, use of these cells is limited by several factors: first, due to high 
seroprevalence, acquiring FCoV-free tissue samples is challenging without an 
established colony of specific pathogen (SPF)-free cats and deriving immune cells from 
bone marrow can take up to two weeks; second, primary cells usually cannot be 
passaged and new cells need to be plated for each experiment leading to increased 
variability, and finally, many genetic techniques such as gene expression or Crispr/Cas 
gene editing cannot be performed in primary cell further limiting the scope of available 
experiments.    
 While each cell type discussed here is important for different aspects of FCoV 
research, ultimately a biologically-relevant, genetically tractable, continuous cell line that 
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replicates high titers of type I FCoVs is needed. Although this seems like a lofty 
challenge, such a cell line is critical for the discovery of the type I FCoV entry receptor, 
recovery of clinical isolates without TC-adaptation, determining the function of FCoV 
proteins that antagonize innate immunity and for intensive study of vaccine strains 
developed through rational design. One of the goals of this dissertation was to identify 
and characterize such a cell line to enable future research of these important animal 
pathogens.  
Objective of Dissertation Research. 
Since the 1980’s FCoVs have been predominantly studied in veterinary settings 
where the focus was on diagnosis of sick cats and describing the pathogenesis of 
strains isolated in-house using any cells available. In this environment, researchers 
emphasized use of protocols and cells that allowed growth of the virus and as a result, 
the nearly three decades of reports and reviews contain a high degree of variability 
amongst the basic virology techniques, cell lines and virus strains characterized. This 
issue of variability has led to much confusion and over-complication of the literature 
making study of serotype I FCoVs an exercise in extrapolation of data collected from 
either highly-diverged type I lab strains or serotype II viruses rather than well-controlled 
experimentation of biologically-relevant type I viruses in a natural environment.  
The long sought-after goal of FCoV research is the development of a broadly-
effective type I vaccine to protect young kittens from developing FIP. Immunization 
against serotype I FIPV is likely to be the most effective method to prevent this disease 
as this represents the majority of circulating virus (Pedersen, 2009), but due to the 
issues discussed in this section, development of a type I FIPV vaccine has been 
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challenging and ultimately unsuccessful (Kiss et al., 2004; Pedersen, 2014b, 2009). 
Furthermore, conventional vaccination methods using inactivated, high-passage or 
temperature-sensitive viruses have been restricted to serotype II FCoV [e.g. (Haijema et 
al., 2004)]. Indeed, Felocell® FIP, the only currently available FIP vaccine, contains a 
temperature-sensitive version of the serotype II virus, DF2. However, this vaccine fell 
out of favor as it failed to protect against the dominant, circulating serotype I virus. Thus, 
the challenge posed to researchers in the field, and the ultimate goal of this dissertation, 
is to develop a set of “tools” – methods, reagents, genetically-tractable cell types, that 
will facilitate efficient investigation of serotype I FCoV. Here, I describe my efforts to i) 
characterize a new variant of Fcwf-4 cells that rapidly produce high-titers of cell-free 
FCoVs comprising both bio- and serotypes and use these cells to establish a uniform 
plaque assay to determine cell titer; ii) demonstrate the genetic malleability of these 
new Fcwf-4 cells through Crispr/Cas guided disruption of the type I IFN receptor and the 
expression of a feline surface protease, TMPRSS2. The ultimate goal of this 
dissertation is to facilitate the generation of live-attenuated type I FCoV vaccine strains 
through investigation and mutagenesis of IFN antagonists. Thus, in the final section, I 
describe iii) establishing a reverse genetics system to produce a lab-sequenced strain 
of FIPV Black, which can be specifically attenuated through direct mutation. Together, 
the contribution of this dissertation is to provide several basic virology tools to bolster 
basic science research of type I FCoVs and help develop an effective type I FIPV 
vaccine.  
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CHAPTER TWO 
MATERIALS AND METHODS 
Viruses and Cells 
Viruses.  
Feline coronavirus strains including type I feline infectious peritonitis virus (FIPV) 
Black (TN406), type II FIPV WSU 79-1146, and type II feline enteric coronavirus (FECV) 
WSU 79-1683 were kindly provided by Dr. Fred Scott, Cornell University College of 
Veterinary Medicine, Ithaca, NY. Viruses were propagated in Fcwf-4 Cornell University 
(CU) cells and recovered from supernatants for stock virus preparation. Briefly, sub-
confluent T-75 flasks of Fcwf-4 CU cells were infected with virus at 1 multiplicity of 
infection for 1 hour in 2 mL serum-free media at 37oC and 5% CO2. Infectious media 
was replaced with 8 mL EMEM (see below) containing 5% FCS, and the monolayer was 
incubated at 37oC and 5% CO2. After 24 hours, supernatants were collected and 
clarified by centrifuging at 1,000 xg for 10 minutes at 4oC. Virus-containing cell-free 
supernatants were then aliquoted (100 – 300 μL) and stored at -80oC. Titers of stock 
virus were determined by plaque assay on AK-D or Fcwf-4 CU cells. Virus aliquots that 
were thawed more than twice were pooled and a new titer was determined.  
HEK 293T and 293T/17 Cells.  
Human embryonic kidney (HEK) 293 T cells were maintained in DMEM (#10-
017-CV, Corning) containing 10% FCS, supplemented with 1% nonessential amino
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acids, 1% HEPES, 1% L-glutamine, 1% sodium pyruvate, and 1% pen/strep
(penicillin/streptomycin). For generation of lentivirus transducing particles, a second line 
of HEK 293T/17 (ATCC® CRL-11268TM) was purchased from ATCC and maintained in 
the same media formula. When cells were confluent, the monolayer was washed with 
PBS, then cells were removed by addition of 1.5 mL 0.25% trypsin-versene solution for 
1-2 min at room temperature. For routine passaging, cells were transferred (1:10 split) 
to a new T-75 flask every 2 days. 
Felis catus Whole Fetus (Fcwf-4) ATCC Cells.  
Fcwf-4 cells were purchased from the ATCC (ATCC® CRL-2787TM), and 
designated Fcwf-4 ATCC cells. Fcwf-4 ATCC cells were maintained in Minimal 
Essential Medium Eagle (EMEM) (Sigma, #M0268) containing 10% FBS, supplemented 
with 1.5 g/L sodium bicarbonate, 1% non-essential amino acids, 1% HEPES, 1% 
sodium pyruvate, 1% L-glutamine and 1% penicillin/streptomycin. As described by the 
ATCC, the doubling time for these cells is >31 h. When cells were confluent in T-25 
flask, the monolayer was washed with PBS, then cells were removed by addition of 1.5 
mL 0.25% trypsin-versene solution for 2-3 min at room temperature. For routine 
passaging, cells were transferred (1:3 split) to a new T-25 flask every 3 days.  
Felis catus Whole Fetus (Fcwf-4) Cornell University Cells.  
A second source of Felis catus whole fetus cells were provided by Dr. Edward J. 
Dubovi, Cornell University College of Veterinary Medicine, Ithaca, NY, designated Fcwf-
4 CU, and maintained in the same medium as the Fcwf-4 ATCC cells. When cells were 
confluent, the monolayer was washed with PBS, then cells were removed by addition of 
2 mL 0.25% trypsin-versene solution for 1-2 min at room temperature. For routine 
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passaging, approximately 3.3x106 cells were transferred (1:3 split) to a new T-75 flask 
in a total of 20 mL complete media every 2-3 days.  
Generation and Maintenance of Fcwf-4 CU IRN Cells.  
To generate the Fcwf-4 CU IFNαR null (IRN) cell line, a modified Crispr-Cas 
protocol, based on the GeCKO system (Shalem et al., 2014) was used to disrupt the 
type I IFN alpha receptor 2 (IFNαR2) in Fcwf-4 CU parental cells. Guide DNAs were 
designed using Benchling (Benchling, Inc.) to target the second and third exons 
(felis_catus_6.2; range = cgrC2: 11959183-11979720) of the feline ifnar2 gene 
(Accession NM_001278859.1). Single guide DNA sequences are listed in Appendix B 
(Primer Index 2). For each exon target, guide DNAs were phosphorylated and 
annealed by combining 10 uM of the forward and reverse guide DNA oligos, 1x T4 DNA 
ligase buffer containing ATP, T4 PNK ligase (NEB; M0201S) and nuclease-free H2O in 
a total reaction volume of 10 μL. The reactions were then incubated at 37oC for 30 min; 
95oC for 5 min; 95-25oC ramping down at 5oC intervals holding at each temperature for 
5 min. In parallel, the lentiCrisprV2-puroR+ plasmid (Addgene #52961) was linearized 
with BsmBI (NEB), the 13 kb band was extracted from an agarose gel then column 
purified using a SV gel and PCR clean-up system (Promega). Annealed and 
phosphorylated oligo sets were diluted 1:200 in nuclease-free H2O then inserted into the 
linearized lentiCrisprV2-puroR+ cassette between flaking BsmBI sites using T4 DNA 
ligase (NEB) at 16oC overnight. Following transformation into Top10 E. coli and 
subsequent miniprep purification (Promega), plasmid DNAs were double digested with 
AgeI (NEB) and KpnI (NEB) to reveal a fragment of 621 bp confirming proper insertion 
of guide DNA sequences; plasmids were confirmed by sequencing using the U6 
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universal forward primer 5'-GGG CAG GAA GAG GGC CTA T-3'. To disrupt the ifnar2 
gene, transducing particles (TPs) carrying the lentiCrisprV2-puroR+ plasmids, encoding 
guide DNA, cas9 endonuclease and puromycin resistance cassettes, were generated. 
Briefly, 3.3 μg each of lentiCrisprV2-puroR+ (empty [EV] or carrying guide DNA 
sequences), psPax2 (lentiviral packaging plasmid) and pHEF-VSV-G (vesicular 
stomatitis virus glycoprotein) plasmids (generously supplied by Edward M. Campbell, 
Department of Microbiology and Immunology, Loyola University Chicago, Stritch School 
of Medicine, Maywood, IL) were co-transfected into a 10 cm dish containing 5x106 HEK-
293T/17 cells using polyethylenimine (PEI) (5 μg PEI / 1 μg DNA) in antibiotic-free 
DMEM 10% FCS for 24 h followed by replacement with complete DMEM containing 
10% FCS with antibiotics. Alternatively, the 10 μg of total plasmid DNA was transfected 
into 5x106 HEK-293T/17 cells using TransIT LT1 (Mirus) (3 μL LT1 / 1 μg DNA) without 
media replacement in DMEM 10% FCS with antibiotics. For either method, after 48 h, 
supernatants containing TPs were collected and stored at 4oC and cells were 
replenished with 10 mL DMEM containing 5% FCS with antibiotics. After an additional 
24-hour incubation (72 hours total) at 37oC and 5% CO2, supernatants were collected 
and combined with the previously collected lot. Total supernatants were centrifuged 
1000 xg at 4oC for 10 min to remove cell debris, then centrifuged overnight (16+ hours) 
at 5,000 xg and 4oC. To concentrate, supernatants were poured off and pellets were 
suspended in 1/10 – 1/100th the original volume with EMEM (-FCS). A minimal volume 
of concentrated TPs was added to parental Fcwf-4 CU cells for 1 hour at 37oC and 5% 
CO2 followed by addition of EMEM 10% FCS and incubation for 48 h. Transduced cells 
were positively-selected by replacing media with EMEM containing 10% FCS and 10 
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µg/mL puromycin (InvivoGen) for 96 h. Puromycin-selected cells were grown as a 
heterologous population designated Fcwf-4 CU 2.2 (for the guide DNA sequence 
specific for the second target on the second ifnar2 exon). A clone of the Fcwf-4 CU 2.2 
cells, confirmed for reduction in responsiveness to type I IFN (see CHAPTER THREE: 
EXPERIMENTAL RESULTS), was isolated and designated Fcwf-4 CU IRN (Interferon 
alpha Receptor Null). Briefly, >10,000 Fcwf-4 CU 2.2 cells were sorted using a FACS 
Aria Cell Sorter (BD) into a 96-well plate at 1 cell/well. Clones were grown over several 
weeks and expanded into 24- then 6-well plates in EMEM containing 10% FCS and 10 
µg/mL puromycin. Clones that were positive for permissively to FIPV Black infection 
were evaluated for IFN responsiveness (see CHAPTER THREE: EXPERIMENTAL 
RESULTS). The Fcwf-4 CU IRN cell line was isolated in this manner and confirmed to 
be both permissive to FIPV Black infection and have low IFN-responsiveness. The 
sequence of the IFNαR mRNA expressed in the Fcwf-4 CU IRN cell line was 
determined by sequencing 15 PCR clones of the region (Appendix D). Briefly, total 
RNA was isolated from Fcwf-4 CU or IRN cell monolayers and cDNA was generated 
with random hexamer primers via the RevertAID First-Strand cDNA Synthesis kit 
(Thermo Fisher). The full IFNαR region was amplified from cDNA using the F IFNaR2 
Full FWD and F IFNaR2 Full REV primer set (Appendix B; Primer Index 1) in a 
thermocycler set at 92oC for 2 min; 35 cycles at 92oC for 1 min, 50oC for 1 min and 68oC 
for 100 min; and 68oC for 7 min. The resulting 1600 bp band was gel extracted from a 
0.8% SeaPlaque GTGTM Agarose (Lonza) gel and column purified using an SV gel and 
PCR clean-up system (Promega) prior to insertion into TA cloning pCR-XL-TOPO® 
plasmids using the TOPO® XL PCR Cloning Kit (Life Technologies). 15 plasmids for 
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each cell type were then transformed into Top10 E. coli and purified by MiniPrep 
(Promega) and sequenced using M13 FWD, M13 REV, f IFNaR2 SEQ 1 FWD and f 
IFNaR2 SEQ 1 REV sequencing primers (Appendix B; Primer Index 1). Consensus 
sequences were compared using Clone Manager 9 (Sci-Ed Software) revealing a 14-
nucleotide deletion in the cas9 target region of the IFNαR Fcwf-4 CU IRN cells resulting 
in a truncated protein sequence. These cells were maintained in the same medium as 
the parental Fcwf-4 CU cells. For routine passaging, confluent monolayers were 
washed with PBS, cells were removed by addition of 2 mL 0.25% trypsin-versene 
solution for 1-2 min at room temperature, and approximately 3.3x106 cells were 
transferred (1:3 split) to a new T-75 flask in a total of 20 mL complete media every 2-3 
days. 
Feline Airway Epithelial (AK-D) Cells.  
AK-D cells were purchased from the American Type Culture Collection (ATCC) 
(ATCC® CCL-150TM) and maintained in Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco, #12100-046) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
#S11150), supplemented with 2.2 g/L of sodium bicarbonate (Sigma, #S5761), 1% non-
essential amino acids (HyClone, #SH30238.01), 1% HEPES (HyClone, #SH30237.01), 
1% sodium pyruvate (Corning, #25-000-CI), 1% L-glutamine (HyClone, #SH30034.01), 
and 1% penicillin/ streptomycin (Corning, #30-002-CI). When cells grew to a confluent 
monolayer, the medium was removed, and the monolayer was rinsed with PBS. The 
cells were removed by addition of 2 mL of 0.25% trypsin (Gibco, #15090-046) in 
versene solution (0.48 mM EDTA in PBS) for 1-2 min at room temperature. For routine 
passaging cells were transferred (1:5 split) to a new T-75 flask every 3 days.  
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Generation and Maintenance of AK-D 2.2 (IFNαR-disrupted) Population. 
A heterologous population of AK-D cells with reduced responsiveness to type I 
interferon, termed AK-D 2.2, were recovered after transduction with Crispr/Cas guide 
RNAs targeting the second exon of the interferon alpha receptor using the same 
protocol as the Fcwf-4 CU IRN cells, however a clone was not obtained. Briefly, 
concentrated TPs were diluted 3:1 in DMEM containing 10% FCS and applied to 
parental AK-D cells for 48 h followed by selection in DMEM containing 10% FCS and 10 
µg/mL puromycin (InvivoGen) for 96 h. Puromycin-selected cells were grown as a 
heterologous population designated AK-D 2.2 cells and verified for permissively to FIPV 
Black infection and reduced IFNα responsiveness. AK-D 2.2 cells were maintained in 
the same media as the parental AK-D cells. For routine passaging, cells were 
transferred (1:5 split) to a new T-75 flask every 3 days after a PBS wash and disruption 
with 0.25% trypsin-versene.    
Felis catus Bone Marrow-derived Macrophages (fBMDMs).  
For generation and culture of feline bone marrow-derived macrophages, feline 
femurs were harvested by Cornell University Veterinary Biobank from specific 
pathogen-free cats euthanized according to IACUC approved protocols, and total bone 
marrow content was collected. Red blood cells and fatty tissue were removed by lysis in 
ACK lysis buffer and straining through a 0.70 𝜇m filter (Falcon). The remaining cells, 
predominantly hematopoietic stem cells, were cryopreserved at 5.0x107 cells/mL in 90% 
FBS and 10% DMSO. Feline bone marrow derived macrophages (fBMDMs) were 
differentiated as previously reported (Gow et al., 2013) with slight modification. Briefly, 
5.0x107 bone marrow cells were plated in 100 x 26 mm petri dishes (VWR, #25387-030) 
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in DMEM (Corning, #10-017-CV) supplemented with 20% FBS, 10,000 IU/mL 
recombinant human (rh) M-CSF (PeproTech, #300-25) and 50 𝜇M 𝛽-mercaptoethanol 
then incubated at 37oC and 5% CO2. At day 3, supernatant was removed, clarified of 
cells, diluted 1:2 with fresh DMEM supplemented with 20% FCS and 10,000 IU/mL rhM-
CSF, and returned to cells. fBMDMs were recovered on day 6 by gentle aspiration in 
PBS following 30 min, 4oC incubation in PBS. 
Mycoplasma Detection and Removal from Tissue Culture.  
All cells used in this study were monitored for mycoplasma contamination using a 
PCR-based assay. Cell culture supernatants were routinely collected after 3 days of 
culture and then heat-inactivated at 95oC for 10 min. PCR amplification for mycoplasma 
detection was performed using a forward primer: 5’- GGC GAA TGG GTG AGT AAC 
ACG -3’ and a reverse primer: 5’- CGG ATA ACG CTT GCG ACC TAT G -3’. 
Thermocycler settings were as follows: initial denaturation at 95°C for 10 min; 35 cycles 
consisting of denaturation at 95°C for 45 sec, annealing at 60°C for 45 sec, and 
extension at 72°C for 60 sec; and a final extension at 72°C for 10 min. The PCR 
products were analyzed on 1% (w/v) agarose gel. DNA fragments were visualized with 
a UV transilluminator after being stained with ethidium bromide. If mycoplasma was 
detected, the cells were treated for 7 days with 0.5 μg/mL of mycoplasma removal agent 
(Bio-Rad, #BUF035). All results shown here are from mycoplasma negative cells. 
FIPV PLP2 Functional Assays 
Transcleavage Assay.  
FIPV PLP2 protease activity (targeting and cleavage of the LXGG motif) was 
determined using a transcleavage assay. Briefly, 2x105 HEK 293T cells/mL were plated 
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in 12-well plates 24 h prior to transfection. 500 ng of plasmids encoding recFIPV-
PLP2(V5) wild-type, catalytic mutant or empty vector were combined with 25 ng of 
plasmid expressing nsp2/nsp3-GFP substrate and co-transfected into cells using 
TransIT LT1 (Mirus) (3 μL LT1 / 1 μg DNA). After 16-18 h, cells were lysed in 100 μL 
I𝜅B lysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% 
Triton X-100, 12.5 mM Na pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na ortho-
vanadate, 1 mg/mL leupeptin, 1 mM PMSF) on ice then centrifuged at 14,000 xg for 10 
min at 4oC to pellet nuclei.  Lysate supernatants were separated using a 10% SDS-
PAGE gel then transferred to a PVDF membrane using a semi-dry transfer apparatus 
(Bio-Rad). Membranes were blocked overnight in 5% milk-TBST at 4oC then incubated 
with primary antibody diluted in 5% milk-TBST for 1 hour at room temperature: to detect 
the nsp3-GFP cleavage product, a 1:2500 dilution of rabbit-anti GFP (ThermoFisher 
Scientific) was used; to determine PLP2 expression, a 1:5000 dilution of mouse-anti-V5 
tag (Bio-Rad) was applied; a 1:5000 dilution of mouse-anti β-actin (Bio-Rad) was used 
to determine equivalence in protein loading. Membranes were washed three times for 
15 min in TBST buffer, then incubated with donkey anti-rabbit-HRP (1:2500) or goat-
anti-mouse-HRP (1:2500) secondary antibody (SouthernBiotech) for 1 h at room 
temperature. Three more 15 min washes in TBST were performed prior to addition of 
Western Lightning® Plus-ECL (PerkinElmer, Inc.) chemiluminescent substrate and 
visualization on a FluorChemTM E (Protein Simple) imaging system. Band sizes were 
determined relative to PageRulerTM Prestained protein ladder (Thermo Fisher). 
Deubiquitinase (DUB) and DeISGylase Assays.  
The ability of FIPV PLP2 to deconjugate ubiquitin or ISG15 molecules from total 
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proteins was determined using DUB or DeISGylase assays. Briefly, 2x105 HEK 293T 
cells/mL were plated in 12-well plates 24 h prior to assay. Cells were co-transfected with 
500 ng of FLAG-ubiquitin (Flag-Ub) for DUB assay or 500 ng myc-ISG15 and 250 ng 
each of pUbcH8, pUbe1L, pHerc5 for DeISGylase assay, along with 250, 500 or 1000 
ng of plasmid encoding recFIPV-PLP2(V5) wild-type, catalytic mutant or empty vector. 
At 16-18 h, cells were lysed in 100 μL I𝜅B lysis buffer on ice then centrifuged at 14,000 
xg for 10 min at 4oC to pellet nuclei.  Lysate supernatants were separated using a 10% 
SDS-PAGE gel, transferred to a PVDF membrane using a semi-dry transfer apparatus 
(Bio-Rad) and blocked overnight in 5% milk-TBST at 4oC. Primary antibodies were 
diluted in 5% milk-TBST as follows: mouse-anti-FLAG (SigmaAldrich) at 1:2500 (DUB 
assay), mouse-anti-myc (Developmental Studies Data Bank, University of Iowa) at 
1:250 (DeISGylase assay), and mouse-anti-V5 tag (Bio-Rad) at 1:2500 or a 1:5000 
dilution of mouse-anti β-actin (Bio-Rad). Antibody dilutions were applied to membranes 
for 1 hour at room temperature, which were then washed three times for 15 min in TBST 
buffer and incubated in a 1:5000 dilution of goat-anti-mouse-HRP secondary antibody 
(SouthernBiotech) for 1 h at room temperature. Three more 15 min washes in TBST 
were performed prior to addition of Western Lightning® Plus-ECL (PerkinElmer, Inc.) 
chemiluminescent substrate and visualization on a FluorChemTM E (Protein Simple) 
imaging system. Deconjugation is visualized by a reduction in the relative intensities of 
the protein smear. Band sizes were determined relative to PageRulerTM Prestained 
protein ladder (Thermo Fisher). 
IFN Antagonism Assay. 
To determine if recFIPC-PLP2 is a type I IFN antagonist, the following assay was 
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performed as previously described (Niemeyer et al., 2018) with modification. Briefly, 
2x105 HEK-293T cells/mL were transfected with plasmids encoding Renilla (RL) and 
Firefly (FF) luciferases (luc) along with WT or catalytic mutant rec-FIPV-PLP2. An IFN-β 
promoter (p125-luc) controls FF luc gene expression, while RL luciferase gene 
expression is determined by a constitutive herpes simplex thymidine-kinase (TK) 
promoter. Stimulation of the IFN-β promoter triggered by overexpressed, constitutively-
active MDA5 leads to an auto-activation of the IFN pathway and increased FF luc. 
Plasmid amounts for a given 24-well plate format are as follows: pRL-TK (5 ng), p125-
luc (250 ng), pEF- BOS-MDA5-3xFLAG His10 (100 ng) and 100 to 200 ng of PLP2-
expressing plasmids. Cells were lysed at 18 hpt and 20 μL of luc-containing lysate was 
transferred to white-opaque 96-well plates and used for assessment of luc activity using 
a luminometer (Veritas). Relative IFN promotion is determined by calculating the ratio of 
ifn(FF)/luc(RL). Each condition was performed in triplicate in at least three experiments.   
Plaque Assay 
The plaque assay technique was established using AK-D, AK-D 2.2 and Fcwf-4 CU 
cells. 6.5 x 105 cells per well were plated in 6-well plates or 3.0-x105 cells per well were 
plated in 12-well plates. Cells were washed in PBS, then infected with 300 μL of 10-fold 
serial dilutions of viral samples in FCS-free media for 1 h at 37oC. Cells were overlaid 
with a 0.5% Oxoid agar (Oxoid LTD, #LP0028)-DMEM containing 1% FBS mixture. 
Plates were incubated at 37oC for 48 h (or the indicated time) and fixed using 3.7% 
formaldehyde-PBS solution for 30 min. Viral plaques were visualized by staining with 
0.1% crystal violet for 30 min and photographed. We note plaques were clearly evident 
when we used Oxoid agar, but not if we used Noble agar.  
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Virus Growth Kinetics 
We analyzed the growth kinetics of type I FIPV Black in four cell lines: AK-D, AK-D 2.2, 
Fcwf-4 CU, and Fcwf-4 ATCC. Type II FCoV titers were evaluated in Fcwf-4 CU cells. 
For all cell types, 1.5 x 105 cells were plated in 24-well plates or 3.0 x 105 cells in 12-
well plates. After incubating for 24 h, cells were infected with FIPV in serum-free media 
at a multiplicity of infection (MOI) of 0.1 at 37oC. After a 1 h incubation, the infectious 
media were replaced with fresh media containing 2% FBS. At the indicated time points, 
cell-free supernatants and/or infected cells were harvested and used for titration by 
plaque assay on AK-D (FIPV Black) or Fcwf-4 CU (type II FCoVs) cells. 
Evaluating Virus Titers from Cell-free and Cell-associated Samples 
We compared the cell-free and cell-associated growth kinetics of FIPV in several cell 
lines: AK-D, AK-D 2.2, Fcwf-4 CU and Fcwf-4 ATCC cells. For all cell types, 1.2 x 106 
cells were plated in a 60 mm2 dish, 1.5 x 105 cells were plated in 24-well plates or 3.0 x 
105 cells in 12-well plates in DMEM or EMEM containing 10% FBS. After incubating for 
24 h, cells were infected with FIPV Black in serum-free media at a multiplicity of 
infection (MOI) = 0.1 at 37oC. After a 1 h incubation, the infectious media were replaced 
with fresh complete media. Cell supernatants and infected cells were harvested at 
indicated time points and used to prepare cell-free and cell-associated samples, 
respectively, for titration by plaque assay on Fcwf-4 CU cells as described above. The 
supernatant was collected from the cultures at the times indicated and subjected to 
centrifugation at 2,200 xg for 10 min at 4oC to remove any dead cells. This cell free 
supernatant was aliquoted and frozen at -80oC until use. To prepare the cell-associated 
sample, 0.5 mL of medium was added to the infected cells, and the entire plate was 
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frozen at -80oC. The infected cells were then subjected to two additional rounds of 
freezing and thawing (37oC for 1-2 min). After the third thaw, the cells and medium were 
transferred to a centrifuge tube and centrifuged at 2,200-3,000 xg for 10 min at 4oC to 
remove cell debris. The supernatant containing the viruses released from the cells 
during the freeze-thaw process was designated the cell-associated virus sample. Cell-
associated samples were stored at -80oC. To determine FIPV titers, plaque assays were 
performed on Fcwf-4 CU cells as described above.  
Type I Interferon Responsiveness Assay 
To determine feline cell responsiveness to type I interferon, quantification of ISG54 
transcript production by RT-qPCR following stimulation with feline IFN was performed. 
Cells (1.0 x 105 in a 24-well plate) were treated with 10, 100, or 1000 U/mL of purified 
feline IFN-alpha (PBL Assay Science, #15100-1) for 6 h. To determine ISG54 and feline 
β-actin mRNA production, total RNA was extracted using a RNeasy Mini Kit (Qiagen) 
and an equal amount of RNA (1000 ng) was used for cDNA synthesis using RT2 HT 
First-Strand Kit (Qiagen, #330401). qPCR was performed with specific primers 
(Appendix B; Primer Index 1) for feline 𝛽-actin transcript (FWD 5’- CAA CCG TGA 
GAA GAT GAC TCA GA -3’; REV 5’- CCC AGA GTC CAT GAC AAT ACC A -3’) 
(Kessler et al., 2009) or ISG54 transcript (FWD 5’- CCT GAG CTG CAG CCT TTC AGA 
ACA G -3'; REV 5'- CAC GTG AAA TGG CAT TTA AGT TGC CGC AG -3') using RT2 
SYBR Green qPCR Mastermix (Qiagen, #330502). A Bio-Rad CFX96 thermocycler was 
set as follows: one step at 95°C (10 min); 40 cycles of 95°C (15 s), 60°C (1 min), and 
plate read; one step at 95°C (10 s); and a melt curve from 65°C to 95°C at increments 
of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are representative of three 
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independent experiments. The levels of mRNA are reported relative to β-actin mRNA 
and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].  
Immunofluorescence Detection of FIPV Nucleocapsid Protein 
Monolayers of 1.0 x 105 AK-D and Fcwf-4 CU cells were cultured in 8-well chamber 
slides (Nalge Nunc International, #177445) at 37oC for 24 h. Cells were infected with 
FIPV Black at a MOI of 0.1 for 1 h at 37oC. At times indicated, the infected cells were 
fixed with 3.7% formaldehyde-PBS solution for 30 min, permeabilized with 0.1% Triton 
X-100 in PBS for 10 min, and then incubated with blocking solution containing 5% 
normal goat serum and 0.1% Triton X-100 in PBS at 4oC overnight. For 
immunofluorescence staining of FIPV Black-infected cells, the cells were incubated with 
mouse monoclonal anti-FIPV nucleocapsid (CCV2-2) (Poncelet et al., 2008) (Bio-Rad, 
#MCA2594B) as a primary antibody at a dilution of 1:500 at room temperature for 1 h. 
Cells were then incubated with a secondary antibody, Alexa Fluor 568-conjugated goat 
anti-mouse IgG (Thermo Fisher Scientific, #A11004) at a dilution of 1:1000 in the 
presence of Hoechst33342 (Thermo Fisher Scientific, #H1399) at a dilution of 1:1000 
for nucleus stain. After 30 min incubation with the secondary antibody at room 
temperature, the cells were then washed with PBS, mounted, and examined under a 
fluorescence microscope.  
Morphologic Staining 
Feline bone marrow-derived macrophages, Fcwf-4 CU, or Fcwf-4 ATCC cells, grown for 
24 h in 100 x 26 mm petri dishes (VWR, #25387-030), were washed with PBS, 
incubated in PBS for 30 min at 4oC, then collected with gentle pipetting. Using a 
Cytospin (Shandon), 200 𝜇L of cells (10,000 cells/mL) suspended in PBS supplemented 
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with 2% BSA were spun onto glass coverslips (pre-treated with 2% BSA in PBS) at 115 
xg for 6 min. Cells were dried, rinsed in PBS, then fixed in absolute methanol for 1 min. 
Wright-Giemsa (Thermo Fisher Scientific, #9990710) staining was performed per the 
manufacturer’s instructions using a 3 min primary stain and a 2 min counter stain, and 
washed with 1 mL rinse solution. Slides were dried and imaged under oil immersion at 
100x magnification.  
Cloning and Expression of Feline TMPRSS2 in Fcwf-4 CU IRN Cells 
A dsDNA gBlocks® (IDT) fragment containing the coding sequence of feline TMPRSS2 
variant 1 (GenBank accession # XM_023238709.1) was designed with several 
modifications for cloning into the pLVX-Puro vector. The 5’ end was designed to contain 
a pLVX complementarity region (5’-TAC TAG AGG ATC ACC GGA CTC AGA T-3’) 
followed by an XhoI cleavage site and a Kozak consensus sequence (5’-ACC ATG G-
3’). The 3’ end contains a spacer sequence (5’-GGT-3’) followed by an in-frame V5 tag 
coding region (5’-GGT AAG CCT ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT 
ACG-3’), translation termination sequence (5’-TAG-3’), BamHI cleavage site and a 
pLVX complementarity region (5’-ACC GGA TCT AGA TAA CTG ATC ATA A-3’). pLVX-
Puro vector was double-digested with XhoI (NEB) and BamHI (NEB) and the feline 
TMPRSS2 gBlocks fragment was inserted using NEBuilder® HiFi DNA Assembly (NEB) 
using a 1:5 vector to insert ratio as per the manufacturer’s instructions. The assembled 
plasmid was transformed into Top10 E. coli, purified by MaxiPrep (Promega) and 
sequenced using CMV FWD, fTMPR2 SEQ F1, and fTMPR2 SEQ F2 sequencing 
primers (Appendix B; Primer Index 1). Transducing particles (TPs) carrying the pLVX-
fTMPRSS2(V5)-puroR+ plasmids, encoding lentivirus 5’ LTR, psi (𝜓) packaging signal, 
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rev-response element (RRE) and feline TMPRSS2(V5) were generated under the 
direction of Dr. Michael Hantak (Loyola University Chicago). Briefly, 3.3 μg each of 
pLVX-fTMPRSS2(V5)-puroR+, psPax2 (lentiviral packaging plasmid) and pHEF-VSV-G 
(vesicular stomatitis virus glycoprotein) plasmids (generously supplied by Edward M. 
Campbell, Loyola University Chicago) were co-transfected into 10 cm dishes containing 
5x106 HEK-293T/17 cells using polyethylenimine (PEI) (5 μg PEI / 1 μg DNA)  in 
antibiotic-free DMEM 10% FCS for 24 h followed by replacement with complete DMEM 
containing 10% FCS with antibiotics. After 48 h, supernatants containing TPs were 
collected and stored at 4oC and cells were replenished with 10 mL DMEM containing 
5% FCS with antibiotics. After an additional 24-hour incubation (72 hours total) at 37oC 
and 5% CO2, supernatants were collected and combined with the previously collected 
lot. Total supernatants were centrifuged 1000 xg at 4oC for 10 min to remove cell debris, 
then centrifuged overnight (16+ hours) at 5,000 xg and 4oC. To concentrate, 
supernatants were poured off and pellets were suspended in 1/10 – 1/100th the original 
volume with EMEM (-FCS). For expression of feline TMPRSS2(V5), transducing 
particles were diluted 1:5 in serum-free EMEM and a minimal volume was incubated 
with Fcwf-4 CU IRN cells for 1 hour at 37oC and 5% CO2 followed by addition of EMEM 
containing 6.25% FCS. After 48 hours, cells were lysed in either lysis buffer A (4% 
sodium dodecyl sulfate, 3% dithiothreitol, 40% glycerol, and 0.065 M Tris-HCl pH 6.8 in 
H2O) for evaluation of TMPRSS2(V5) by western blot, or lysed in RLT buffer (Qiagen) 
for evaluation of TMPRSS2 mRNA levels by qPCR. For western blot, lysates were 
sonicated, and 50,000 cell-equivalents were loaded and electrophoretically separated 
through 7-15% acrylamide Mini-PROTEAN® TGXTM precast SDS-PAGE gels (Bio-Rad) 
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in 1x Running Buffer (0.19 M glycine, 0.025 M trizma base, and 1% sodium dodecyl 
sulfate in H2O). The acrylamide gels, methanol-activated Immun-Blot® PVDF 
membranes (Bio-Rad) and filter paper (Bio-Rad) were soaked for 10 min in semi-dry 
transfer buffer (48 mM trizma base, 39 mM glycine, 1.3 mM sodium dodecyl sulfate and 
20% methanol in H2O at pH 9.2) and proteins were transferred from acrylamide gels to 
the PVDF membranes using a semi-dry Trans-Blot® TurboTM transfer system (Bio-Rad). 
Membranes were blocked at 4oC overnight in 5% milk in TBST (0.02 M trizma base, 
0.15 M NaCl and 1% Tween 20 in H2O) followed by 90 min room temperature 
incubation in primary antibodies specific for TMPRSS2(V5) tag (murine monoclonal IgG; 
Genscript) or 𝛽-actin (murine monoclonal IgG; Genscript) diluted 1:2500 and 1:5000, 
respectively, in 5% milk-TBST. The membranes were washed three times for 15 min 
each in TBST followed incubation for 1 hour at room temperature in goat-anti-mouse-
HRP (SouthernBiotech) secondary antibody diluted 1:5000 in 5% milk-TBST. Three 
more 15 min washes in TBST were performed prior to addition of Western Lightning® 
Plus-ECL (PerkinElmer, Inc.) chemiluminescent substrate and visualization on a 
FluorChemTM E (Protein Simple) imaging system. Band sizes were determined relative 
to PageRulerTM Prestained protein ladder (Thermo Fisher). For detection of feline 
TMPRSS2 mRNA transcript levels, quantitative PCRs were performed. Briefly, total 
RNA was extracted from RLT lysates using a RNeasy Mini Kit (Qiagen) and an equal 
amount of RNA (500 ng) was used for cDNA synthesis using RT2 HT First-Strand Kit 
(Qiagen, #330401). qPCR was performed with specific primers for feline TMPRSS2 
(feline tmprss2 FWD / feline tmprss2 REV) or feline 𝛽-actin transcript (f𝛽-Actin FWD / 
f𝛽-Actin Actin REV) (Kessler et al., 2009) (Appendix B; Primer Index 1) using RT2 
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SYBR Green qPCR Mastermix (Qiagen, #330502). A Bio-Rad CFX96 thermocycler was 
set as follows: one step at 95°C (10 min); 40 cycles of 95°C (15 s), 58°C (1 min), and 
plate read; one step at 95°C (10 s); and a melt curve from 65°C to 95°C at increments 
of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are representative of three 
independent experiments. The levels of mRNA are reported relative to 𝛽-actin mRNA 
and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].  
Determining IFNαR2 Expression and Amplicon Melt Temperature 
Expression and amplicon melt temperature of feline ifnar gene exons 1-4 were 
determined by qPCR. Briefly, confluent monolayers of Fcwf-4 CU and Fcwf-4 CU IRN 
cells were grown overnight in complete EMEM, lysed in RLT (Qiagen) and total RNA 
was isolated using the RNeasy RNA isolation kit (Qiagen). Equivalent amounts of RNA 
were used to generate cDNA using RevertAID cDNA synthesis kit (ThermoFisher).  
Feline 𝛽-actin (primers: f𝛽-Actin FWD / f𝛽-Actin REV) and IFNαR2 exon 1-4 (primers: 
Fel ifnar mRNA Exon1-4 RT FWD / Fel ifnar mRNA Exon1-4 RT REV) transcript levels 
were determined by qPCR using Sybr Green Master Mix (Qiagen) (Appendix B; 
Primer Index 1). qPCRs were performed in a CFX96 thermocycler (Bio-Rad) using the 
following settings: 95oC for 10 min; 40 cycles of 95oC for 15 s, 58oC for 1 min and SYBR 
read; 95oC for 10 s; melt curve from 65°C to 95°C at 0.5°C/0.5 s. For qPCR, samples 
were evaluated in triplicate and data represent three independent experiments. The 
levels of mRNA are reported relative to 𝛽-actin mRNA and expressed as 2−ΔCT [ΔCT = 
CT(gene of interest) −CT(β-actin)]. Melt temperatures were determined by plotting the change in 
fluorescence with temperature [-d(RFU)/dT] versus temperature (oC) then calculating 
the point at which the largest change in fluorescence occurs (Krenke et al., 2005). 
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Detecting FIPV N gene in FIPV-infected Fcwf-4 CU IRN Cells Expressing 
TMPRSS2 
To determine effects of TMPRSS2 on FIPV replication, Fcwf-4 CU IRN cells were 
transduced with increasing dilutions of lentiviruses expressing TMPRSS2 then infected 
with FIPV Black. N gene expression was determined by qPCR. Briefly, 24-well Cell-Bind 
plates (Corning) were seeded with 0.5 mL Fcwf-4 CU IRN cells at 3.0 x105 cells/mL in 
complete EMEM and incubated overnight at 37oC and 5% CO2. Media was replaced 
with 100 uL EMEM (-FCS) (mock), or cells were transduced with 100 uL fTMPRSS2(V5) 
lentivirus TPs left undiluted, or diluted 1:20, 1:10, 1:5 and 1:2.5 in EMEM (-FCS). After 1 
h incubation, 400 uL EMEM (6.25 % FCS) was added to each well (without media 
replacement) to give 500 uL and 5% FCS. Cells were incubated for 48 h to allow 
expression of TMPRSS2 then infected with FIPV Black at MOI of 0.1 or left uninfected 
(mock; mock expressing TMPRSS2). After an additional 18 h infection, cells were lysed 
in RLT (Qiagen) and RNA was isolated using RNeasy Mini Kit (Qiagen). Equivalent 
amounts of RNA were used to generate cDNA using the RevertAID cDNA Synthesis Kit 
(ThermoFisher). FIPV Black N gene (primers: FIPV-N-qpcr-F / FIPV-N-qpcr-R) and 𝛽-
actin (primers: f𝛽-Actin FWD / f𝛽-Actin REV) transcript levels were determined by qPCR 
using Sybr Green Master Mix (Qiagen) (Appendix B; Primer Index 1). qPCRs were 
performed in a CFX96 thermocycler (Bio-Rad) set to: 95oC for 10 min; 40 cycles of 95oC 
for 15 s, 58oC for 1 min and SYBR read; 95oC for 10 s; and a melt curve from 65°C to 
95°C at increments of 0.5°C/0.5 s. Samples were evaluated in triplicate and data are 
representative of three independent experiments. The levels of mRNA are reported 
relative to 𝛽-actin mRNA and expressed as 2−ΔCT [ΔCT = CT(gene of interest) −CT(β-actin)].  
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Reverse Genetics Methods 
Genomic RNA Isolation from FCoV Virions.  
Genomic RNA (gRNA) was isolated from 600 μL cell-free supernatants 
containing FCoV virions at concentrations greater than 1.0x105 PFU/mL. 100 μL aliquots 
of supernatant were mixed with TriReagent (MRC, Inc.) at a ratio of 1:10 in 1.5 mL 
eppitubes. The mixture was incubated for 5 min at room temperature to dissociate the 
nucleoprotein complexes. 0.25 mL of chloroform (Sigma-Aldrich) was added per 0.75 
mL of TriReagent used in the initial homogenization, the mixtures were shaken 
vigorously by hand for 1 min, incubated at room temperature for 15 min then centrifuged 
at 12,000 xg for 10 min at 4oC for phase separation. The top aqueous layers containing 
RNA were extracted into new RNase-free 1.5 mL eppitubes and 5 μg of glycogen was 
added (1 μL at 5 mg/mL). Room temperature 200 proof isopropanol (Sigma-Aldrich) 
was added at a 1:1 ratio and the six tubes were inverted to mix, incubated at room 
temperature for 10 min then centrifuged 12,000 xg for 60 min at 4oC. The supernatants 
were discarded, the pellets were washed in 1.25 mL 75% ethanol then centrifuged 
7,500 xg for 5 min at 4oC. The RNA was washed in 75% ethanol three times total. The 
final ethanol washes were discarded, and the pellets were allowed to air dry. To 
dissolve, 10-20 μL RNase-free water was added directly to the pellets and tubes were 
incubated at 55oC for 15 min. The six dissolved pellets were then combined, and 
concentrations were determined by spectrophotometer (NanoDrop). 
Deep-sequencing, Cloning and Modification of a Lab Strain of FIPV Black.  
The FIPV Black (TN406) strain used as the backbone for the reverse genetics 
system was kindly provided by Dr. Fred Scott, Cornell University College of Veterinary 
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Medicine, Ithaca, NY. The genomic sequence of this specific FIPV Black laboratory 
strain was determined by deep sequencing. Briefly, AK-D cells were infected with FIPV 
Black for 24 hours, the cell monolayer and supernatant were freeze-thawed by 
alternating -80oC and 37oC incubations, then centrifuged for 10 min at 2,000 xg and 4oC 
to remove cell debris. The supernatant was sent to the Veterinary Diagnostic Laboratory 
(Department of Diagnostic Medicine and Pathology, College of Veterinary Medicine, 
Kansas State University) and subject to Ion Torrent Next Generation Sequencing. The 
resulting sequencing reads were aligned to a reference FIPV Black genome (GenBank 
Accession #EU186072.1) and a consensus sequence of this laboratory strain of FIPV 
Black was generated (Appendix C). The concept for the contiguous cDNA FIPV Black 
reverse genetics system was based on the previously described method for generating 
murine hepatitis virus (Yount et al., 2002) and involves sub-cloning cDNA segments of 
the coronavirus genome onto individual plasmids, ligation and transcription of the full-
length cDNA into genomic RNA followed by electroporation into cells. Based on the 
deep-sequenced genome of the FIPV Black lab strain, seven contiguous cDNA 
segments (A-G) (Table 8), comprising the entire genome, were designed, amplified 
using specific primer sets from genomic RNA and sub-cloned onto individual plasmids. 
Each cDNA fragment contains unique restriction sites, which overlap only with the 
adjacent fragment and ensures that the seven excised fragments ligate in a specific A to 
G order and reflect a complete cDNA version the original FIPV genomic sequence. To 
generate the seven cDNA plasmids, 1.5 μg of FIPV Black genomic RNA was used as a 
template for cDNA synthesis with random hexamer primers via the RevertAID First-
Strand cDNA Synthesis kit (Thermo Fisher) as per the manufacturer’s specifications. 
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Using the resulting cDNA as a template, PCR reactions were set up using the ExpandTM 
Long Range dNTPack (Roche via Sigma-Aldrich) kit and segment-specific primer sets 
(Appendix B; Primer Index 3) were included to amplify cDNA segments B-F using the 
following specifications: 0.2 mM dNTP mix, 0.2 uM forward primer, 0.2 uM reverse 
primer, 3.75% DMSO, 1x reaction buffer, 1.5 U enzyme mix and 2 μL cDNA per 50 μL 
reaction. The amplified cDNA segments were gel extracted from a 0.8% SeaPlaque 
GTGTM Agarose (Lonza) gel and column purified using an SV gel and PCR clean-up 
system (Promega) prior to insertion into TA cloning pCR-XL-TOPO® plasmids using the 
TOPO® XL PCR Cloning Kit (Life Technologies). Plasmids were then transformed into 
Top10 E. coli and purified by MaxiPrep (Promega). cDNA segments A and G were 
individually synthesized and cloned into pUC57(AmpR+) vectors by BioBasic Inc. 
(Markham, ON, Canada). The A segment sequence was modified from the genomic 
FIPV Black sequence in the following ways: a T7 polymerase promoter sequence 5’-
TAA TAC GAC TCA CTA TAG-3’ was added at position -21 relative to the start of the 
FIPV Black genome and a natural BsmBI cut site was removed at position 3806 (GAG 
to GAA). The G segment sequence was modified to include a stretch of 21 consecutive 
adenine nucleotides at the 3’ end. Additionally, the nucleocapsid (N) gene sequence 
was amplified from the FIPV Black total cDNA using specific primers (Appendix B; 
Primer Index 3) and cloned into pcDNA-3.1 using NEBuilder® HiFi DNA Assembly 
(NEB) as per the manufacturer’s specifications. Large-scale preparations of the cDNA 
plasmids A-G, and N gene were obtained using a MaxiPrep kit (Promega) then 
sequenced (Appendix B; Primer Index 4) prior to long-term storage at -80oC.  
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Assembly of Full-length FIPV Black Infectious Clone cDNA.  
The method of assembling the full-length infectious clone of the FIPV Black 
sequenced laboratory strain was based on the previously described reverse genetics 
method for murine hepatitis virus (Yount et al., 2002). Similarly, our design for the 
reverse genetics system for FIPV involves ligation of the seven contiguous cDNA 
fragments at specific junctions in order to generate the full-length cDNA infectious 
clone. First, each of the plasmid DNAs containing specific cDNA segments of the FIPV 
genome, (FIPV plasmids A-G) was grown to a high concentration, isolated by Maxiprep 
(Promega), and 40 μg was digested with BsmBI, or double digested with BsmBI and 
BamHI, or SfiI according to the manufacturer’s specifications (NEB) (Table 8) FIPV 
cDNA plasmids D and G were singly digested with BsmBI resulting in desired fragment 
sizes of 2,339 and 4,385 bp respectively, while the FIPV Black A plasmid was double-
digested with BsmBI and BamHI resulting in a desired fragment size of 4,810 bp. FIPV 
plasmids B, C, E and F were double digested with BsmBI and SfiI resulting in desired 
fragment sizes of 4,064 bp for B plasmid, 4,609 bp for C plasmid, 4,762 bp for E 
plasmid and 4,272 bp for F plasmid. The SfiI cut site is located on the pCR-XL-TOPO® 
vector and was included to allow clearer band separation when purifying the fragments. 
Additionally, 40 μg of the N gene plasmid (pcDNA-3.1 encoding the FIPV Black 
nucleocapsid gene) was linearized by DraIII digestion. The digests were then diluted in 
6x loading dye (Ambion) and run through a 0.8% SeaPlaque GTGTM (Lonza) low-melt 
agarose gel in TAE (tris-acetate-EDTA) buffer. The desired bands (FIPV Fragments A-
G and linearized N plasmid) were visualized on a DarkReader transilluminator (Clare 
Chemical Research) to prevent UV-induced nucleotide cross-linking, cut from the 
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agarose gel, purified using an SV gel and PCR clean-up system (Promega), and eluted 
in 120 μL nuclease-free H2O. To remove excess agarose, the fragments were further 
purified by addition of chloroform at a ratio of 1:1. The chloroform-DNA solutions were 
mixed by vortex for 1 min, centrifuged 5 min at 15,000 rpm (21,130 xg) and the top 
aqueous layers containing DNA were recovered and placed into new 0.6 mL eppitubes. 
The concentration of each purified cDNA fragment was determined, and aliquots were 
stored at -80oC. To generate the full-length infectious clone cDNA, molar equivalents 
(0.02-0.05 pmol) of each fragment were combined, totaling approximately 6 μg DNA, 
and ligated using 6,000 U of T4 DNA Ligase (NEB) and 1x T4 ligase buffer (50 mM Tris-
HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT) in a 200 μL reaction for 16-24 hours at 
16oC. The full-length ligation product (~29.2 Kb) was purified using phenol-chloroform-
isoamyl alcohol extraction then precipitated with isopropanol. Briefly, 20 μL (1:10) of 3M 
NaOAc at pH 5.2 and 220 μL (1:2) phenol-chloroform-isoamyl alcohol (25:24:1 ratio) at 
pH 8.0 were added to the 200 μL ligation reaction. The solution was shaken vigorously 
by hand for 1 min and centrifuged at room temperature for 2 min at 14,000 rpm (18,407 
xg) for phase separation. The top aqueous phase containing DNA was extracted into a 
new tube, followed by addition of room temperature 200 proof isopropanol (1:1 ratio) 
and inversion to mix. The DNA was allowed to precipitate for 10 min at room 
temperature before centrifuging at 14,000 (18,407 xg) for 10 min at room temperature. 
The pellet was washed two times in 500 μL of 75% ethanol (chilled in -80oC) and once 
in 500 μL 95% ethanol (chilled in -80oC) with pelleting at 14,000 (18,407 xg) for 3 min in 
between washes. The pellet was allowed to air dry until translucent and 11.5 μL 
nuclease-free H2O was added. To dissolve the pellet, the tube was held at room 
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temperature for 1 hour with intermittent flicking. The dissolved pellet was used 
immediately for in vitro transcription without storage.    
Full-length Ligation Junction PCR.  
To determine if ligation of the seven cDNA fragments was contiguous, PCRs 
across each junction were performed. Briefly, molar equivalents of purified fragments A-
G were ligated overnight at 16oC using T4 Ligase (NEB). Using 10 ng of ligation product 
as template, PCRs were performed using Expand Long-Range Taq Polymerase (Roche 
via Sigma) to amplify each junction using junction-specific primers (AB, A5/B1R [761 
bp]; BC, B5/C1R [903 bp]; CD, C6/D1R [900 bp]; DE, D3/E1R [730 bp]; EF, E7/F1R 
[1057 bp]; FG, F6/G1R[1154 bp]) (Appendix B; Primer Index 4). Reactions were 
performed in an Eppendorf thermocycler set at 92oC (2 min); 25 cycles at 92oC (10 s), 
52 or 55oC (15 s), and 66oC (80 s); and held at 66oC for 7 min. PCR products were 
diluted in 6x loading dye (NEB) and electrophoretically separated through a 0.9% 
agarose gel. Bands were visualized under UV due to intercalation of ethidium bromide.  
In Vitro Transcription and RNA Electroporation.  
Full-length mRNA copies of the FIPV infectious clone cDNA and additional 
mRNA copies of the FIPV N gene were synthesized using the mMessage mMachine T7 
(Ambion) in vitro transcription kit as per the manufacturer’s specifications with the 
following modifications. To generate full-length infectious clone mRNAs, the 11.5 μL 
purified cDNA ligation (see above) was combined with 3.5 μL of 30 mM GTP (2.1 mM 
final), 25 μL 2x NTP/CAP (1x final), 5 μL 10x reaction buffer (1x final) and 5 μL T7 
polymerase/enzyme mix. N gene transcripts were generated by combining 500 ng 
purified linearized N gene plasmid with 12.5 μL 2x NTP/Cap (1x final), 2.5 μL 10x 
  
127 
reaction buffer (1x final), 2.5 μL T7 polymerase/enzyme mix and nuclease-free H2O in a 
25 μL reaction. The reactions were incubated at 40oC for 25 min, 37oC for 50 min, 
40.5oC for 25 min then held at 4oC in the thermocycler. During the in vitro transcription 
incubation time, Fcwf-4 CU cells were prepared for electroporation. Briefly, Fcwf-4 CU 
cells were grown to confluence in T-75 flasks (Corning) in complete EMEM over 24-48 
hours prior to electroporation. The Fcwf-4 CU cells were washed in 10 mL 1x PBS, 
dissociated from the plate with 2 mL 0.25% trypsin-versene at 37oC for 2 min then 
diluted 1:10 in complete EMEM. The cells were pelleted at 4oC for 7 min at 760 rpm 
(104 xg), washed twice in 10 mL cold 1x PBS with centrifuge cycles at 4oC for 7 min at 
760 rpm (104 xg) to pellet in between, and counted on a hemocytometer using a 1:10 
dilution of cells in 0.4% trypan blue-PBS. Washed and pelleted Fcwf-4 CU cells were 
suspended to 1x107 cells/mL in cold Opti-MEM® I (Gibco, #11058-021) and held on ice. 
Completed in vitro transcription reactions were used directly for electroporation without 
additional purification. Briefly, 22 μL N gene transcript, 45 μL full-length infectious clone 
transcript and 600 μL Fcwf-4 CU cells (1x107 cell/mL) were combined, in order, in a 
chilled 0.4 cm gap Gene Pulser® cuvette (Bio-Rad, #1652081) and electroporated with 
3 pulses of 850 V, 25 𝜇F capacitance and ∞ resistance at 5 sec intervals using a Gene 
Pulser XcellTM (Bio-Rad) apparatus. As a positive control, 500 ng of purified FIPV Black 
genomic RNA and 250 μg N gene transcript were combined and electroporated into 600 
μL Fcwf-4 CU cells (1x107 cell/mL) using the same conditions as above. As a negative 
control, 600 μL Fcwf-4 CU cells (1x107 cell/mL) with no added RNA were electroporated 
using the same conditions as above. All electroporated cells were allowed to recover at 
room temperature for 10 minutes then diluted in 10 mL complete EMEM and plated into 
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T-75 flasks. After 3-5 hours, when the cells had settled and begun attaching to the flask, 
media was gently removed and replaced with 10 mL complete EMEM. The cells were 
then incubated for 24-72 hours at 37oC and 5% CO2, or until cell cytopathic effects were 
observable in the positive control.           
Detection of FIPV Black N gene Subgenomic RNA.  
Virus nucleocapsid (N) gene subgenomic (sg) RNAs containing the FIPV Black 
leader sequence were detected by reverse-transcriptase PCR (RT-PCR). Briefly, cell 
monolayers containing electroporated FIPV RNA were lysed in RLT buffer (proprietary 
lysis and binding buffer containing guanidinium thiocyanate) as per the manufacturer’s 
instructions (Qiagen) at room temperature between 24- and 72-hours post-
electroporation. Total RNA was extracted using a RNeasy Mini kit (74104, Qiagen) and 
eluted in 30 μL RNase-free water. Equivalent amounts of RNA, up to 4 μg, were 
converted to cDNA using the RevertAid First Strand Synthesis kit (Thermo Scientific, 
K1621) using random hexamer primers. PCR to amplify N gene sgRNA was carried out 
using Expand Long-Range dNTPack (Roche) with the following specifications: 0.2 mM 
dNTP mix, 0.2 uM FWD primer, 0.2 uM REV primer, 3.75% DMSO, 1x reaction buffer, 
1.5 U enzyme mix and 1 μL cDNA per 20 μL reaction. To amplify N gene, the following 
primers were used: Forward FIPV Black Leader Primer 5’- GTG CTA GAT TTG TCT 
TCG GAC ACC -3’; N Gene Reverse 5’- CAT CAG CAT GAG GTC CTG TAC CTG A -
3’ (Appendix B; Primer Index 1) resulting in a 331 bp amplicon. PCR reactions were 
heated to 92oC for 2 min, cycled 35 times between 92oC for 20 s, 61oC for 20 s, and 
68oC for 20 s, then incubated at 68oC for 7 min for a final extension. PCR products were 
electrophoretically separated on a 0.9% agarose gel and visualized under UV light.   
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Generation of Figures, Graphics, Tables and Reference Management 
The open source illustration program INKSCAPE (Inkscape.org) was used to create 
original graphic figures. All other figures that incorporate experimental data and 
statistical analyses were generated using GraphPad Prism 6 software (Graphpad.com). 
Tables were created using Microsoft Word for Mac version 16.22 (Microsoft.com). All 
reference materials were organized and incorporated using Mendeley software version 
1.19.3 (©Mendeley Ltd.; Mendeley.com).
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CHAPTER THREE 
EXPERIMENTAL RESULTS 
Section 1: Characterizing Replication Kinetics and Plaque Production of Serotype 
I Feline Infectious Peritonitis Virus in Three Feline Cell Lines 
Rationale.   
 It is critical that we investigate type I FIPV in laboratory cell culture in order to 
understand the basic virology of natural infection, characterize type I clinical isolates, 
test novel therapeutics, and develop effective feline vaccines with broader coverage. 
However, this has been challenging because type I FCoVs cannot be easily adapted to 
laboratory cell culture; furthermore, the receptor for type I is not known (Cham et al., 
2017; Dye et al., 2007; Hohdatsu et al., 1998), making the identification of highly 
permissive cell types difficult. Select type I isolates, such as the FIPV Black strain used 
in this study, have been adapted to growth in tissue culture at the cost of reduced in 
vivo virulence (Black, 1980; Pedersen, 2009; Tekes et al., 2008; Thiel et al., 2014). 
Feline airway epithelial (AK-D) cells propagate FIPV Black (Regan et al., 2012); 
however, these cells do not represent natural tropism for FIPV. Felis catus whole fetus 4 
(Fcwf-4) cells are a more physiologically-relevant feline macrophage-like cell line 
(Jacobse-Geels and Horzinek, 1983), but these cells come with several technical 
drawbacks for studying type I FIPV: Typical replication of serotype I FIPV in Fcwf-4 cells 
takes between 15 and 96 hours to reach maximum titers, which usually range between 
103 and 104 pfu/mL. Additionally, FIPV produced in these cells tends to be very cell-
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associated and requires multiple freeze-thaw cycles to release – a technique that further 
reduces the final titer. Together, these factors have made investigation of type I FIPV 
challenging. 
  As part of this study, we characterized three feline cell lines– two from the 
American Type Culture Collection (ATCC) and one from Cornell University– and 
evaluated the replication kinetics, efficiency of plaque formation, and responsiveness of 
these cells to type I interferon in order to identify the optimal cell culture conditions for 
serotype I FIPV Black. The experiments performed here were done in collaboration with 
Dr. Amornrat O’Brien (Loyola University Chicago) and culminated in a co-first author 
manuscript: O’Brien and Mettelman et al., 2018. In this study, we found that an Fcwf-4 
cell line established at Cornell University College of Veterinary Medicine, designated 
Fcwf-4 CU, propagates type I FIPV to significantly higher titers in cell-free supernatant 
and with more rapid kinetics compared to commercially available Fcwf-4 cells. We show 
that Fcwf-4 CU cells are less responsive to exogenous type I interferon than Fcwf-4 
cells from the ATCC and are permissive to infection by both biotypes of type II FCoV. 
To facilitate quantitation of FIPV Black, we established a standardized plaque assay 
method using Fcwf-4 CU cells and commercially available AK-D cells and show that 
both cell types permit rapid and consistent quantitation of infectious titers of type I FIPV 
as well as type II FIPV and FECV from cell-free supernatants.  
Results.   
Type I FIPV Black replication kinetics vary between feline cell types. To 
determine the optimal cell type and conditions required to grow the type I FIPV Black 
strain, we evaluated virus growth kinetics using a standard infection time course. Cells 
 
 
 
132 
were infected at a multiplicity of infection (MOI) of 0.1 and virus titer was determined by 
plaque assay from cell-free supernatants over 96 hours. FIPV Black, a distinct type I lab 
strain that replicates in feline epithelial cells, replicated as expected in AK-D cells 
reaching a maximum titer >106 pfu/mL at 36 hours post-infection (hpi) (Figure 8A). In 
our hands, using Fcwf-4 cells purchased from the ATCC, the replication of FIPV Black 
reached a maximum titer >104 pfu/mL over 72-96 hpi (Figure 8A). Strikingly, FIPV 
Black replication kinetics and maximum titer were drastically different in an Fcwf-4 cell 
line established at Cornell University College of Veterinary Medicine (Fcwf-4 CU). Using 
these cells, the virus reached a significantly higher maximum titer of >106 pfu/mL at 20 
hpi. In other words, nearly 100 times more virus was produced from the Fcwf-4 CU cells 
a full 2-3 days faster than in Fcwf-4 ATCC cells.  
To address whether the differences in titer observed between AK-D, Fcwf-4 CU, 
and Fcwf-4 ATCC cells were due to differences in cell-free and cell-associated virus, we 
compared the cell-associated and cell-free virus titers from each cell type at the time 
points around the respective maximum titers. Surprisingly, the cell-free virus titers were 
higher than the cell-associated titers at all time points and in all cell types assayed 
(Figure 8B). This indicates that FIPV Black virions are released into cell supernatant 
during infection of cell culture and freeze-thaw cycles are not necessary to obtain high 
virus titers. 
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Although the maximum titers of FIPV Black were comparable between AK-D and 
Fcwf-4 CU cells, the progression of cell cytopathic effects (CPE) induced by the virus 
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Figure 8: Fcwf-4 Cornell University (CU) Cells Produce High Titers of Cell-free 
Type I FIPV With Rapid Growth Kinetics. A) Virus growth kinetics measured from 
cell-free supernatants of AK-D (black), Fcwf-4 ATCC (blue), and Fcwf-4 CU (red) cells 
infected with FIPV Black (MOI=0.1) over 96 hours. Arrows indicate time of peak titer 
presented as plaque-forming units (pfu)/mL. Titer determined by plaque assay on AK-
D cells in triplicate; error bars ±SD. B) Cell-associated and cell-free virus titers were 
determined following infection of Fcwf-4 CU, AK-D, and Fcwf-4 ATCC cells with FIPV 
Black (MOI=0.1). Cell-free titer was determined from cell-clarified supernatants; cell-
associated titer was determined from suspended cell monolayers following three 
freeze-thaw cycles alternating between -80oC and 37oC. Samples were taken at hours 
post-infection (hpi) just prior to, at, and following the maximum (max) virus titer for 
each cell type. Titers determined by plaque assay on AK-D cells in triplicate; error 
bars ±SD. 
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differed. FIPV Black formed large, uniform syncytia in Fcwf-4 CU cells, while individual 
cell-death-induced clearings were observed in infected AK-D cells (Figure 9A). Of note,  
maximum titers from both cell types were obtained just prior to the appearance of major 
CPE, allowing a visual guide to virus collection. To further demonstrate this point, Fcwf-
4 CU and AK-D cells infected with FIPV Black were labeled with an anti-nucleocapsid 
antibody (CCV2-2) (Poncelet et al., 2008) and visualized by immunofluorescence prior 
to the induction of major observable CPE. As expected, the majority of cells were 
positive for virus antigen (Figure 9B) and the differences in CPE are clearly shown: 
note the syncytial membrane fusion in infected Fcwf-4 CU cells and the maintenance of 
distinct cell membranes in infected AK-D cells (Figure 9B). Together, these results 
demonstrate the ability of the Fcwf-4 CU cells to rapidly produce high levels of type I 
FIPV Black in cell-free supernatants.   
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AK-D and Fcwf-4 CU cells facilitate rapid and consistent plaque assays for 
FIPV Black. After observing the rapid and uniform development of CPE and release of 
virus into cell supernatants during infection of AK-D and Fcwf-4 CU cells, we reasoned 
Fcwf-4 CU
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Figure 9: FIPV Black-induced Cell Cytopathic Effect Varies Between Infected Cell 
Types. A) Progression of cell cytopathic effects (CPE) induced by FIPV Black over time 
in Fcwf-4 and AK-D cells (MOI=0.1). Localized cell syncytia formation (black, closed 
arrows) and discrete cell death (white, open arrows) indicated on brightfield images 
taken at 20x magnification. B) Immunofluorescence staining of FIPV Black-infected 
Fcwf-4 CU and AK-D cells (MOI=0.1) at indicated hours post-infection (hpi). 
Nucleocapsid protein staining (Red; CCV2-2) indicates infected cells; nuclei stained in 
blue (Hoesch3342). Images taken at 60x magnification. 
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that these cells would be employable in a standardized plaque assay to consistently 
determine FIPV Black titer. To this end, we calculated the endpoint titer and compared 
the size, uniformity, and timing of virus plaque development over time in AK-D, Fcwf-4 
ATCC, and Fcwf-4 CU cells following infection with 10-fold dilutions of the same FIPV 
Black virus stock initially grown on Fcwf-4 CU cells. A detailed description of the plaque 
assay is provided in the Materials and Methods; we note here that Oxoid agar is critical 
for visualizing clear plaques. At 2 days post-infection (dpi), FIPV Black formed 
enumerable plaques on both AK-D and Fcwf-4 CU cells with the latter cells producing 
more numerous and larger plaques at higher dilutions (Figure 10 top). Plaques were 
not observed in Fcwf-4 ATCC cells at 2 dpi (Figure 10 top). Plaques were detected at 3 
dpi (Figure 10 middle); and were clearer at 4 dpi in Fcwf-4 ATCC cells (Figure 10 
bottom). Calculated titers overall were higher in Fcwf-4 CU (>107 pfu/mL) than in AK-D 
cells (≥106 pfu/mL); however, we report that both cell types are useful for determining 
virus titer, whereas the Fcwf-4 ATCC cells are not ideal for use in this assay.  
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Figure 10: Evaluating FIPV Black Plaque Development and Titer Over Time in 
Different Feline Cell Lines. Tenfold serial dilutions (10-3-10-6) of virus inoculum, 
derived from 24-hour cell-free supernatant of Fcwf-4 CU cells infected with FIPV Black 
at a MOI=0.1, were applied to AK-D, Fcwf-4 ATCC, and Fcwf-4 CU indicator cells. 
Following Oxoid agar/media overlay, plates were incubated for 2 (top), 3 (middle), or 4 
(bottom) days before cells were fixed with 3.7% formaldehyde and stained with 0.1% 
crystal violet. Titers were calculated by plaque counts and are presented as plaque-
forming units (pfu)/mL. ND indicates that titers were not determined. 
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Fcwf-4 CU cells are distinct in morphology and IFN-responsiveness. The 
apparent differences in production and kinetics of FIPV Black virus in two Fcwf-4 cell 
lines led us to ask if there are morphologic or functional differences between the two cell 
types. To answer this question, we first compared the single-cell morphologies of Fcwf-
4 ATCC, Fcwf-4 CU cells, and primary feline bone marrow-derived macrophages 
(fBMDMs) by Wright-Giemsa staining. The typical morphologic characteristics of feline 
macrophages (large cytoplasmic inclusions, a non-dominant nucleus, a non-ruffled cell 
membrane) (Bienzle et al., 2003) were observed for the fBMDMs (Figure 11A). 
Comparison of the two Fcwf-4 cell lines revealed stark differences in morphology. Fcwf-
4 ATCC cells were large with a smooth cell membrane and had large and abundant 
cytoplasmic inclusions comparable to the fBMDMs (Figure 11A). Fcwf-4 CU cells were 
more similar in size to fBMDMs; however, the Fcwf-4 CU cell line exhibited fewer 
cytoplasmic inclusions and more cell membrane ruffling (Figure 11A) than either the 
fBMDMs or Fcwf-4 ATCC cells. Neither Fcwf-4 cell line had a “true” macrophage 
morphology further corroborating their original “macrophage-like” description (Jacobse-
Geels and Horzinek, 1983). As macrophages are innate immune cells that restrict virus 
replication through production of interferon-stimulated genes (ISGs) in response to type 
I IFN, we reasoned that differences in virus replication may be due to variation in cell 
IFN-responsiveness. Therefore, we asked if Fcwf-4 ATCC and CU cell lines differed in 
responsiveness to exogenous type I IFN by measuring the resulting ISG54 transcript 
production following treatment with IFN. Remarkably, Fcwf-4 ATCC cells produced 
significantly higher ISG54 transcripts in response to IFN stimulation compared to Fcwf-4 
CU cells (Figure 11B), suggesting that the Fcwf-4 CU cells are much less responsive to 
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IFN. This is not to say, however, that Fcwf-4 CU cells are insensitive to IFN since they 
also exhibit significant, dose-dependent ISG54 transcript production. Together, these 
data highlight the distinct morphology of the Fcwf-4 CU cells and suggest that enhanced 
virus replication in these cells may be due, at least in part, to reduced IFN-
responsiveness.  
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Figure 11: Fcwf-4 CU Cells Differ in Morphology and IFN-responsiveness From 
Fcwf-4 ATCC. A) Single-cell morphology of feline bone marrow-derived macrophages 
(fBMDMs), Fcwf-4 CU, and Fcwf-4 ATCC cells determined by Wright-Giemsa stain 
following cytospin preparation. Images were taken at 100x. B) Interferon-stimulated 
gene (ISG) 54 transcript levels from Fcwf-4 ATCC (grey) and Fcwf-4 CU (black) cell 
lines stimulated with increasing concentrations of feline type I interferon (IFNα). After 6 
hours, total RNA was extracted and analyzed by qPCR for ISG54 and feline beta-
actin. ISG54 mRNA expression was normalized to 𝛽-actin via the delta Ct method  
(2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]), then presented as relative expression over 
corresponding mock (basal) expression. Data are representative of three independent 
experiments performed in triplicate and presented as means ±SD. Values were 
analyzed by unpaired t-test. ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
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Fcwf-4 CU cells replicate both biotypes of type II FCoV. Due to the high titer 
and rapid kinetics of type I FIPV Black replication in the Fcwf-4 CU cells, we next 
addressed whether these cells are permissive to type II FCoV infection. Fcwf-4 CU cells 
were infected with type I FIPV Black or one of two type II viruses, FIPV 79-1146 or 
FECV 79-1683. Cell cytopathic effects were observed over time in these cells, with the 
viruses all forming similar, large syncytia (Figure 12A). Cell-free virus titers were 
determined at 12 and 24 hpi. All three viruses accumulated to titers >106 pfu/mL in 
supernatants by 24 hpi (Figure 12B), with FIPV 79-1146 reaching the highest titer. The 
kinetics of the type II viruses were faster than the type I FIPV Black strain, producing 
higher titers by 12 hpi (Figure 12B) and inducing more substantial syncytial CPE by 16 
hpi (Figure 12A). Next, we asked if the Fcwf-4 CU cells could be utilized in a plaque 
assay for determining the titer of type II FCoV. Indeed, both FIPV 79-1146 and FECV 
79-1683 formed clear, uniform, enumerable plaques at 24 hpi (Figure 12C). Thus, we 
have demonstrated that the Fcwf-4 CU cells replicate both FCoV types and biotypes to 
high titers and are employable in a plaque assay to consistently determine the titers of 
all viruses assayed.  
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Figure 12: Fcwf-4 CU Cells and are Permissive to Both Biotypes of Type II 
FCoV. A) Cell cytopathic effect at 12- and 24-hours post-infection (hpi) of Fcwf-
4 CU cells infected with indicated FCoV strains (MOI=0.1). B) FCoV growth 
kinetics in Fcwf-4 CU cells (MOI=0.1) determined by C) plaque assay on Fcwf-
4 CU indicator cells. Tenfold serial dilutions of cell-free virus inoculum were 
applied to cells. Following Oxoid agar/media overlay, cells were fixed in 3.7% 
formaldehyde and stained using 0.1% crystal violet after 24 hours. FCoV used 
were the type I strain FIPV Black and the type II strains FIPV WSU 79-1146 
and FECV WSU 79-1683. Plaque assay performed in triplicate; error bars ±SD. 
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Section 2: Generation of Feline Cell Lines to Study Attenuated or Clinically-
important FCoV Strains 
Rationale.   
Immunization against serotype I FIPV is likely to be the most effective 
vaccination method to protect against FIP (Pedersen, 2009). To date, implementing an 
effective serotype I FCoV vaccine has been unsuccessful and new strategies and 
approaches are needed in order to achieve wide-spread protection. Targeted 
elimination of coronavirus type I IFN antagonists resulting in a hyper interferon-inducing 
(HII) phenotype has been a successful method to generate live-attenuated coronavirus 
strains and successful vaccines (Deng et al., 2019b, 2017; Kindler et al., 2017). In these 
studies, two conducted by our group, permissive cells deficient in type I IFN signaling 
were a key component allowing for recovery and characterization of IFN antagonist-
deficient viruses. The lack of the type I IFN receptor (IFNαR) allows recovery, 
propagation and accurate determination of virus titer of mutant viruses produced by 
reverse genetics without negative selective pressure or induction of suppressive 
mutations in the viral genome. I hypothesized that feline cell lines that are i) highly 
permissive to serotype I FCoV and ii) deficient in IFNαR signaling would allow for the 
development and investigation of IFN antagonist-deficient FIPV viruses and could be 
employed in future studies to recover vaccine candidate strains using reverse genetics. 
A feline IFNαR-deficient cell type, however, is not currently available. In this section of 
my dissertation, I proposed to eliminate IFN responsiveness in two serotype I FCoV-
permissive cell lines: feline airway epithelial (AK-D) cells and Fcwf-4 CU cells by 
employing the Crispr/Cas gene-editing system to disrupt domain 2 of the type I IFN 
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receptor (IFNαR2). First, I demonstrate that a polyclonal population of Crispr/Cas-
transduced AK-D cells (termed AK-D 2.2) display a significantly reduced response to 
exogenous IFNα stimulation. Infection of AK-D 2.2 cells with serotype I FIPV induces 
rapid development of cytopathic effect, while maintaining production of infectious virus. 
Further, I demonstrate the utility of the AK-D 2.2 cells in determining the titer of serotype 
I FIPV by plaque assay. Second, using parental Fcwf-4 CU cells, which we 
demonstrated grow high titers of FIPV Black and had reduced IFN-responsiveness 
(above) (O’Brien et al., 2018), I again used Crispr/Cas9 gene editing to disrupt IFNαR2 
and expanded clones from the resulting total population of transductants. One isolate, 
termed IFNαR2 null (IRN), was found to have significantly reduced IFN-responsiveness. 
Comparison of the amino acid sequences of the parental (Fcwf-4 CU) and clone (IRN) 
interferon alpha receptor indicates that the reduction in IFN-responsiveness observed in 
the clone is likely due to early termination of the protein. Growth kinetics of serotype I 
FIPV Black was similar in both cell lines.  
As the overall goal of this dissertation is to develop tools to investigate clinically-
important serotype I FCoV strains, I proposed to further modify the Fcwf-4 IRN cells to 
express host proteases to enhance replication efficiency of type I FCoVs. The presence 
and density of specific host cell proteases are important determinants of coronavirus 
entry (Millet and Whittaker, 2015) and several groups have reported that ectopic 
expression of proteases, such as the transmembrane serine protease 2 (TMPRSS2), 
can enhance coronavirus entry and replication (Glowacka et al., 2011; Park et al., 2016; 
Regan et al., 2008). Serotype I FCoV spikes contain two protease cleavage sites, which 
can be cleaved to induce membrane fusion. The S1/S2 site contains a multibasic 
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cleavage sequence (RRXRR), which is processed by cell-surface proteases including 
furin and furin-like proteases such as TMPRSS2. Cleavage at the S1/S2 site mediates 
viral entry at the cell surface. The downstream S2’ site is cleaved within host 
endosomes by cathepsin-L, allowing virus entry at this later stage. The serotype I spike 
protein encoded by the TC-adapted TN406 (Black) strain used in our experiments 
contains a multibasic S1/S2 cleavage (RSRR) site (Whittaker et al., 2018) and therefore 
we predicted that expression of TMPRSS2 would enhance FIPV Black replication. 
Indeed, using the parental Fcwf-4 IRN cells, which are already highly permissive to 
FIPV Black and deficient in type I IFN signaling, I cloned and expressed feline 
TMPRSS2 and demonstrate increased production of virus over time. 
Together, the data presented in this section describe the generation of two feline 
cell lines that are deficient in IFN-signaling and one that expresses TMPRSS2, both 
characteristics that will be useful in recovery of live-attenuate type I FIPV strains and 
clinical isolates from infected cats.      
Results.   
Evaluating the interferon response in AK-D and IFNaR2-deficient AK-D 2.2 
cells. Wild type feline airway epithelial (AK-D) cells were used as the first parental cell 
type to knock down the feline type I interferon receptor (IFNaR2). AK-D cells were 
chosen because they are permissive to serotype I feline coronavirus and have a defined 
genotype. To knock down the IFNaR2, wild type AK-D cells were transduced with 
pLentiCRISPRv2 encoding a specific guide RNA targeting the second exon of the feline 
ifnαr2 gene (2.2). Positive selection was performed using puromycin and cells were 
cultivated as a heterogeneous population termed AK-D 2.2. As there is no available 
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IFNaR-specific antibody to detect the presence of feline IFNaR2 protein, we used a 
functional assay to evaluate the AK-D 2.2 cells for the IFNaR2-deficient phenotype. 
Increasing concentrations of purified feline IFNa were exogenously applied to AK-D or 
AK-D 2.2 cells and RNA levels of IFN stimulated gene (ISG) 54 were determined by 
quantitative PCR (qPCR). ISG54 expression is prominently upregulated following 
activation of the type I IFN receptor (Fensterl and Sen, 2011) and is used here to report 
on the functionality of the IFNaR. As expected, wild type AK-D cells responded to 
exogenous IFNa with a dose-dependent increase in ISG54 expression. The AK-D 2.2 
cell population, however, produced significantly fewer ISG54 transcripts than wild type 
(Figure 13), indicating a disruption of the IFN-I response-pathway. The subtle but 
concentration-dependent ISG54 transcription observed from AK-D 2.2 cells may be 
attributed to the presence of an additional receptor, or incomplete silencing in some 
cells in the population.  Nonetheless, these results indicate that the AK-D 2.2 cells have 
a diminished total response to IFNa, which is likely due to disruption of the IFNαR2.  
 
 
 
147 
Evaluating growth kinetics of serotype I FIPV Black in AK-D 2.2 cells. To 
determine if knocking down the IFNaR2 had any effect on replication of FIPV Black we 
evaluated the growth kinetics of FIPV Black in AK-D and AK-D 2.2 cells. We infected 
cells with FIPV Black at a MOI = 0.1 and titers were evaluated over time by plaque 
assays. FIPV Black achieved a maximum titer >106 plaque-forming units (PFU)/mL in all 
cell types tested. The kinetics of FIPV Black were similar in AK-D and AK-D 2.2 cells 
(Figure 14A), with both cell types producing peak titers at 42 hours post-infection (hpi), 
suggesting that the IFNaR2 does not significantly impact virus growth in this cell type. 
This is likely due to the multiple IFN antagonists expressed by FIPV, which permit 
 
Figure 13: AK-D 2.2 Cells Exhibit Diminished Response to Type I IFN. AK-D 
(black) or AK-D 2.2 (red) cells were treated with increasing concentrations of feline 
interferon alpha (IFNα). After 6 h, total RNA was extracted and analyzed by qPCR for 
ISG54 and feline beta-actin. ISG54 mRNA expression was normalized to beta-actin 
via the delta Ct method (2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]), then presented as relative 
expression over corresponding mock (basal) expression. Data are representative of 
two independent experiments performed in triplicate and presented as means ± SD. 
Values were analyzed by unpaired t-test. *** P < 0.001. 
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replication in AK-D cells independent of an IFN response (Dedeurwaerder et al., 2014, 
2013). 
While evaluating the virus kinetics, we also observed that high virus titers were 
obtained from the cell-free supernatants. This was intriguing as it has previously been 
reported that FIPV is highly cell-associated and that multiple freeze-thaw cycles are 
required to release infectious virus (Jacobse-Geels and Horzinek, 1983). Therefore, we 
asked if FIPV Black virus titer was comparable in supernatant (cell-free) and freeze-
thawed cell monolayers (cell-associated) in AK-D or AK-D 2.2 cells. We report that, 
between 30-42 hpi when maximum virus titers are achieved, FIPV Black titers are 
higher in cell-free supernatants than in the cell-associated fractions (Figure 14B) for 
both cell types. These results demonstrate that high virus titers can be derived from the 
supernatants alone and that further processing of cell monolayers by freeze-thaw cycles 
may even be detrimental to virus titer. 
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Determining the utility of AK-D 2.2 cells in visualizing FIPV Black plaques. 
Next, we asked if AK-D 2.2 cells can be used as an indicator cell type to accurately 
determine FIPV-Black titers by plaque assay. An ideal indicator cell type allows a virus 
A. 
B. 
 
Figure 14: Characterization of Replication Kinetics and Cell Association of FIPV 
Black in AK-D 2.2 Cells.  Cells were infected with serotype I FIPV Black at MOI = 0.1, 
and samples were collected at the indicated hours post-infection (HPI). A) Growth 
kinetics of FIPV Black determined by plaque assay of infected AK-D (black) and AK-D 
2.2 (red) cell supernatants. B) Cell-free (solid) and cell-associated (dashed) virus titers 
were determined by plaque assay analysis from infected AK-D (black) and AK-D 2.2 
(red) cells. Cell-free titer was determined from cell supernatants. Cell-associated titer 
was determined from suspended cell monolayers following three freeze-thaw cycles 
alternating between -80oC and 37oC. Each experiment was performed in triplicate, and 
results are expressed as means ± SD. 
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to form well-defined and easily enumerable plaques; therefore, we sought to determine 
if plaque size is affected by the absence of IFNaR2 in AK-D 2.2 cells. We infected AK-D 
or AK-D 2.2 cells with serotype I FIPV-Black at a MOI = 0.1 and evaluated how the 
reduced IFNα response in AK-D 2.2 cells affected virus-induced cytopathic effect (CPE). 
Over 48 h, we observed increased CPE in AK-D 2.2 cells compared to wild type AK-D 
cells (Figure 15A), suggesting an increase in virus spread that we speculate is due to 
the reduction in induced ISGs in AK-D 2.2 cells. A plaque assay utilizing AK-D 2.2 cells 
resulted in large and enumerable plaques that allowed for more accurate determination 
of FIPV Black titer compared to wild type AK-D cells (Figure 15B). In AK-D 2.2 cells, 
plaques were more easily identified at 72 hpi, and plaque sizes were comparable to 
those on Fcwf-4 CU cells at 48 hpi. It was difficult to accurately determine virus titer 
using wild type AK-D cells, as the plaques were too small to count accurately at both 
time points and led to an underestimation of PFU/mL. Our results highlight the utility of 
the AK-D 2.2 cells in determining the titer of serotype I FIPV and indicate that this cell 
line will be critical in future studies investigating IFN antagonist-mutant strains of FIPV.  
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A. 
B. 
Figure 15: AK-D 2.2 Cells Can Be Used to Determine Serotype I FIPV Titer. A) 
Representative images of AK-D (top row) and AK-D 2.2 (bottom row) of uninfected 
(Mock) cells or cells infected with FIPV Black (MOI = 0.1) taken at indicated hours 
post-infection (HPI). Mock images were taken at 24 h post-plating. B) Fcwf-4 CU cells 
were infected with MOI = 0.1 serotype I FIPV Black and supernatants were collected at 
24 HPI after which plaque assay analysis was performed on AK-D, AK-D 2.2, or Fcwf-
4 CU indicator cells. Images were taken at 48 (top) and 72 (bottom) HPI. (A-B) Images 
are representative of three independent experiments. 
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Evaluating the IFN-responsiveness and FIPV Black replication kinetics in a 
clone of Fcwf-4 2.2 Poly cells. In addition to disrupting IFN signaling in AK-D cells, I 
also targeted the IFNαR2 in the feline macrophage cell line, Fcwf-4 CU. These cells are 
a more physiologically relevant cell type in which to study FIPV and grow Black to high, 
cell-free titers (O’Brien et al., 2018). To knock down the IFNaR2, wild type Fcwf-4 CU 
cells were transduced with pLentiCRISPRv2 targeting the second exon of the feline 
ifnαr2 gene (2.2), the same sequence targeted in AK-D cells. Positive transductants 
were selected using puromycin and cells were cultivated as a heterogeneous population 
termed Fcwf-4 2.2 Poly (polyclonal). To evaluate the IFN-responsiveness of the 2.2 Poly 
cells, cultures were treated with 1000 U of feline type I IFN for 6 hours and evaluated for 
expression of ISG54. Compared to the parental Fcwf-4 CU cells and a population 
transduced with an empty pLevtiCRISPRv2 (EV), the Fcwf-4 2.2 Poly cells had reduced 
ISG54 production suggesting positive disruption of the ifnar2 gene (Figure 16A). 
Further, FIPV Black replication kinetics were similar in parental and 2.2 Poly cells 
(Figure 16B). As this polyclonal population of cells had reduced IFN-responsiveness 
and no negative impact on virus replication, I decided to isolate and evaluate several 
clonal cell lines to decrease genetic variability. A total population of Fcwf-4 CU 2.2 Poly 
cells were sorted into a 96-well plate at 1-2 cells per well then grown over 30 days. 
Three clones, CL1-3, were evaluated for IFN-responsiveness and, as before, by first 
stimulating with 1000 U of IFN then evaluating the ISG54 response (Figure 16C). Clone 
3 had the most subtle ISG54 response, which was further demonstrated using 
increasing concentrations of IFN stimulation (Figure 16D). The Fcwf-4 CU 2.2 Clone 3 
cells were termed “IRN” for IFNα Receptor Null. FIPV Black replication kinetics were 
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similar in the parental Fcwf-4 CU and Fcwf-4 IRN clonal cell line as determined by 
plaque assay measuring infectious particles (Figure 16E) and by qPCR measuring 
production of N gene transcript (Figure 16F). Cell cytopathic effects induced by the 
virus were also similar between the Fcwf-4 CU and IRN cell lines, although CPE was 
more robust late in infection, possibly due to slightly higher virus titers observed at 30 
hpi (Figure 16G). Together, these results describe the successful generation and 
isolation of an IFNα response-deficient Fcwf-4 CU cell line, which will be highly useful in 
the recovery and study of IFN-antagonist mutant FCoVs in future studies. 
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Figure 16: Fcwf-4 IRN Cells Have Reduced IFN-responsiveness and Replicate 
FIPV Black to High Titer. A, C, D) Fcwf-4 CU (CU), empty vector-transduced (EV), 
Fcwf-4 CU 2.2 Poly, Clones CL1 and CL2 or Fcwf-4 CU IRN cells treated with 0, 100 or 
1000 U feline IFNα for 6 h and ISG54 and 𝛽-actin detected by qPCR. B, E) FIPV Black 
growth kinetics (MOI=0.1) in given cell type over time. >2 replicate plaque assays done 
at each time using Fcwf-4 CU indicator cells. Values reported as mean plaque forming 
units (PFU) / mL. F-G) N gene expression by qPCR (F) and CPE (outlined) (G) taken 
over time during FIPV Black infection (MOI = 0.1) of Fcwf-4 CU or IRN cells. mRNA 
expression normalized to 𝛽-actin and presented as relative expression over mock. Data 
represent >2 independent experiments in triplicate. Mean ± SD analyzed by unpaired t-
tests. * P < 0.05; ** P < 0.01; *** P < 0.001; non-significant (ns). 
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Determining how IFN signaling is disrupted in Fcwf-4 IRN cells. The 
Crispr/Cas gene editing system targets and cleaves a specific sequence leading to non-
homologous repair and in/del mutations that can lead to disruption in gene transcription, 
point mutations or early termination of the protein. To determine how the IFNaR gene 
was disrupted in the Fcwf-4 IRN cell line, I first isolated total RNA from these cells and 
compared the expression of IFNaR2 by qPCR. In these experiments, the expression of 
IFNaR2 was actually higher than the parental cells (Figure 17A) indicating that the 
disruption did not occur at the level of transcription. I also compared the melting 
temperatures of the amplicons produced during qPCR (Krenke et al., 2005) and found 
that they differed, on average, by 1oC (Figure 17B) suggesting a possible difference in 
the nucleotide composition. To determine what the difference in sequence was, I cloned 
and sequenced the IFNaR2 mRNAs produced in Fcwf-4 CU and IRN cells (Appendix 
D). From the sequencing, I found that the IRN IFNaR mRNA encoded a 14-nucleotide 
deletion at the intended Cas9 cleavage site (Figure 17C), which translated to a frame-
shift and an early termination at residue 27 (Figure 17C) resulting in a shortened, non-
functional IFNaR.  
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Figure 17: Fcwf-4 IRN Cells Encode a Shortened, Null Mutant IFNαR Protein. A) 
Feline IFNαR2 exon 1-4 expression determined from total RNAs collected from Fcwf-4 
CU and Fcwf-4 CU IRN confluent monolayers. mRNA expression normalized to 𝛽-actin 
(2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]) and presented as such. Data represent two 
independent experiments in triplicate. Mean ± SD analyzed by unpaired t-tests. ** P < 
0.01. B) Melt curves and maximum melt temperatures of IFNαR2 exon 1-4 amplicons 
produced during qPCR of RNAs obtained from Fcwf-4 CU or Fcwf-4 CU IRN cells. Melt 
temps determined by plotting change in fluorescence with temperature [-d(RFU)/dT] 
versus temperature (oC) then calculating the point at which the largest change in 
fluorescence occurs (Krenke et al., 2005). C) Amino acid sequence alignment of the 
IFNαR2 region targeted by Crispr/Cas9 in Fcwf-4 CU and Fcwf-4 CU IRN cells. 
Disruption of the IFNαR2 in the Fcwf-4 CU IRN cells due to a 14 nt deletion resulting in 
a nonsense mutation, a shortened protein and a null phenotype. Nucleotide site 
targeted by Cas9 cleavage indicated by arrow; asterisk indicates termination codon; 
blue highlights indicate positional differences between the amino acid sequences.  
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Expression of feline TMPRSS2 improves FIPV Black replication. Host-cell 
proteases are critical to coronavirus entry and replication. As the goal of this dissertation 
is to develop a number of tools to aid in investigating feline coronavirus, I determined if 
of a host protease, TMPRSS2, may enhance FCoV replication. The feline TMPRSS2 
protein carrying a C-terminal V5 tag was cloned into a pLVX lentivirus backbone vector 
and termed pLVX-fTMPRSS2(V5). To demonstrate subcellular localization and to 
visualize expression, HEK 293T cells were transfected with the pLVX-fTMPRSS2(V5). 
The V5 antibody was detected by immunofluorescence within the cell cytoplasm and at 
the cell surface (Figure 18A) and both the full-length (55 kDa) and the cleavage product 
(>25 kDa), indicating an active protein, were detected from these cells by western blot 
(Figure 18 B, left). Fcwf-4 CU IRN cells that were transduced with pLVX-
fTMPRSS2(V5) lentivirus also had detectable levels of the full-length and active forms 
of feline TMPRSS2 (Figure 18 B, right) demonstrating that expression of an active 
feline protease was achievable in this cell line. Therefore, I next sought to determine if 
TMPRSS2 had an impact on replication of FCoV. Fcwf-4 CU IRN cells were transduced 
with increasing dilutions of pLVX-fTMPRSS2(V5) lentivirus for 48 hours then infected 
with FIPV Black at 0.1 multiplicity of infection (MOI) for 18 hours. Expression of 
TMPRSS2 at dilutions below 1:20 (Figure 18C) resulted in significant increases in FIPV 
N gene transcript (Figure 18D) compared to cells that did not express TMPRSS2, 
suggesting that addition of a feline protease can enhance virus replication. Interestingly, 
N gene expression was reduced at lower dilutions of TMPRSS2 (1:2.5) suggesting that 
expression of these proteases needs to be carefully titrated and too much protein can 
result in reduced titers. It should be noted that uninfected Fcwf-4 CU IRN cells that were 
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transduced with the 1:2.5 dilution of lentivirus had significant morphologic differences 
and were more detached from the plate compared to cells transduced with higher 
dilutions (data not shown) indicating that the lower N gene expression observed at  
higher expression of TMPRSS2 likely impacts the ability of the virus to enter cells.  
Together, these data describe the successful generation of two IFNαR-null cell 
lines by Crispr/Cas, the isolation of an Fcwf-4 CU IFNαR-null clone and, further, 
demonstrate that expression of a feline protease in these cells can enhance replication 
of serotype I FIPV.  
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Figure 18: Feline TMPRSS2 Improves FIPV Black Replication in Fcwf-4 IRN Cells. 
A) Immunofluorescence detection of feline TMPRSS2 (V5) in HEK 293T cells. 200 ng of 
pLVX-fTMPRSS2(V5) or pLVX (mock) was transfected into HEK 293T/17 cells for 18 h. 
Cells were fixed with 3.7% PFA, permeabilized with 0.1% Triton X-100, blocked in 5% 
NGS / 0.3% Triton X-100 and stained with mouse-anti-V5 (1:500). 1:1000 goat-anti-
mouse AlexaFlor568 (TRITC) was used to visualize TMPRSS2(V5); Hoesch 3342 
(1:1000) was used to stain nuclei. B) Detection of feline TMPRSS2(V5) by western blot 
following transfection of HEK 293T cells (left) or transduction of Fcwf-4 CU IRN cells 
with pLVX lentiviruses encoding TMPRSS2(V5) (right). The full length (< 55 kDa) and 
cleavage product (> 25 kDa) of TMPRSS2 are indicated. Feline 𝛽-actin used to visualize 
protein loading. C-D) The impact of feline TMPRSS2 expression on FIPV replication 
evaluated in Fcwf-4 CU IRN cells. Indicated dilutions of pLVX-fTMPRSS2(V5) or Mock 
(empty) transducing particles were applied to Fcwf-4 CU IRN cells for 48 hours prior to 
infection with FIPV Black (MOI = 0.1). RNA was isolated after 18 h infection and qPCRs 
were performed to detect TMPRSS2 (C), N gene (D), and 𝛽-actin transcripts. mRNA 
expression normalized to 𝛽-actin (2-ΔCt [ΔCt=Ct(gene of interest)-Ct(β-actin)]) and presented as 
such. Data represent two independent experiments in triplicate. Mean ± SD analyzed by 
unpaired t-tests. ** P < 0.01; *** P < 0.001; non-significant (ns). 
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Section 3: Progress Toward Developing an Infectious Clone Reverse Genetics 
System of Serotype I FIPV Black 
Rationale.   
One consideration for serotype I FIPV vaccine design is the strength of the innate 
immune response to immunization. A strong innate immune response, characterized by 
high levels of type I interferon (IFN), typically results in robust adaptive responses and 
development of immune memory (Hoebe et al., 2004; Siegrist, 2013). Coronaviruses 
including FCoV, however, prevent or subvert innate signaling using a number of virus-
encoded type I IFN antagonists (Dedeurwaerder et al., 2014; Deng et al., 2017; Rose 
and Weiss, 2009; Totura and Baric, 2012) that limit development of an appropriate 
inflammatory response  (Channappanavar et al., 2016). In the case of FIPV infection, a 
large, unregulated inflammatory response is mounted, which ultimately leads to the 
immune-mediated pathology observed in FIP. The adaptive responses, including 
cytotoxic T cell and humoral B cell stimulation/recruitment are generally weak and do 
not typically result in long-lasting immune memory (Tang et al., 2011). As a further 
complication, antibodies that are produced against the spike and envelope proteins of 
FIPV mediate antibody-dependent enhancement of disease (Corapi et al., 1992; Olsen 
et al., 1992). Although it is not known how ADE affects circulating FCoV, it remains a 
significant concern for vaccine development (Huisman et al., 2009). 
Strong cytotoxic T cell responses during FIPV infection are associated with 
positive disease outcomes (de Groot-Mijnes et al., 2005; Pedersen, 2014a; Satoh et al., 
2011) as are increased levels of IL-12, IL-21, IL-10 and type II IFN gamma 
(Dedeurwaerder et al., 2013; Kipar et al., 2006; Kipar and Meli, 2014). One group even 
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argued that a lack of IL-12, which functions to promote T cell differentiation and 
activation, may be the major determinant for progression to FIP (Kipar et al., 2006). 
Importantly, type I IFN signaling has been shown to enhance cytotoxic T cell responses 
through promotion of IL-12, IL-21, MHC-I, and IFN-𝛾 [reviewed in (Meager, 2006; 
Tough, 2012)] as well as promote memory T cell development [reviewed in (Huber and 
Farrar, 2011)]. Thus, enhancing the type I IFN response early during FIPV infection may 
lead to development of long-lasting T cell responses, which may effectively clear 
subsequent infections.  
Several groups have shown that the elimination of coronavirus IFN antagonists, 
therefore stimulating production of type I IFN, has been a successful method of 
generating attenuated coronavirus strains (Deng et al., 2019b, 2017; Haijema et al., 
2004; Kindler et al., 2017). Our group and others have demonstrated that functional 
elimination of the conserved endoribonuclease (EndoU) in mouse hepatitis virus (MHV) 
leads to the stimulation of multiple IFN-I signaling pathways, rapid cellular apoptosis in 
macrophages, and complete protection of mice against lethal challenge. Therefore, an 
EndoU FIPV mutant virus that stimulates high type I IFN and causes apoptosis in 
macrophages may be considered a vaccine candidate. The FIPV group-specific regions 
ORF7 and ORF3 have also been implicated in innate immune antagonism, and are 
thought to act on interferon stimulated genes (ISGs) rather than type I IFN signaling 
directly (Dedeurwaerder et al., 2014, 2013). Removal of these group-specific regions or 
individual proteins from serotype II FIPV leads to reduced virus replication in 
macrophage-like cells. Haijema and colleagues demonstrated that individual deletion of 
ORF3, or to a lesser extent ORF7, was attenuating to a serotype II FIPV and led to 
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protection against a second challenge without ADE (Haijema et al., 2004). These 
studies suggest that elimination of one set of the group-specific genes can be used to 
attenuate the more dominant serotype I FIPV. Thus, deletion of a set of group-specific 
genes may enhance the attenuation phenotype of an EndoU-mutant FIPV, thereby 
producing strong innate and adaptive T cell responses.  
To facilitate investigation of FCoV interferon antagonists for attenuation studies, I 
designed a reverse genetics system based on a sequenced laboratory strain of the 
model type I feline coronavirus FIPV Black. Similar to the MHV, SARS- and MERS-CoV 
systems (Scobey et al., 2013; Yount et al., 2003, 2002), our approach utilizes 
contiguous cDNA plasmids to produce full-length copies of the FIPV genomic RNA. The 
cDNA plasmids can be prepared and purified to high concentration while maintaining 
sequence fidelity and allow more straightforward mutagenesis. Together, this system 
facilitates genetic manipulation of targeted genes and allows for production of infectious 
virions with a defined genotype. The FIPV Black reverse genetics system described 
here complements previously-established systems for feline coronavirus (Tekes et al., 
2008). 
Results.   
Designing, constructing and evaluating a contiguous plasmid reverse 
genetics system of FIPV Black. The reverse genetics system described here was 
developed based on the genomic sequence of an in-lab strain of FIPV Black generously 
provided by Fred Scott (Cornell University). To determine the genomic sequence of the 
FIPV Black laboratory strain, cell-free and cell-associated fractions obtained from 
infected AK-D cells were combined and sent to the Kansas State Veterinary Diagnostic 
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Laboratory for deep-sequencing. A consensus sequence of our in-lab FIPV Black was 
generated by aligning the deep-sequencing reads to a known FIPV Black genome 
(EU186072.1). The resulting genomic sequence of the in-lab FIPV Black genome was 
then used as a template off of which the reverse genetics system was design and from 
here will simply be referred to as FIPV Black. The design of the FIPV Black contiguous 
cDNA plasmid reverse genetics system, based on work from Yount and colleagues 
(Yount et al., 2002), is diagrammed in Figure 19.  
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Figure 19: FIPV Black Infectious Clone Reverse Genetics Schematic. (1) RNA 
genome of lab-seq FIPV Black sub-cloned on 7 cDNAs, each containing two unique 
terminal restriction sites. A T7 promoter was added to the 5’ end of A frag and a poly-A 
tail was added to the 3’ end of G frag; (2) Large-scale plasmid preps digested to release 
frags, which were gel isolated, column purified, and chloroform extracted. Molar 
equivalents of frags ligated using T4. (3) Ligation product and linear plasmid encoding 
the Black nucleocapsid (N) gene in vitro transcribed using T7 into full-length, capped 
mRNAs and (4) electroporated into Fcwf-4 CUs. (5) After 24-72 h, CPE visualized. RNA 
isolated for detection of subgenomic (sg) RNA by RT-PCR, or virus recovered. 
1. cDNA Subclones  
2. Digest, Purify and Ligate Fragments 
A B C D E F G 
3. In vitro Transcription 
4. Electroporate Fcwf-4 CU 
5. Visualize CPE 
Detect sgRNA 
Recover Virus 
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First, the consensus FIPV Black genome was divided into seven sections (A-G) 
in silico (Table 8).  For segments B-F, PCR fragments were amplified from total cDNA, 
generated using isolated FIPV Black gRNA as a template, using specific primer sets 
(Appendix B; Primer Index 3). These primers appended two terminal BsmBI sites on 
each segment that produce unique 4 nt overhangs upon digestion and only base-pair 
with the next contiguous fragment (Table 8). PCRs were performed using a high-fidelity 
Taq Polymerase (Roche), which appends a T/A residue on the terminal ends of each 
segment and allows insertion of each segment into pCR-XL-TOPO® using TA cloning. 
The A and G segments could not be PCR amplified (without mutation) due to the 
complexity of the 5’ and 3’ ends of the gRNA, which contain low GC%, multiple 
repeating nucleotide stretches and secondary structures. Instead, these segments were 
synthesized by BioBasic, Inc and inserted into pUC57 vectors. The sequence of the A 
segment was modified at the 5’ end to encode an in-frame T7 RNA transcription 
promoter sequence (5’- TAA TAC GAC TCA CTA TAG -3’) upstream of the genomic 
sequence, and a natural BsmBI site was eliminates at position 3,806. The G segment  
was modified to carry a 21-nt poly-A tail. All other segments were unmodified and large-
scale DNA preparations were purified and sequenced to confirm sequence fidelity 
(Appendix B; Primer Index 4). Thus, each of these seven cDNA subclones encodes a 
specific cDNA segment of the FIPV Black gRNA. The sequence of the FIPV Black 
nucleocapsid protein was also amplified and cloned onto pCDNA-3.1 with a 5’ T7 
promoter sequence.   
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Following subcloning, the seven cDNA segments were excised from the cloning 
vectors using restriction enzyme digest (Table 8) and purified by separation through a 
low-melt agarose gel, cutting out the appropriate cDNA fragment and cleaning on a 
DNA-binding column. In addition to BsmBI, cDNA clones B, C, E and F were also 
digested with SfiI, which cleaves the cloning vector into smaller fragments allowing 
better visualization of the intended cDNA fragments on an agarose gel. The plasmid 
encoding the N gene was linearized by digestion with DraIII. The seven eluted 
segments of cDNA, now referred to as “A-G Fragment”, and the linearized N gene were 
further purified by chloroform extraction in order to concentrate the DNA and remove 
excess agarose gel. The size and purity of each cDNA fragment was confirmed by 
separation on an agarose gel (Figure 20A).  
Next, to generate a full-length cDNA copy of the FIPV Black genome, molar 
equivalents of each fragment were combined and ligated overnight using T4 Ligase. In 
cDNA 
Clone 
Cloning 
Plasmid 
Genome 
Location 
Restriction 
Enzymes  
5’ Restriction 
Junction  
3’ Restriction 
Junction  
Frag Size 
(Kb) 
A pUC57  (AmpR+) 
1 –   
4,810 BamHI / BsmBI 
5’-G_GATCCAGTTT 
   CCTAG_GTCAAA-3’ 
5’-A_AGACTGAGACG 
   TTCTG_ACTCTCG-3’ 4.810 
B pCR-XL-TOPO
®  
(KanR+) 
4,811 –  
8,875 
BsmBI / SfiI 
(vector) 
5’-CGTCTCA_AGACA 
   GCAGAGTTCTG_T-3’ 
5’-A_TTACTGAGACG 
   TAATG_ACTCTGC-3’ 4.064 
C pCR-XL-TOPO
®  
(KanR+) 
8,876 – 
13,485 
BsmBI / SfiI 
(vector) 
5’-CGTCTCA_TTACC 
   GCAGAGTAATG_G-3’ 
5’-G_CATCTGAGACG 
   CGTAG_ACTCTGC-3’ 4.609 
D pCR-XL-TOPO
®  
(KanR+) 
13,486 – 
15,825 BsmBI 
5’-CGTCTCG_CATCA 
   GCAGAGCGTAG_T-3’ 
5’-CGTCTCA_TAATG 
   GCAGAGTATTA_C-3’ 2.339 
E pCR-XL-TOPO
®  
(KanR+) 
15,826 – 
20,588 
BsmBI / SfiI 
(vector) 
5’-CGTCTCA_TAATG 
   GCAGAGTATTA_C-3’ 
5’-A_CTGTGGAGACG 
   TGACA_CCTCTGC-3’ 4.762 
F pCR-XL-TOPO
®  
(KanR+) 
20,589 – 
24,861 
BsmBI / SfiI 
(vector) 
5’-A_CTGTGGAGACG 
   TGACAC_CTCTGC-3’ 
5’-G_CCATTGAGACG 
   CGGTA_ACTCTGC-3’ 4.272 
G pUC57  (AmpR+) 
24,862 – 
29,198 BsmBI 
5’-CGTCTCG_CCATT 
   GCAGAGCGGTA_A-3’ 
5’-A_AAAAAGAGACG 
   TTTTT_TCTCTGC-3’ 4.341 
 
Table 8: FIPV cDNA Sub-cloning, Fragments and Restriction Digest Junctions. 
Genome Location: the genome locations given are based on the genome of the Baker 
Lab strain of FIPV Black, which was sequenced by Kansas State. Restriction Junction: 
the (_) indicates the enzyme cleavage site; bold sequences indicate unique overhangs 
produced following enzyme digestion. 
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order to confirm that fragments aligned in the proper order, PCRs were performed to 
amplify each junction using junction-specific primers (AB, A5/B1R; BC, B5/C1R; CD, 
C6/D1R; DE, D3/E1R; EF, E7/F1R; FG, F6/G1R) (Appendix B; Primer Index 4) using 
the full-length cDNA as template. The PCR products of each junction were successfully 
amplified (Figure 20B) and the size of full-length cDNA was confirmed (Figure 20C, 
second lane). Once confirmed, the ligation product was extracted using phenol-
chloroform-isoamyl alcohol, precipitated using isopropanol and washed with ethanol.   
In the third, fourth steps of the reverse genetics process (Figure 19), the purified 
ligation product and the linearized N gene DNAs were in vitro transcribed using T7 
polymerase into 5’-capped mRNAs encoding the FIPV Black infectious clone (ic) or the 
N gene (Figure 20C). These mRNAs can be directly co-electroporated into Fcwf-4 cells 
to produce infectious virus and are detectable visually by CPE development and by 
amplifying subgenomic RNA by RT-PCR. 
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Figure 20: Experimental Evaluation of FIPV Reverse Genetics Steps. A) cDNA 
frags (A-G) electrophoretically separated on an agarose gel observed using ethidium 
bromide under UV. B) PCR amplification of full-length ic cDNA ligation junctions 
visualized on an agarose gel under UV. C) Agarose gel depicting the full-length cDNA 
ligation (LIGATION), and the in vitro transcribed N gene (NG TSC.) and the full-length 
infectious clone (IC FV TSC.) RNAs. D) Prototypic “syncytial” and “melted” cell 
cytopathic effects (CPE) observed after 24 h electroporation of Fcwf-4 CU cells with 
purified genomic (g) RNA from FIPV Black. E) Determining the optimal electroporation 
voltage needed to introduce gRNA and N gene transcript into Fcwf-4 CU cells. 600 uL 
Fcwf-4 CU cells at 1x107 cells/mL in Opti MEM pulsed three times at indicated voltage 
(V) and plated in 10 cm dishes. Brightfield images taken at 24-48 h at 40x magnification.      
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To determine the optimal electroporation conditions needed to introduce RNA 
into Fcwf-4 CU cells, I used purified gRNA isolated from lab-stocks of FIPV Black. Fcwf-
4 CU cells were washed twice in PBS and diluted to 1x107 cells/mL in OptiMEM. In a 
cuvette, 600 uL of Fcwf-4 CU cells were added to 500 ng of FIPV Black gRNA and 250 
ng of in vitro transcribed N gene RNA. Cells and RNA were pulsed three times at 
increasing voltages (450-1200 V), with constant 25 μF capacitance and ∞ resistance, 
then plated into 100 cm dishes for 24 and 48 hours. Cells electroporated at all voltages 
developed CPE by 48 hours-post electroporation (hpe) (Figure 20E), however, optimal 
conditions were achieved at 850 V as cells were healthy, and CPE was the most robust 
(Figure 20E). Two types of CPE were observed including the classic syncytial formation 
and a “melted cell” phenotype (Figure 20E) and were used as first indicators of 
successful generation of infectious FIPV Black.  
The use of IFNα signaling-deficient cells is critical to recovery IFN-antagonist-
deficient FIPV Black mutant viruses. As this is the primary future use of this reverse 
genetics system, it was important to determine if the IFNαR-deficient cell line, Fcwf-4 
CU IRN cells, could also be used to successfully recover wild-type FIPV Black from 
electroporated gRNA. Indeed, substantial CPE was observed over 44 hpe in Fcwf-4 CU 
IRN cells electroporated with gRNA and N gene RNAs (Figure 21B). Interestingly, the 
CPE was more robust in the IRN cells compared to the CU cells (Figure 21A), 
corroborating previous results obtained during traditional infection (Figure 16 E-G).   
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Figure 21: FIPV gRNA Electroporation Produces Infectious Virus in Fcwf-4 CU and 
IRN Cells. A-B) FIPV Black gRNA (500 ng) was combined with N gene transcript (250 
ng) and electroporated into 6x106 Fcwf-4 CU (A) or Fcwf-4 CU IRN (B) cells at 850 V, 
25 μF C and ∞ R. Images taken at indicated hours post-electroporation (hpe). Arrows 
indicate CPE development. Mock cells electroporated without RNA. 
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Together, these data demonstrate that all steps of the reverse genetics process 
have been successfully optimized and describe the successful and reproducible 
generation of FIPV Black from electroporated gRNA in both Fcwf-4 CU and Fcwf-4 CU 
IRN cells as a positive control.  
Generation and detection of a wild-type infectious clone FIPV Black. To 
determine if this reverse genetics system could produce infectious virus, a full-length, 
mRNA infectious clone (ic) of the FIPV Black lab strain was constructed by digestion 
and ligation of fragments A-G and subsequent in vitro transcription. The icFIPV mRNA 
and N gene transcripts were co-electroporated into Fcwf-4 CU cells using optimized 
electroporation conditions. Fcwf-4 CU cells electroporated with 500 ng of purified FIPV 
Black gRNA and 250 ng N gene transcript was used as a positive control; Fcwf-4 CU 
cells electroporated without RNA (mock) were used as a negative control. The 
development of syncytial CPE was observed at 24 hpe in cells electroporated with both 
the icFIPV and FIPV gRNA (Figure 22A) suggesting that virus was produced in both 
cases. These syncytia were not observed in the mock-electroporated cells indicating 
that this cell morphology was not a side-effect of electroporation and was a result of 
virus replication. The detection of subgenomic (sg) RNAs, which are only produced 
during active CoV replication, was used in order to confirm the presence of FIPV. Mock, 
icFIPV- and FIPV gRNA-electroporated Fcwf-4 CU cells with were lysed at 24 or 48 hpe 
(depending on CPE development in the positive control) and I used RT-PCR to 
determine if L-containing subgenomic N gene mRNA was present. Indeed, sgRNA was 
detectable in both the positive control and the icFIPV (331 bp) (Figure 22B) confirming 
successful generation of an ic of FIPV Black using our reverse genetics system.   
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Figure 22: FIPV Infectious Clone Produces Syncytial CPE and N gene 
Subgenomic RNA. A) Development of syncytial cell cytopathic effect (black arrows) at 
24 hours post-electroporation (hpe) of Fcwf-4 CU cells with mock (0 ng RNA), genomic 
(g) RNA (500 ng + 250 ng N gene transcript) or infectious clone (ic) RNA (total 
transcription product with 350 ng N gene transcript), respectively. Representative 
brightfield images taken at 60 x magnification. B) Detection of nucleocapsid (N) gene 
subgenomic (sg) RNA by RT-PCR. Total RNA was isolated from Fcwf-4 CU cells 
electroporated with mock, gRNA, or icFIPV RNA, as in (A), at 24-48 hpe. cDNA was 
generated using random hexamer primers. RT-PCRs using primers specific to the 
leader sequence (forward) and the N gene (reverse) were run using the cDNAs from 
each cell type as templates. The products were separated on an agarose gel and 
visualized with ethidium bromide under UV. Positive amplicons present as a 331 bp 
band. Image representative of > 3 experiments.   
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CHAPTER FOUR
DISCUSSION 
Summary and Implications 
Overview.  
A number of issues related to the growth and characterization of serotype I feline 
coronavirus have slowed investigation of these important animal pathogens and 
hindered the development of effective vaccines. The goal of the research presented in 
this dissertation was to begin to establish a “tool box” containing protocols, reagents, 
cell lines and genetic techniques to facilitate the study of clinically relevant and mutant 
serotype I feline coronaviruses. In the first section, colleagues and I identified and 
characterized the growth kinetics of FIPV Black in a new, physiologically-relevant feline 
cell line, termed Fcwf-4 CU, and found that these cells were capable of rapidly 
producing high titers of cell-free virus. In the next section, I successfully disrupted IFN 
signaling in these Fcwf-4 CU cells and a second cell line, AK-D, using Crispr/Cas 
demonstrating that advanced genetic manipulations could be successfully performed in 
either cell type. A clonal cell line, termed Fcwf-4 CU IRN was isolated and found to be 
both IFN insensitive and also permit growth of high titers of FIPV Black. Expression of 
feline TMPRSS2 in these cells also increased FIPV replication indicating that these cells 
may be useful for isolation of serotype I strains directly from animal tissues and further 
highlights the importance of having a genetically plastic cell line. Finally, using the 
sequence of a laboratory strain of FIPV Black, I generated an infectious clone reverse 
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genetics system using seven contiguous cDNA plasmids and demonstrated successful 
detection of a wild-type FIPV Black produced in this system. In future experiments, the 
Fcwf-4 CU IRN cells will be used to recover and characterize IFN-antagonist-mutant 
FCoV strains exhibiting a hyper-interferon inducing phenotype for use as live-attenuated 
vaccine development.   
Characterizing Replication Kinetics and Plaque Production of Serotype I FIPV in 
Three Cell Lines. 
Summary. Investigating type I feline coronaviruses (FCoVs) in tissue culture is 
critical for understanding the basic virology, pathogenesis, and virus-host interactome of 
these important veterinary pathogens. This has been a perennial challenge as type I 
FCoV strains do not easily adapt to cell culture and viruses that do adapt, lose 
pathogenicity. We characterized the replication kinetics and plaque formation of a model 
type I strain FIPV Black (TN406) in Fcwf-4 cells established at Cornell University (Fcwf-
4 CU). We determined that maximum virus titers (>107 pfu/mL) were recoverable from 
infected Fcwf-4 CU cell-free supernatant at 20 hours post-infection. Type I FIPV Black 
and both biotypes of type II FCoV formed uniform and enumerable plaques on Fcwf-4 
CU cells. Therefore, these cells were employable in a standardized plaque assay. 
Finally, we determined that the Fcwf-4 CU cells were morphologically distinct from feline 
bone marrow-derived macrophages and were less sensitive to exogenous type I 
interferon than were Fcwf-4 cells purchased from ATCC. 
Implications. Since the isolation of the FIPV Black strain in 1980 (Black, 1980) it 
has remained a predominant model of type I FIPV because it is cultivatable in 
commercially available Fcwf-4 cells. However, different groups have reported major 
 
 
 
175 
variations in the growth kinetics, maximum obtainable titer, and techniques for recovery 
of this virus from tissue culture (Jacobse-Geels and Horzinek, 1983; Pedersen et al., 
1984; Tekes et al., 2012, 2008; Thiel et al., 2014). For example, maximal titers 
measured by determining the TCID50 can range between >103 (Jacobse-Geels and 
Horzinek, 1983) and 104 TCID50/mL (Takano et al., 2015) at 24-48 hpi, or measured by 
plaque assay between >104 (36 hpi) (Tekes et al., 2012, 2008) and >107 pfu/mL (20 hpi) 
(O’Brien et al., 2018). This suggests either high variability in the Fcwf-4 cell lines used 
or co-adaptation between a particular virus and Fcwf-4 cell line used during laboratory 
cultivation. Indeed, we report significant differences in FIPV Black replication properties 
between an Fcwf-4 cell line that was newly purchased from the ATCC, and the Fcwf-4 
cells that were established at Cornell University (CU). The enhanced rate of FIPV Black 
virus growth and increased maximum titer (>107 pfu/mL by 20 hpi) obtained from 
infected Fcwf-4 CU cells, however, may not be due to co-adaptation with our particular 
strain of FIPV Black, as these cells also replicated both biotypes of serotype II viruses. 
Instead, the Fcwf-4 CU cells may be highly susceptible to FCoV infection in general and 
therefore may be particularly useful in generating highly-permissive cell types to isolate 
and grow clinical type I FCoVs. The increased infectibility of Fcwf-4 CU cells could be 
due to any number of cellular factors including increased abundance of specific entry 
co-factors (e.g. DC-SIGN) or host proteases, which have been shown to enhance 
coronavirus entry (Millet and Whittaker, 2015; Regan et al., 2010). However, as 
infection by both serotype I and serotype II viruses were enhanced, it is tempting to 
speculate that the reduced IFN-responsiveness of the Fcwf-4 CU cells relative to the 
Fcwf-4 ATCC cells may also significantly enhance infection in the former. Further, these 
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Fcwf-4 CU cells may express a higher density of the yet unknown serotype I virus 
receptor (Cham et al., 2017; Dye et al., 2007) and therefore may be critical in identifying 
the receptor or other cellular characteristics that allow for enhanced type I virus 
replication.  
FIPV Black infection of Fcwf-4 cells has also been reported to be highly cell-
associated (Jacobse-Geels and Horzinek, 1983; Pedersen et al., 1984), requiring 
suspension and freeze-thaw cycling to release infectious virus. In contrast, we found 
significantly higher titers of virus in cell-free supernatants and speculate that multiple 
freeze-thaw cycles may actually decrease virus titer by damaging the virus envelope. 
The release of virus into cell supernatants and the uniform CPE observed in AK-D and 
Fcwf-4 CU cells were critical in establishing a standardized plaque assay using either 
cell type. Further, we report that the stage of CPE development can be used as an 
indicator of when maximal virus titers can be recovered. These findings are an 
important step in standardizing how the FCoV field measures and reports serotype I 
virus titer and may reduce the overall variability in the literature.  
One possible explanation for the varied reports on FIPV Black replication kinetics 
and maximum titer could be that laboratory lines of Fcwf-4 cells have deviated from the 
original ATCC stock. The Fcwf-4 cells deposited with the ATCC in the 1980’s were 
characterized as “macrophage-like” (Jacobse-Geels and Horzinek, 1983), which hints 
that these original cells were not terminally differentiated and may further develop 
distinct characteristics under different growth conditions. Further, as per the ATCC, 
Fcwf-4 cells grow as a “dual population” of adherent and suspended cells that need to 
be pelleted during routine passaging (ATCC personal communication) – a technique 
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that, if not followed, may significantly impact the characteristics of these cells in culture 
over time. Subtle changes in Fcwf-4 characteristics and morphology is likely what 
occurred at Cornell University to produce the Fcwf-4 CU cell line, given that Fcwf-4 cells 
were obtained from the ATCC and then passaged for many years. To our knowledge, 
O’Brien and Mettelman et al. (2018) is the first report describing the phenotypic 
differences between the original Fcwf-4 cells available from the ATCC and a distinct 
lineage that was derived from the original cells.   
Finally, as these Fcwf-4 CU cells are “macrophage-like” they represent a more 
physiologically relevant cell type in which to propagate serotype I FIPV strains, not just 
tissue culture (TC)-adapted strains. One of the major issues in serotype I FCoV 
research is attempting to extrapolate information about clinical viruses from studies 
using TC-adapted strains, which harbor many genetic mutations. The majority of type I 
FIPV strains that grow well in tissue culture, including the Black strain used here, have 
lost in vivo pathogenicity due to TC adaptation posing the question of biologic relevance 
when investigating such strains. It is likely that forcing serotype I FCoVs to grow in sub-
optimal conditions selects for adapted virus genotypes at the cost of virulence traits 
such as the sequence of S and the presence of accessory genes 3c and 7b. These 
specific gene regions have been shown to be altered or lost during TC adaptation and 
demonstrate that the genetic cost of TC adaptation is loss of virulence (Pedersen, 
2014a; Thiel et al., 2014). The characterization of the Fcwf-4 CU cells is an important 
step away from forcing viruses to adapt to sub-optimal conditions as these cells are 
highly permissive to serotype I FIPV. Future studies will be needed to determine if the 
Fcwf-4 CU cells can replicate new clinical isolates of type I FIPV without forcing genetic 
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mutations and allow propagation and investigation of more clinically relevant viruses in 
lab without the use of live animals.   
Many challenges are still associated with the growth of type I FCoV in tissue 
culture, including the lack of a known cell-entry receptor and no highly-permissive cell 
type that rapidly grows clinical samples of these viruses. However, our studies with the 
Fcwf-4 CU cell line demonstrate that rapid, high titers of type I FIPV Black can be 
recovered from cell-free supernatants and enumerated using a standardized plaque 
assay. It is our hope that the Fcwf-4 CU cells will alleviate some of the technical 
hardships associated with the growth of type I FCoV and expedite investigation of a 
wider range of type I FCoV strains. The Fcwf-4 CU cells, due to their distinct growth 
kinetics and enhanced replication of FIPV Black virus, will be deposited at the ATCC to 
facilitate their distribution to the research community.  
Generation of Feline Cell Lines to Study Attenuated or Clinically-important FCoV 
Strains.  
Summary and implications. The development of live-attenuated serotype I 
FCoV vaccine strains may be possible through mutation of encoded IFN antagonists. 
Generating and subsequent characterization of these so-called “hyper interferon-
inducing” (HII) FCoVs requires cell lines that lack IFN signaling in order to avoid 
selective pressures and determine the mechanism(s) behind the virus attenuation. To 
my knowledge, such IFN-nonresponsive feline cell lines were not available and studies 
using gene-modifying tools such as Crispr/Cas had not been performed in feline cells 
permissive to FCoVs. In the previous section, my colleagues and I characterized the 
growth kinetics of FIPV Black in AK-D and Fcwf-4 CU cells and demonstrated that rapid 
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growth of wild-type serotype I FIPV could be achieved given the right cell type and 
conditions. However, these cells still produced IFN upon stimulation suggesting that 
neither cell line would not be appropriate for recovery of HII viruses by reverse genetics. 
Previous studies from our lab using mouse hepatitis virus (MHV), a model murine 
coronavirus, strongly imply that production of IFN antagonist-deficient CoVs by reverse 
genetics absolutely requires the use of an IFN-nonresponsive cell type (Deng et al., 
2017). In these studies, we determined by deep-sequencing that mutant MHV strains 
produced in IFN-responsive cells acquired additional mutations that suppressed the 
original IFN antagonist mutation. This phenomenon likely occurred in response to 
selection imposed by the antiviral activity of type I interferon, which selected against the 
attenuated HII phenotype. Cells lacking the type I IFN response allowed for recovery of 
“clean” mutant viruses that contained only the desired mutation. Subsequent 
characterization of novel MHV IFN antagonists, as well as the relevant mechanisms 
underlying their activities, were undertaken using IFNαR-/- cells, highlighting the need of 
such cell lines in investigating attenuated feline coronavirus strains. 
  Building on this idea, the goal of this section of my research was to genetically 
modify AK-D and Fcwf-4 CU cells to generate feline cell lines that are i) highly 
permissive to serotype I FCoV and ii) deficient in IFNαR signaling. I predict that feline 
cells with these two characteristics will allow for future investigation of not only IFN 
antagonist-deficient HII viruses, but also isolation of clinically-important FIPV strains. To 
this end, I first disrupted the type I interferon alpha receptor domain 2 (IFNαR2) in two 
feline cell lines, AK-D and Fcwf-4 CU using the Crispr/Cas gene editing system, 
referring to the total population of positive transductants as AK-D 2.2 and Fcwf-4 2.2 
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Poly, respectively. Both populations of total positive transductants had diminished IFN-
responsiveness and replicated FIPV Black to high titers. Although I was unable to 
isolate clone of the AK-D 2.2, I showed that the polyclonal population of these cells 
produced higher FIPV Black virus titers from cell-free compared to cell-associated 
fractions of infected cells and were employable in a standardized plaque assay, a 
technique that will be useful in future studies for determining the titers of HII mutant 
FCoV strains without the negative impact of IFN on virus growth. From the Fcwf-4 2.2 
Poly cell line, I isolated a clonal cell line, termed Fcwf-4 CU IRN, which I determined to 
have significantly diminished IFN-responsiveness. Further, I sequenced the IFNαR from 
these cells and determined that the “null” phenotype was likely due to a 14-nucleotide 
deletion in the Crispr/Cas-targeted region of the IFNαR mRNA, which led to early 
termination in the second exon and a shortened protein product. Replication of FIPV 
Black in this cell line was comparable to kinetics of the same virus in Fcwf-4 CU cells 
and rapidly produced high titers of cell-free virus. 
 Interestingly, isolation of clones that both maintained the reduced IFN-
responsiveness phenotype and remained permissive to FIPV Black was difficult in Fcwf-
4 2.2 Poly- and ultimately unsuccessful in AK-D 2.2 cells. For both cell populations, the 
majority of isolated clones were non-permissive to FIPV Black infection regardless of 
the degree of IFN-responsiveness. This suggests that, within a given population of AK-
D or Fcwf-4 cells, a portion of cells are non-permissive to FIPV, or can become non-
permissive in different culture or selection conditions such as those used in the 
Crispr/Cas protocol. Further, this supports the speculation that continuous passage and 
inadvertent selection of Fcwf-4 cells in tissue culture may alter expression of host 
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proteases, entry co-factors, or virus receptor over time and that infectability of these 
cells can change.  
FIPV Black replication in parental and IFNαR-null (IRN) cells was relatively 
equivalent and only slightly higher virus titers were observed in IFN-unresponsive cells. 
Initially, I expected that virus growth would be significantly enhanced in the AK-D 2.2 
and Fcwf-4 CU IRN cells as these cells are not stimulated to express high levels of 
ISGs in response to IFN signaling. However, the observed growth kinetic results are 
consistent with the function of the IFN antagonists encoded on the FIPV genome, which 
allow replication of the virus in the wild-type cells without significant triggering of the IFN 
response. In future studies, it will be very intriguing to compare the replication kinetics of 
WT FIPV to HII mutants in Fcwf-4 CU and IRN cells. Here, I would expect to see 
significantly reduced titers of HII viruses and production of type I IFN in the wild-type CU 
cells, but equivalent titers and no IFN production in the IRN cells. This will be a highly 
critical set of experiments moving forward and requires the Fcwf-4 CU IRN to 
demonstrate that IFN is responsible for difference in virus replication.  
TMPRSS2, a transmembrane serine protease, has been shown to mediate or 
enhance cell-surface entry of a number of coronaviruses including HCoV 229E (Bertram 
et al., 2013; Shirato et al., 2017), MERS-CoV (Park et al., 2016; Shirato et al., 2013) 
and SARS-CoV (Glowacka et al., 2011; Reinke et al., 2017). To further demonstrate the 
utility of the clonal Fcwf-4 CU IRN cell line in investigation of type I FCoVs, I transduced 
these cells with feline TMPRSS2, and observed a significant, though modest, increase 
FIPV Black replication as detected by an increase in N gene expression. This is an 
important observation as it demonstrates that Fcwf-4 CU IRN cells can be transduced to 
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express functional proteins, and that addition of host factors is a viable way of 
enhancing serotype I FIPV infection in these cells. It should be noted that the TC-
adapted Black strain used here contains a polybasic TMPRSS2 S1/S2 cleavage site 
(RSRR). Interestingly, the N gene expression dropped when expression of TMPRSS2 
was further increased and significantly altered the morphology of the cells in culture 
causing cell rounding and detachment from the surface, which may have prevented 
efficient access to these cells by the virus. The increased presence of active TMPRSS2 
could also be affecting the virus entry/exit by over-processing of the spike protein. The 
pre-fusion form of the CoV spike must be processed at the appropriate spatiotemporal 
stage of infection in order to mediate efficient membrane fusion, and it is possible that 
excess TMPRSS2 may have pre-maturely cleaved S leading to reduced replication 
efficiency. Ultimately, a stable, inducible cell line is needed to temporally control 
TMPRSS2 expression. As Fcwf-4 CU cells have been shown to be amenable to genetic 
modification by Crispr/Cas, inserting a Tet-On inducible TMPRSS2 should not be too 
technically challenging.  
Coronavirus S-mediated membrane fusion and subsequent entry into host cells 
has been shown to occur at both the cell surface and within endosomes depending on 
the availability of host proteases (Belouzard et al., 2012; Millet and Whittaker, 2015) 
(Figure 23, top). For feline coronaviruses, cleavage of spike at the S1/S2 site by 
transmembrane serine proteases (e.g. furin; TMPRSS2) typically mediates entry at the 
cell-surface, while cleavage at the S2’ site by cathepsins typically mediates entry within 
endosomes. The route of FCoV entry can differ between serotypes. Most all serotype II 
viruses do not contain an S1/S2 site and rely on the S2’ for mediating membrane fusion, 
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while most serotype I FCoV spikes contain both the S1/S2 and the S2’ and can enter by 
either route (Belouzard et al., 2012; Whittaker et al., 2018). For FIPV Black, we consider 
that the presence of a trypsin-like protease (e.g. TMPRSS2) at the cell surface can 
functionally replace the usual endogenous protease to promote virus replication.  
Importantly, entry of serotype I FCoV can be further impacted by tissue culture 
adaptation. de Haan and colleagues demonstrated that the spike protein encoded on a 
Fcwf-4 TC-adapted serotype I FCoV strain, FIPV-UCD1, had reduced cleavage at the 
S1/S2 site, but exhibited increased binding to heparan sulfate (de Haan et al., 2008). 
Interestingly, the serotype I FCoV clinical isolate, FECV-UCD, contains a full furin 
cleavage site at S1/S2 and did not bind heparan sulfate, resulting in no replication of 
this virus in Fcwf-4 cells. This suggests that tissue culture-adapted strains may forfeit 
the S1/S2 cleavage site in favor of binding to heparan sulfate, which may be a more 
abundant entry receptor on Fcwf-4 cells compared to the yet unknown natural receptor 
in these cells (Figure 23, left).  
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The concept that TC-adaptation can alter the preferred virus entry pathway may 
be common amongst lab-adapted CoV strains. A recent study by Shirato et al. showed 
that clinical isolates of HCoV 229E, much like serotype I FCoV clinical strains, favored 
TMPRSS2-mediated cell-surface entry while high passage, TC-adapted strains 
preferentially adopted cathepsin-mediated entry in endosomes (Shirato et al., 2017).  
These results have a major impact on the recovery of clinical serotype I FCoV. If 
  
Figure 23: Dual Mechanisms of CoV Entry. Serotype I FIPV entry likely occurs within 
endosomes (cathepsin cleaves S2’) or at the cell surface (furin cleaves S1/S2) (top). 
TC-adapted S loses S1/S2 cleavage in favor of heparan binding (left). Expressing host 
factors, like TMPRSS2, may promote natural receptor usage and cell-surface entry, 
limiting S mutation and aiding in recovery of clinical serotype I strains (right).  
 
Coronavirus Entry 
TC-Adapted Serotype I FIPV (Proposed) Serotype I FIPV Clinical Strain (Proposed) 
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serotype I FCoV growth in Fcwf-4 cells positively selects for the use of heparan sulfate 
as an entry receptor, and by extension the loss of the furin/TMPRSS2 site, then this 
may explain why tissue culture-adapted strains lose pathogenicity. Cell-surface level 
entry, mediated by S1/S2 cleavage by furin or TMPRSS2, has been shown to be 
involved in pathogenicity and spread of coronaviruses in vivo (Park et al., 2016; Shirato 
et al., 2013) possibly by increasing the kinetics of virus entry (Earnest et al., 2017). 
Therefore, the loss of the S1/S2 cleavage site in tissue culture-adapted strains may 
significantly contribute to both the loss of pathogenicity of tissue culture-adapted strains 
and the inability to cultivate true clinical isolates without several rounds of passage. 
Interestingly, serotype II FCoVs do not contain an S1/S2 cleavage site, do not 
apparently utilize heparan sulfate, and use feline aminopeptidase N (fAPN) - a different 
entry receptor than serotype I FCoV (Hohdatsu et al., 1998). As such, tissue culture 
adaptation of serotype II FIPV strains does not typically correspond with a loss in 
pathogenicity (Tekes et al., 2012; Thiel et al., 2014) suggesting that maintenance of the 
natural receptor/entry route may allow recovery of pathogenic type I strains. Thus, 
increasing the expression of S1/S2-targeting host enzymes such as furin or TMPRSS2 
along with expression of other host factors that have been shown to enhance entry at 
the surface-level including tetraspanins, as has been shown with other coronaviruses 
(Earnest et al., 2017; Hantak et al., 2019), may lead to more efficient recovery of clinical 
type I FIPV strains (Figure 23, right). Other host proteases, such as cathepsins, have 
been shown to be important for FCoV entry within endosomes (Regan et al., 2008) and 
could also be expressed in Fcwf-4 CU or Fcwf-4 CU IRN cells using a similar system 
described here for TMPRSS2.  
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Together, the results in this section describe the successful disruption of the 
IFNαR in two feline cell lines and suggest that overexpression of feline proteases, in at 
least one of these cell lines, may be useful for enhancing infection of serotype I FCoVs. 
Importantly these data also demonstrate the genetic malleability of the Fcwf-4 CU cells 
and, to my knowledge, represent the first genetically-modified Fcwf-4 cell line. Thus, 
both the AK-D 2.2 and the Fcwf-4 CU IRN cells will be useful in future studies 
evaluating feline viruses that lack interferon antagonists and may be an important tool in 
isolating serotype I clinical strains from infected cats. 
Progress Toward Developing an Infectious Clone Reverse Genetics System of 
Serotype I FIPV Black.  
Summary. In this final section, I worked to establish a reverse genetics system 
based on a deep-sequenced laboratory strain of the model type I FCoV, FIPV Black. 
Using this FIPV Black sequence as a template, the genome was subcloned as seven 
cDNA segments (A-G) into cloning vectors. I demonstrated that each fragment could be 
excised from the vector, purified and ligated into a full-length cDNA version of the 
genomic RNA and, using in vitro transcription, that mRNAs of the full-length icFIPV and 
nucleocapsid gene could be produced.  Using purified WT gRNA isolated from FIPV 
Black virions, I optimized the electroporation protocol and established the positive 
control conditions necessary to reproducibly recover infectious virus from Fcwf-4 CU or 
IRN cells electroporated with gRNA. Electroporation of Fcwf-4 cells with WT gRNA or 
icFIPV resulted in the development of CPE over 24-48 hours. Finally, sgRNA, a positive 
indicator of ongoing virus replication, was detectable by RT-PCR from these cells 
further demonstrating that viable FIPV was produced from our reverse genetics system. 
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Implications. One of the major challenges with developing the FIPV Black 
reverse genetics system was the high degree of sequence variability within the S and 
7b regions observed following deep-sequencing. These two regions, which are critical 
for virus replication and cell tropism, varied greatly within the sequenced population of 
viruses obtained from the same supernatant and resulted in stretches of “n” reads 
denoting the lack of consensus. This suggested that the in-lab FIPV Black strain was 
likely a quasispecies populated by several dominant strains. Initially, this complicated 
the reverse genetics design as the system must be based on a single, consensus 
genome derived by giving the most abundant nucleotide at any given position. In 
addition to the “n” reads in S and 7b, it was also difficult to determine if the consensus 
generated for the rest of the genome represented a viable virus strain or a sequence 
mix between dominant sub-strains. To overcome this, I compared deep-sequencing 
results of two independent FIPV Black stocks, obtained from different sequencing 
facilities (Kansas State and University of Chicago) with a published sequence 
(EU186072.1) to construct a consensus genome that represented the population. 
Ultimately, this FIPV Black genome (Appendix C) resulted in detectable replication of 
infectious clone FIPV Black as determined by the presence of CPE and N gene sgRNA 
following electroporation.  
Additional challenges were confronted when attempting to propagate the 
infectious clone FIPV Black strain. Unlike the positive control gRNA, syncytia induced 
by icFIPV did not progress after 48 hpe. Further, passage of supernatants containing 
icFIPV did not cause CPE nor produce sgRNAs in new Fcwf-4 CU cells. This lack of 
second-round infectivity suggests that the icFIPV may harbor a sub-optimal genomic 
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sequence preventing the de novo construction of infectious virions. Indeed, there are 
numerous possible sequence or assembly defects that could lead to non-infectious 
virions, several of which we addressed. First, we can detect the presence of 
subgenomic nucleocapsid mRNA, the production of which requires both the translation 
of the replicase polyprotein and the activity of the nonstructural proteins encoded on 
pp1a and pp1ab. This suggests that the defect is likely not within the 5’ UTR, as this 
structure directs translation, nor the components of the replicase polyprotein necessary 
to produce subgenomic mRNA transcripts. Second, the electroporated material 
produces syncytia, a process mediated by spike-receptor engagement. This suggests 
that, at the very least, the spike protein is produced, engages a receptor and is able to 
mediate membrane fusion. However, it does not necessarily rule out the possibility that 
the spike sequence is sub-optimal or mediates low-efficiency fusion, which may impact 
virus entry. To determine if the spike sequence was limiting the infectivity of the ic 
virions, I replaced our ic S with the S sequence obtained from the published serotype I 
sequence (EU186072.1), which was shown to be infectious (Tekes et al., 2008). 
However, this sequence did not produce infectious, passable virus (data not shown) 
and we concluded that the spike was likely not the issue. Finally, we looked at the 7b 
accessory region to determine if variability in this region could be contributing to the 
infection defect. Indeed, after deep-sequencing we observed a large amount of 
variability in the 7b accessory protein region resulting in an approximately 35 nt stretch 
of “n” residues indicating the lack of consensus. In our ic genome, this region was 
deleted entirely. While the loss of the 7b protein is commonly observed with TC-adapted 
FCoV strains (Thiel et al., 2014) and likely not the direct cause of the defect, the ORF7 
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sequence directly precedes the 3’ UTR region, which is critical for efficient initiation of 
subgenomic mRNA. Thus, if the sequence of 7b is not correct in the consensus, it may 
impose changes to the loop-structure of the downstream 3’ UTR thereby affecting the 
efficiency of subgenomic mRNA transcription. To attempt to answer this question, we 
replaced the 7b sequence of our infectious clone with the published 7b sequence 
(EU186072.1). Again, this did not solve the problem and no infectious virions were 
produced (data not shown) allowing us to conclude that the 7b region is likely not the 
issue.   
Thus, I speculate that a possible defect preventing the production of infectious 
virions may be housed within the E and/or M structural proteins, which influence the 
formation of the virions but do not impact the production of sgRNAs or syncytia 
formation. The M protein is the main structural component of the coronavirus outer 
membrane and, along with the E protein, directs the formation of the mature virion (de 
Haan and Rottier, 2005). If one or both of these proteins have an incorrect sequence or 
are not produced at high enough levels, this may impact the formation of infectious 
virus. Future experiments are needed to detect production of E and M sgRNAs by RT-
PCR and to attempt to visualize the completely-formed, mature virions by electron 
microscopy. Ultimately, the genomes of several “Baker-Lab strain” FIPV populations 
need to be compared following multiple rounds of plaque purification to determine the 
most common genomic RNA sequences and eliminate variability arising from the viral 
quasispecies. In parallel, individual syncytia could be isolated after icFIPV 
electroporation and deep-sequenced to determine if these infected cells contain a more 
optimal genomic sequence. Together, these experiments are the most direct means of 
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rectifying the issues with the consensus sequence and may help produce a fully-
infectious virus by reverse genetics.   
Interestingly, a recent study by Ehmann and colleges offers a different 
perspective on the inability of our icFIPV to passage. This group constructed the first-
ever reverse genetics system for a field strain of serotype I FECV (Ehmann et al., 
2018). During production of this FECV, however, they also found that virions obtained 
directly from electroporated cells could not be passaged, even though they were 
observable by EM and produced sgRNAs. Interestingly, infectious virus could only be 
recovered following direct injection of concentrated electroporated cell-supernatant into 
live felines. I speculate that infection efficiency of the icFECV was enhanced in vivo due 
to the presence of high concentrations of host cell proteases or other infection-
enhancing cell surface molecules not present in tissue culture. Intriguingly, this same 
phenomenon was observed during generation of another coronavirus, porcine epidemic 
diarrhea virus (PEDV), by reverse genetics. Like the Ehmann study, icPEDV could only 
be recovered following in vivo injection, in this case of porcine intestine (Beall et al., 
2016). Thus, several groups have demonstrated that production of some CoV strains by 
reverse genetics might require additional factors present in whole animal tissue in order 
to replicate. The observations made by these two groups may, in part, explain the lack 
of passage in my FIPV Black system – although injection of live cats is outside the 
scope of our current research protocol. In future studies, Fcwf-4 CU IRN cells 
expressing additional feline proteases, like TMPRSS2, may provide a compromise to in 
vivo injection and may facilitate recovery of FIPV Black by reverse genetics.  
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The goal of the reverse genetics system described above was to have a platform 
on which to generate live-attenuated serotype I FIPV strains by non-functional mutation 
of interferon antagonists. Investigation of interferon antagonists encoded by 
alphacoronaviruses, including FCoVs, have been limited to studies involving group-
specific accessory proteins (Cruz et al., 2013, 2011; Dedeurwaerder et al., 2014). Early 
work using recombinant FCoV demonstrated that attenuation of serotype II FIPV (strain 
79-1146) could be achieved through single deletion of group-specific protein clusters 
3abc or 7ab, respectively (Haijema et al., 2004). Cats vaccinated with these mutant 
serotype II strains generated protective humoral immunity and survived subsequent 
challenge with homotypic strains. Although this group did not evaluate IFN production in 
these animals, both accessory regions 3abc and 7ab have since been shown to be 
involved in IFN antagonism (Dedeurwaerder, 2014; Dedeurwaerder et al., 2014, 2013). 
Further investigation of FCoV nonstructural proteins (e.g. PLP2 or EndoU), as has been 
described extensively in betacoronaviruses (Deng et al., 2019b, 2017; Frieman et al., 
2009; Kindler et al., 2017; Mielech et al., 2014; Niemeyer et al., 2013; Sun et al., 2012), 
may also result in the discovery of new FCoV IFN antagonists. It is tempting to 
speculate that combined deletion of individual accessory regions with mutation in 
nonstructural protein IFN antagonists (e.g. PLP2 or EndoU) may lead to a HII virus 
phenotype and, ultimately, stimulation of immune memory.  
Final Thoughts 
As this research program progresses, it is my hope that the tools described in this 
dissertation will aid in the generation, recovery and characterization of IFN antagonist-
deficient serotype I feline coronaviruses and stand as a successful means of creating 
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live-attenuated vaccine strains. To this end, we have recently begun a dual 
collaboration with the Tekes group at Justus-Liebig University (Giessen, Germany), and 
the Whittaker group at Cornell University (Ithaca, NY). Our combined research efforts 
aim to produce serotype I FIPV HII viruses using an established serotype I FIPV reverse 
genetics system in the Tekes lab (Tekes et al., 2008), to characterize these strains in 
our lab using the tools and techniques described in this dissertation and, finally, to 
evaluate attenuated strains as vaccine candidates in the Whittaker lab who have 
capacity to do experimental work on felines. Together, we hope to develop a successful 
means to prevent this highly pathogenic feline illness. 
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APPENDIX A 
ANTIBODIES USED TO DETECT FELINE CORONAVIRUS 
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 Anti-dsRNA TRITC   Anti-nsp15 FITC   Merge 
M FV 
180 
130 
100 
70 
55 
40 
35 
Nsp15 Protein 
(39 kDa) 
L 
N Protein 
(42 kDa) 
M FV 
180 
130 
100 
70 
55 
40 
35 
25 
L 
A. 
B. C. 
Antibody Detection of FIPV Black Nsp15, dsRNA and N Gene Production. A-B) 
Affinity-purified rabbit-anti-FIPV nsp15 (EndoU) polyclonal antibodies were generated 
by GenScript against a purified H227A catalytic mutant FIPV Black nsp15 protein 
immunogen. This antibody is effective at detecting FIPV Black nsp15 by 
immunofluorescence or by western blot. A) Immunofluorescence detection of FIPV 
Black nsp15 (FITC) and double-stranded (ds) RNA (TRITC) following 18 h infection 
(MOI = 0.1) in Fcwf-4 CU cells. Composite image shows localization of nsp15 to 
replication complexes. Images representative of two independent experiments. B-C) 
Western blot analysis of FIPV Black (B) nsp15 or (C) N protein from Fcwf-4 CU cell 
lysates following 16 h mock or FIPV Black infection (MOI = 0.1). The black arrows 
indicate the ~40 kDa nsp15 protein and the ~42 kDa N protein. The CCV2-2  
biotinylated monoclonal antibody (Bio-Rad) detects FIPV N protein and has been 
previously described (Poncelet et al., 2008).   
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ANTIBODY BLOCKING TARGET  (DILUTE in 1/10 BLOCKING) VOLUME VISUALIZE 
1o 5% FCS-PBS Nsp15 (1:300) dsRNA (1:500) 300 uL/well N Protein 
2o n/a 
Hoesch (1:500) 
AlexaFlor568 (1:1000) 
AlexaFlor488 (1:1000) 
300 uL/well 
Nuclear 
Anti-mouse 
Anti-rabbit 
Antibody Application for Immunofluorescence. 
ANTIBODY 1
o ANTIBODY 
(DILUTION) 
TIME & 
TEMPERATURE BLOCKING 
2o ANTIBODY 
(DILUTION) 
TIME & 
TEMPERATURE 
CCV2-2 
(biotin) 
monoclonal 
Mouse-α-FV N 
protein 
(1:2000)  Overnight at 4
oC 
with gentle 
rocking 
5% milk in 
TBST 
g-α-m-HRP 
(1:5000) 
1.5 hours at RT FV nsp15 
H227A 
polyclonal 
Rabbit-α-FV 
nsp15 
(1:10,000) 
d-α-r-HRP 
(1:2500) 
Antibody Application for Western Blot.  
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PRIMER INDICIES 
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ASSAY PRIMER NAME SEQUENCE (5' - 3') GC % Tm (ºC)  NOTES 
qPCR  
FIPV-N-qpcr-F ACCAGCCAATTCCTAGAACAG 47.6 62 FIPV Black  
N Gene FIPV-N-qpcr-R GAACGGGATTTTCTTTGCCTC 47.6 61.7 
f𝛽-Actin FWD CAACCGTGAGAAGATGACTCAGA 47.8 63.7 Fel 𝛽-Actin f𝛽-Actin REV CCCAGAGTCCATGACAATACCA 50 63.5 
F ISG54 FWD CCTGAGCTGCAGCCTTTCAGAACAG 56 68.6 Fel ISG54 F ISG54 REV CACGTGAAATGGCATTTAAGTTGCCGCAG 48.3 69.9 
F IFN Beta FWD CCAGAAGGAGGAAGCCATATT 47.6 61.6 Fel IFN-𝛽 
(Kessler et al., 
2009) F IFN Beta REV 
TCTCAACAGTGGTCTCATTCC 47.6 61.6 
Fel IFNaT FWD CACGTGACGAACCAGAAGAT 50 61.9 Fel IFN-α;  
all subtypes Fel IFNaT REV GATCAAGTCCCGTGCAGAAT 50 62.2 
F IFNa11 FWD CACGTGACGAACCAGAAGAT 50 61.9 Fel IFN-α11 F IFNa11 REV GATCAAGTCCCGTGCAGAAT 50 62.2 
Fel tmprss2 FWD TGTCTACAACAACCTGGTCAC 47.6 62 Fel TMPRSS2 Fel tmprss2 REV CCACCAGATGTGACTCTTCATAG 47.8 62 
Fel tmprss2 V5 FWD GTGTATGGAAATGTGACCGTATTTA 36 61.5 TMPRSS2 V5 
Tag Fel tmprss2 V5 REV TAGAATCGAGACCGAGGAGAG 52.4 61.8 
Fel ifnar mRNA  
Exon2 qPCR FWD CAGAATACTTCCTGGATTAGAC 40.9 57.8 Fel IFNαR  
exon 2 mRNA Fel ifnar mRNA  
Exon2 qPCR REV AGTACAAGATTCGTCTGACA 40 58.5 
RT-PCR 
FIPV Black Leader 
Fwd GTGCTAGATTTGTCTTCGGACACC  50 64.8 
L-containing 
sgRNA 
N Gene Rev CATCAGCATGAGGTCCTGTACCTGA  52 67.1 N gene sgRNA 
PCR TA  
Cloning 
 
Fel ifnar mRNA  
Exon1-4 RT FWD 
AAGATGCTTTGGAGCCAGAATA 40.9 62.3 Fel IFNaR2 exon1-4 
Fel ifnar mRNA  
Exon1-4 RT REV CCAGGAAGAAATCGCTGATACA 45.4 62.2 
Fel IFNaR2 
exon1-4 
F IFNaR2 Full FWD ATATCTATTTCCTTTCAGATGTG 30.4 56.6 Fel IFNaR2 full mRNA 
F IFNaR2 Full REV TCATCTCATTATATAACCATCCCTG 36 60.1 Fel IFNaR2 full mRNA 
PCR Myco Fwd 
GGCGAATGGGTGAGTAACACG 57.1 64.9 Mycoplasma 
Detection Myco Rev CGGATAACGCTTGCGACCTATG 54.5 64.8 
SEQ 
U6 – Fwd GGGCAGGAAGAGGGCCTA 66.7 65.1 Seq sgDNA; LentiCrisprV2 
F IFNaR2 Seq 1 
FWD GACAAGCTGATTCCAAACACAAAC  41.7 63.1 
 
F IFNaR2 Seq 2 
REV 
TTCATCTGAATCCTCTAGGT 40 57.6 
CMV Fwd CGCAAATGGGCGGTAGGCGTG 66.7 69.8 
fTMPR2 SEQ F1 GAATAGTTTCTATTCTAGCCAC  36.4 56.4 
fTMPR2 SEQ F2 GTTGCAACAGCAAGTATGTCTAC 43.5 61.9 
M13 Fwd GTAAAACGACGGCCAGT 52.9 59.4 
M13 Rev CACACAGGAAACAGCTATGACCAT 45.8 64.8 
Primer Index 1: PCR Primers. 
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PRIMER NAME SEQUENCE (5' - 3') GC % Tm (ºC)  NOTES 
Exon2 sg1F CACCGCGTGGTGTGTATCGGCCTCA 64 66.7  
Exon2 sg1R AAACTGAGGCCGATACACACCACGC 56 63.2 
Exon2 sg2F CACCGTGTGTATCGGCCTCATGGT 58.3 63 These primers 
generated the Fcwf-
4 CU IRN and AK-D 
2.2 cells 
Exon2 sg2R AAACACCATGAGGCCGATACACAC 50 59.5 
Exon3 sg1F CACCGCTTCCGGCTTATCTTGTCA 54.2 61.3  
Exon3 sg1R AAACTGACAAGATAAGCCGGAAGC 45.8 57.6 
Primer Index 2: IFNαR2 Single Guide DNA Primers. 
NAME SEQUENCE (5' - 3') GC % Tm (ºC)   NOTES 
B-Fwd CGTCTCAAGACACTGTGAATCAAAAGCGTGTGTCTG 47.2 64 
 B-Rev CGTCTCAGTAATCAGCCTCTCCCATTGAACCAG 51.5 63.8 
C-Fwd CGTCTCATTACCGCATGGCTTGTTATGCTCATTTGGGTAAGGC 48.8 67.2 
C-Rev CGTCTCAGATGCTACAAGTAATGTGGGGTCAGTGAC 50 61.8 
D-Fwd CGTCTCAGCATCAAGCCCTGCATTGTTAGATCAGCGCACTGTC 53.5 68.9 Incorrect "A" at 7 nt 
D-Rev GTAAGGCACCAATGTGGTATAGGCCTCCGC 56.7 65.2  
D-a mutF CAGAATTCGCCCTTCGTCTCGCATCAAGCCCTGCATTGTT 52.5 69 
Circular mutagenic 
primers to remove 
"A" introduced by 
D-Fwd on D clone 
in pCR-XL-TOPO D-a mutR AACAATGCAGGGCTTGATGCGAGACGAAGGGCGAATTCTG 52.5 69 
E-Fwd CGCTGCTGAAACCGTGAAAGCAAAGGAGGAATC 51.5 65.2 
 
New 
E-Rev CGTCTCCACAGTAGGGTAGGTAACCGCCTAGAATAG 52.8 64.5 
F-Fwd CCTACTGTGAGAGACGGCCCGAATTGTGGATG 56.2 65.6 
F-Rev CGTCTCAATGGCGTTTAACTCGTCAAGTACAGCG 50 64.2 
F-a mutF GAATTCGCCCTTCCTACTGTGGAGACGGCCCGAATTGTGG 57.5 69.6 Circular mutagenic 
primers to eliminate 
"A" introduced by 
F-Fwd on F clone 
in pCR-XL-TOPO 
F-a mutR CCACAATTCGGGCCGTCTCCACAGTAGGAAGGGCGAATTC 57.5 69.6 
FIPV-N-F  CTTGGACCGAGCTCGGATCCACCATGGCCACACAGGGACAACG 62.8 72.6 Gibson Assembly 
primers; insertion 
into pcDNA 3.1/V5-
His B 
FIPV-N-R  GCGGGCCCTCTAGACTCGAGTTAGTTCGTAACCTCATC 55.3 66.8 
Primer Index 3: Reverse Genetics Cloning Primers. 
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CLONE PRIMER NAME SEQUENCE (5' - 3') GC % Tm (ºC)  
A 
A1a CTTAAACCTGTTCTCCTTACCGAACC 46.2 57.2 
A1b GGACTGGTTTTAAGACTGCTTGTTG 44 56.4 
A1 GATGTAGTGGCATCACTCTGCAC 52.2 57.8 
A2 TCGCCGCTGCTGTTACTAAGG 57.1 59.6 
A3 GTGGCAACGTCACAACTGACGAC 56.5 60.7 
A4 GGTTGCCGATGGTGAAGACTTTG 52.2 58.6 
A5 CGATTACTGTGTGGATGGTATGG 47.8 58 
B 
B1R ACAGTTCCTTTGAGTTGCTCACCAT 44 58.8 
B1 GTGTTAGAGGTACGGTGGCTATC 52.2 56.7 
B2 GGCATGTAGTGGTAGTGTTCAAGC 50 57.9 
B3 GAATGTTCCGAAGGGTTTTACAGG 45.8 56.1 
B4 GAATCAGTGTCAGCAAAGAACGG 47.8 56.4 
B5 GAGCACGCTAGTGGTAACATGG 54.4 57.8 
C 
C1R CAGACTGTAGTGTTGAGTTAACACTGAC 42.9 57 
C1 GCACCACTTGGAATTAGGTAATGG 45.8 58.6 
C2 GCTACTGCACACAATTTTGTCTGGG 48 56.3 
C3 CCACTGTGCAGTCTAAACTTACAG 45.8 55.5 
C4 CCAGCTGCCTCAGCTACAAGAC 59.1 60 
C5 CTCTCAAATGGTGCCGGTAATGG 52.2 58.1 
C6 CGGTAATGTTGCACGTAAGGATC 47.8 56 
D 
D1R ACCTGGTTTCACTGTCTGGTAT 45.5 55.8 
D1 TGCCACACGTAACGCTACCGTAG 56.5 58.4 
D2 CATTGGTGCGTTTAAGGCCACC 54.5 59.3 
D3 GTCTATCACACCGTATGTGTGTAGC 48 57 
E 
E1R TACCAGGAGGACCTTGGATAGTT 47.8 56.8 
E1 GCACAGTTAATGCTTTGCCTGAAG 45.8 57.1 
E2 GCATTCTCTGTGTCATGTGTGACAG 48 58 
E3 GCGACTATTTCGACGGCTTGTC 54.5 58.3 
E4 GTACCCAGAGTTCTCAATTGTCTG 45.8 57.9 
E5 GCAAAGCGCAAACTTGGACTCAC 52.2 59.6 
E6 CCACCATTGGTGGTATGCATCTTC 50 58.2 
E7 CGACGCAGACTTCAGTGTTACAG 52.2 57.7 
F 
F1R CAATGACAGATTTTAACAGCCACATG 38.5 55.1 
F1 CTGTGCTGGTTATGCTAAGAACG 47.8 56 
F2 CAGGTTGTTCTATTGCGACTCAC 47.8 58.5 
F3 CAACTATGCCAAGGGCACAGCTG 56.5 60.8 
F3-1 GATGGTGCTATGATAACAACTATGCC 42.3 55.7 
F4 GGCAATACACATTGCCGTAGCTTG 50 58.8 
F5 CCATTGGTAACATCACACTAGCAC 45.8 55.9 
F6 CCTCAGATGAGTGATTTCGTGC 50 55.8 
G 
G1 REV GACGGTTGTTGTCACAATTCCATC 45.8 56.6 
G1 GATGGAATTGTGACAACAACCGTC 45.8 56.6 
G2 REV GCATGGCGTGCAGGTAGTACTAT 52.2 59 
G2 ATAGTACTACCTGCACGCCATGC 52.2 59 
G3 CTACCCTTAGATGGTACACCAACGG 52 59.3 
G4 GAGTCTTCTGGGTTGCAAGGGATG 54.2 59.7 
G5 ACCTTCTGAAGTGGCTAAGGATCAG 48 58.2 
G6 CAGATCTTAGCACTACCGCTTGG 52.2 57.3 
Primer Index 4: Reverse Genetics cDNA Segment Sequencing. 
 
 
 
 200 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C 
FIPV BLACK LABORATORY SEQUENCE 
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ORGANISM    Feline infectious peritonitis virus Baker Laboratory    
               Strain (Origin: AK-D Cells; Consensus) 
REFERENCE   Bases 1 to 29198 
  AUTHORS   Robert C. Mettelman, Susan C. Baker 
  TITLE     Generating biologic and genetic research tools to 
investigate serotype I feline coronaviruses 
  JOURNAL   Ph.D. Dissertation; Loyola University Chicago; 2019 
FEATURES    (1..29198) 
 
    [A_SEGMENT]   1..4810 
     5'UTR.          1..311 
     PP1AB.          312..20407            
     PP1A.           312..12407 
                      
    [B_SEGMENT]   4811..8875 
                      
    [C_SEGMENT]   8876..13485 
                      
    [D_SEGMENT]   13486..15825 
                      
    [E_SEGMNENT]  15826..20588 
     SPIKE.          20404..24792 
                      
    [F_SEGMENT]    20589..24861                      
     ORF3ABC.        24293..25819 
                      
    [G_SEGMENT]    24862..29198                    
     ENVELOPE.       25820..26068                   
     MEMBRANE.       26079..26870                   
     NUCLEOCAPSID.   26883..28016                 
     7A.             28021..28326                   
     7B.             28331..28905                  
     3'UTR           28906..29198 
 
ORIGIN 
        1 acttttaaag taaagtgagt gtagctgggc tataactctt catttacttt aactagcctt 
       61 gtgctagatt tgtcttcgga caccaactcg aactaaacga aatatttgtc tctctatgaa 
      121 gccatagaag acaagcgttg attatttcat ccagtttggc aatcactcct aggaacgggg 
      181 ttgagagaac gacgcgccag ggttccgtcc ctgtttggta agtcgtctag tattagctgc 
      241 ggcggttccg cccgtcgtag ttgggtagac cgggttccgt cctgtgatct ccatcgccgg 
      301 ccgccaggag aatgagttcc aaacaattta agatcctcgt taatgaggac caccaagtca 
      361 acgtgcctag ccttcctttc cgtgacgtgc tgcaggacat taagtactgc taccgcaacg 
      421 gttttgaggg ctatgttttc gtgcctgaat actgtcgtga cctagttgat tgcgatcgta 
      481 aggatcacta cgtcattggt gttctgggta acggaataag tgatcttaaa cctgttctcc 
      541 ttaccgaacc ttccgtcatg ttgcaaggct tcattgttag agccaattgc aatggcgttc 
      601 ttgaggactt tgaccttaaa atcgcccgta ctggaaatgg cgccatatat gtggaccaat 
      661 acatgtgtgg tgctgatgga aaacctgtca ttgatggcga atttagggat tacttcggtg 
      721 atgaggatgt tatcatttat gaaggggaag agtatcattg tgcttggtta actgtgcgcg 
      781 atgaaaaacc tttgtgtcaa caaactcttc tcacaattag ggaaatccaa tacaacctgg 
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      841 acatcccaca taaattgcca aattgtgcta ttagagaagt agcaccacca gtcaagaaga 
      901 actctaaggt tgttctttct gaggagtata gaaaactcta tgacatcttc ggctcaccat 
      961 ttatgggcaa tggagatagt cttaacaagt gttttgacag cctccacttc attgctgcta 
     1021 ctcttaagtg tccttgtggc gccgaaagta gtggtgttgg tgattggact ggttttaaga 
     1081 ctgcttgttg tggtcttctt ggcaaagtta aaggtgtcac attaggtgct gttaagccag 
     1141 gtgacgccgt tgtcactagc atgagtgctg gcaagggtgt aaaattcttt gctaatagtg 
     1201 tactccaata tgctggtgat gtggaaaatg tctctgtttg gaaagtgatt aaaactttca 
     1261 ctgttaatga gactgtctgc accactgatt ttgaaggcga attgaacgcc ttcattagac 
     1321 ctgagagtac ttcacttgtc tcatgctcca ttaagagagc tttcatcaca ggggaagttg 
     1381 atgatgcagt ccatgattgt attatcacgg gaaagttgga tcttagtact aacctgtttg 
     1441 gtagtgctag cctacttttt aagaaaacac cctggtttgt gcaaaagtgt ggtgcaattt 
     1501 ttgtcgatgc ttggaaagtt attgaggaac tgctttgttc tcttaaactt acatacaagc 
     1561 aaatctatga tgtagtggca tcactctgca cttccacctt tactattatg gactacaaac 
     1621 ctgtgtttgt ggtttcatct aatagcgtta agagtctcgt tgacaagtgt gtcaaaattc 
     1681 ttgtgaaagc ctttgacgtt ttcacacagg caattacaat tgcaggtgtg gaggctaaat 
     1741 gctttgtgct tggttctaaa tacttgcttt ttaacaacgc acttgtcaag cttgtcagtg 
     1801 ttaaaatact cggtaagaga cagaaaggtc ttgatagtgc attttttgcc actaatttga 
     1861 ttggtgccac tgttaatgtg acaccacaga ggaccgaggc tgctaacatt agcctgaata 
     1921 aggtagagga tgttgtcaca ccaggtgaag gtcatattgt catcgttggc gatatggctt 
     1981 tttacaagag tggagaatac tattttatga tggcaagccc tgattcagtc cttgttagta 
     2041 atgtttttaa agccgcgcga gtgccgtctt ataacattgt ttatgatgtg aatgatgaca 
     2101 ccaagagtaa gatggtggtc aaaattggaa catcatttga atttgatggt gacctcgccg 
     2161 ctgctgttac taaggttaat gacttacttg ttgagtttag acaaggaaag ctttatttca 
     2221 gagcacttaa ggatggtgaa aacatcttgg ttgaggcata ctttaagaaa tacaaaatgc 
     2281 cagtttgtct taaaaaccat gtcggtttat gggacattat aaaacgagat tctgacagga 
     2341 agggttttct tgacaccttc aatcatctta atgatttgga ggatgtcaag gatacaaaaa 
     2401 ttcaggccat taaaaacatt ctttgtcctg accttctgct tgaattggac tttggtgcaa 
     2461 tatggtatag atgtatgcca gcctgctctg atgtgtctat tttgggtaat gttaaaatca 
     2521 tgctaggtaa tggtgttaaa gtgatttgtg atggctgtca tagctttgct aaccgcctaa 
     2581 cagttaacta cagcaaactg tgtgatacag ctcgtaaaga cattgaaatt ggtggtatac 
     2641 cattttccac ctttaaaaca ccatctagca gcttcatcga catgaaagat gccatttact 
     2701 ctgtagttga atatggtgaa gcattctctt ttaagactgc aagtgtgcct gtaactaata 
     2761 gtggcaacgt cacaactgac gactggtcag atcccatttt gttagaaccc gcagattatg 
     2821 ttgaacctaa agacaatggc gatgtaattg ttattgctgg atacaccttt tacaaggatg 
     2881 aagatgatca tttttatcca tatggttctg gcatggttgt gcagaaaatg tataacaagt 
     2941 tgggtggtgg tgacaagtca gtttcgtttt cagacaatgt taatgttaga gagatagaat 
     3001 ctgttacacg tgtcaggcta gaatttgagt ttgacaatga ggttgtaaca caggtgcttg 
     3061 aaaaagtcat tggtaccaaa tataagttta taggtaccac ttgggaagag tttgaagatt 
     3121 ctatctccga gacacttgac aaaatttttg acacgcttgc tgaacagggt gtagaacttg 
     3181 aaggttattt tatttatgac acatgcggtg gatttgacat taataaccca gatggtgtta 
     3241 tgatttcaca gtacgatctt aacacagctg ctgatgacaa gagcgactct gatgcaagcg 
     3301 tggaagacac ctctttgatt tctgacaacg aagatgttga acaaattgaa gaggatagtg 
     3361 cttcaactgc tgatgccgaa tacgtttcac ccgtggttgc cgatggtgaa gactttgttg 
     3421 aacaagtttc tcttgtagag gaaagtagtg ttttaactcc tgttgcaaac cctgatgggc 
     3481 aactctcctc agtagaggaa aaaattgaag tttctgctaa gaatgatcca tgggctgctg 
     3541 ccgttgatga acaggaagct gaacaaccaa aaccttcctt ggcacccttt aggacaacaa 
     3601 atcttaatgg taaaatcatc cttaaacaac aagataataa ttgttggata aatgcttgct 
     3661 gttaccagct gcaagctttt gatttcttta aacacgattt gtgggatgat tttaagaaag 
     3721 gtgacgttat gcctttcgtg aatttctgtt atgcagctat aactttgaag caaggtgatt 
     3781 cgggggatgc agaatacctt ttggaaacga tgctcaatga ttatagtaca gctagagtca 
     3841 cacttagtgc taagtgcggc tgtggtgtta aagagatagt tttagaacga actgtgttta 
     3901 agctcacacc tcttaggaat gagtttaaat atggtgtctg tggtgactgt aagcaaatta 
     3961 acatgtgtga gtttgctagc gtggaaggtt caggtgtttt tgttcatgat agaattgaaa 
     4021 aacaaacgcc tatgtcacaa ttcattgtga cacctactat gcatgcagtt tacacaggtt 
     4081 caacacagag tggtcattat atgattgaag attgcattca cgattactgt gtggatggta 
     4141 tgggaattaa accttgtaaa cataagtttt acacatccac tttgtttctt aatgcaaatg 
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     4201 taatgacaac tgaatctaaa actatggttg aactacctgt gcccgtaaag gataagtgcg 
     4261 tagaagaatg tcaaagtcct aaagatctta tactaccctt ctataaagcg ggaaaagtct 
     4321 cattttacca aggagattta gatgttttga ttaactttct tgaacctgat gtcgttgtta 
     4381 acgctgctaa tggtgatctt aagcacatgg gtggcgttgc taaagctatt gatgtattca 
     4441 caggtggtaa gttaacaaaa cgctctaaag aatatcttaa atccaacaaa tcaatagctc 
     4501 ctggtaatgc tgtgcttttt gaaaacgtac ttgagcatct tagtgtgttg aatgctgtag 
     4561 gaccacgtaa tggtgacagt agagttgaag gtaaactctg taatgtctac aaagcaattg 
     4621 ccaggtgtga cggtaagata ctaacaccac ttatcagtgt tggtatcttt aaagtcaaac 
     4681 tggaagtttc attgcagtgt ctacttaaaa ctgtcacaga tagagattta aatgtctttg 
     4741 tttacactga ccaagagaga attaccatag aaaatttctt caatggtact atccctgtca 
     4801 aggtaacgga agacactgtg aatcaaaagc gtgtgtctgt agcacttgat aaaacttatg 
     4861 gtgagcaact caaaggaact gttattatta aagacaaaga tgtcaccaac cagttgccaa 
     4921 gtgtgtcaga tgtcggtgaa aaagttgtta aggcattgga tgttgattgg aatgcttact 
     4981 atggctttcc aaatgcagcg gcttttagcg ccagttccca tgatgcttat aaatttgatg 
     5041 ttgtaacaca taacaacttc attgttcata agcaaactga taataattgt tgggttaatg 
     5101 caatttgttt agcattacag agacttaaac ctacatggaa gtttcctggt gttaaaagtt 
     5161 tgtgggattc gtttctcacg cgtaaaactg ctggatttgt ccacatgcta tatcacattt 
     5221 caggcttaaa gaaaggacaa cctggtgatg ctgagctgac tttacataag cttggtgcgt 
     5281 tgatgtcaag tgatagtgta gtcactgtca cacatacaac tgcatgtgat aagtgtgcaa 
     5341 aagttgaaac tttcaccgga tctgtggtag cagcacccct tctggtctat ggcactgatg 
     5401 aaacttgtgt tcatggtgtg agtgtcaatg ttaaagtgac aagtgttaga ggtacggtgg 
     5461 ctatcacttc tttaataggt cctgtagtag gagatatcat tgatgcaact ggttatatct 
     5521 gttacactgg tttgaactca cgtggccatt acacctacta cgataatcgt aatggtttaa 
     5581 tggtcgatgc tgagaaagcc taccattttg agaaaagtct tttacaggtt acaacatcta 
     5641 ttgctagtaa ttttgttgct aacacaccta aagaggagat tgtgcctacg aatctagtta 
     5701 aagaaccaaa cacggctcgt gtttttattg aggttgaaga aagtcctaaa aatatagttc 
     5761 gtaaagaaaa attgctagct attgagagtg gtgtagatta tacaatcaca acactcggta 
     5821 aatatgctga cgtgttcttt atgactggtg ataaaattct taggtttctc cttgaagtct 
     5881 ttaaatattt attggttgtt tttatgtgtc ttagaaaatc taagatgcct aaagttaaag 
     5941 taaaaccacc acacgtattt agaaacttgg gtgctaaagt tagaacattg aattatgtaa 
     6001 gacaattgaa cagaccagcc ctgtggcgtt acataaaact agtactactt ttaatagcct 
     6061 tatatcattt cttctatttg tttgtcagca taccagtagt gcataaattg gcatgtagtg 
     6121 gtagtgttca agcatatagt aattctagtt ttgtaaagtc agaagtttgt ggtaattcta 
     6181 ttttgtgcaa ggcgtgtctg gcatcttatg atgaattggc agattttgat catctccagg 
     6241 tgtcatggga ttataagtca gacccactat ggaatagagt tatacaattg tcgtatttta 
     6301 tattcttggc tgtttttggt aacaattatg ttagatgcct tcttatgtat tttgtctccc 
     6361 agtaccttaa cctgtggtta tcctattttg gttatgttaa gtatagctgg tttttgcatg 
     6421 tcgtcaactt tgaatcaatc tctgttgaat ttgtaatcat agttgtggtt tttaaggcag 
     6481 ttctcgcact taaacacatt ttcctaccat gcaacaaccc gtcatgtaag acatgttcta 
     6541 aaattgctag gcagacgcgc attcctatac aggttgtggt taacggttca atgaagactg 
     6601 tgtatgtcca tgctaatggt actggtaaac tctgcaaaaa gcataacttt tattgtaaga 
     6661 attgtgactc ttatgggttt gatcacacat tcatttgtga tgagattgtg cgtgatctaa 
     6721 gtaatagcat taagcaaact gtttatgcta ctgataggtc ataccaggaa gtcacaaaag 
     6781 ttgaatgttc cgaagggttt tacaggttct atgttggtga agaattcacg gcatatgact 
     6841 atgatgtaaa acataagaag tatagtagtc aggaggtgct caagacaatg ttcctgcttg 
     6901 atgacttcat tgtttacagc ccatcagggt cttctctttc tagtgttaga aacgtctgtg 
     6961 tttatttttc acaattaatt ggtaggccta ttaagattgt taatagtgat ttgcttgaag 
     7021 atttgtctgt agactttaag ggagcacttt tcaatgccaa gaagaatgtt attaagaatt 
     7081 ccttcaatgt tgatgtctca gaatgtaaaa acctagagga ttgttataag gcgtgtaacc 
     7141 ttgatgttac attttccact tttgagatgg cagttaataa tgctcataga ttcggtgttt 
     7201 taattacaga ccgatctttt aataatttct ggccatcgaa gatcaagcct ggctcttctg 
     7261 gtgtttccgc tatggacatc ggtaagtgca tgacttttga tgctaagatt gtcaatgcaa 
     7321 aggttttaac acaacgtggt aaaagtgttg tatggttaag tcaagatttt tctgcactta 
     7381 gttctacagc acaaaaggtt ttagttaaaa catttgtaga ggagggtgtg aacttttcac 
     7441 ttacgtttaa cgctgtgggt tcagatgaag atttgccata tgagcgattc actgaatcag 
     7501 tgtcagcaaa gaacggttca ggtttctttg atgtactcaa acagcttaaa caacttttct 
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     7561 ggtgtctcgt ttttgtcatt actatttgtg gtctatgctc agtctacagt tttgcaactc 
     7621 agtcttatat tgattctgct gagggttatg attacatggt tattaagaac ggtgttgttc 
     7681 aatcatttga tgattctatt aactgtgtac ataatacata caaaggcttt acagtgtggt 
     7741 ttaaagctaa atatggtttt gtacctacat ttgacaagtc ctgccctatt gttttaggaa 
     7801 ctgtttttga tttaggtaat atgagaccaa tccctgatgt gccagcgtat gtagcacttg 
     7861 ttggtagatc cttagtgttc gcaatcaatg ctgcatttgg cgttactaat gtgtgctatg 
     7921 atcatacggg cgccgctgta agtaagaatt cttactttga cacttgtgtc ttcaattctg 
     7981 cgtgcactac tctaactggc attggtggta cagtcgttta ttgtgccaag caaggacttg 
     8041 ttgagggtgc taagctttat agtgaattgt tacctgatta ttattatgag cacgctagtg 
     8101 gtaacatggt aaaaatacca gccattatta ggggttttgg tctacggttt gtaaaaacac 
     8161 aggctacaac ctattgcaga gtgggagagt gtactgaaag tcaagctggt ttttgctttg 
     8221 gtggtgacaa ctggtttgtc tatgacaaag agtttggaga tggttacatt tgtggaagct 
     8281 ccacactggg attcttcaaa aatgtgttcg cactctttaa ttctaacatg tctgtagtag 
     8341 ccacatctgg tgcaatgttg gctaacatta ttattgcatg tctggctatt gcagtctgtt 
     8401 atggtgttct taagtttaaa aagatctttg gtgattgcac tctcctagta gttatgatta 
     8461 ttgttacatt ggttgttaat aatgtttcct actttgtaac ccaaaacaca ttctttatga 
     8521 ttgtttatgc tattatctat tatttcacaa caagaaaact cgcataccca ggtattttag 
     8581 atgcggggtt cattattgca tacttgaata tggctccgtg gtatgttctt gttttgtatg 
     8641 taatggtatt cctatatgat tccctaccat cactattcaa acttaaggta acaacaaacc 
     8701 tctttgaagg tgataaattt gtgggtagtt ttgaatcagc agctatgggt acttttgtta 
     8761 tagacatgcg ttcatatgaa acactcgtta attctacatc cttagataga attaagtcat 
     8821 atgctaacag ctttaacaag tacaagtact atactggttc aatgggagag gctgattacc 
     8881 gcatggcttg ttatgctcat ttgggtaagg cattaatgga ttattctgtt tcaagaaatg 
     8941 acatgcttta cacgccaccg acggtcagtg ttaactcaac actacagtct ggattgcgaa 
     9001 aaatggcaca gcctagcggt gtcgttgaac cctgtattgt aagggtagcc tacggtaata 
     9061 atgtccttaa tggcttgtgg ctaggagatg aagttatttg ccctagacat gtcattgcta 
     9121 gtgatacatc gcgtgtaatc aattacgaga atgagttgtc tagtgtgcgt ttacataact 
     9181 tttctatagc caaaaataat gtgtttttgg gtgttgtgtc tgccaaatat aagggtgtga 
     9241 atcttgtgct taaggtaaat caggtcaacc ccaacacacc ggaacataaa tttaaatctg 
     9301 tgaggccagg tgagagtttt aacattctcg cttgttatga aggctgtccc ggtagtgttt 
     9361 acggtgtgaa catgagaagt cagggtacta tcaaaggttc gtttattgct ggtacctgtg 
     9421 ggtcagtagg ttatgtatta gaaaatggaa cgctctattt tgtgtacatg caccacttgg 
     9481 aattaggtaa tggctctcat gtcggttcaa atcttgaagg ggagatgtat ggcggttatg 
     9541 aagatcaacc tagcatgcaa ttggagggta ctaatgtcat gtcatcagat aatgtagttg 
     9601 catttttgta tgctgctctt attaatggtg aaagatggtt tgttacaaac acatcaatga 
     9661 cgctagaatc ttacaattca tgggccaaaa ccaatagttt tacggaaatt gtgtcaactg 
     9721 acgcttttaa catgttggcc gcaaaaactg gttatagtgt tgaaaagttg cttgagtgta 
     9781 ttgttagact caataaaggt tttggaggac gtactatact gtcttatggc tccttgtgtg 
     9841 atgagttcac gcctattgaa gtcataaggc aaatgtatgg tgttaatctt cagggtggta 
     9901 aagtgaaatc gctattttac cctgtgatga ctgccattgc cattcttttt gcattttggt 
     9961 tagaattttt catgtataca cccttcacat ggattaaccc gacatttgtt agtattattc 
    10021 tagctattac aacacttgtg tctgtgttat tagttgctgg aattaagcac aaaatgttgt 
    10081 tctttatgtc ttttgtgatg cctagtgtcg ttttagctac tgcacacaat tttgtctggg 
    10141 acatgacctg ttatgaaagt ttacaggtcc ttgtggaaaa tgttaataca actttcttac 
    10201 cagttgatat gcaaggtgtc atgcttgcac ttttctgtgt tgctgtgttt gttacataca 
    10261 ctataagatt ttttacatgc aagcagtcgt ggttttcact atttgcaaca actgtttttg 
    10321 tgatgtttaa cattgttaag ttactaggta tgataggtga gccatggact gatgactaca 
    10381 ttttgttatg tcttgtaaac atgcttacta tgttgataag tcttactaca aaagattggt 
    10441 ttgttgtctt tgtatcatat aaatttgctt attacatagt tgtgtatgta atgcagccag 
    10501 cttttgttca agattttggt tttgttaagt gcataagcat aatttacatg gcttgcggtt 
    10561 acctattctg ttgttattac ggcatccttt actgggttaa caggtttaca tgcatgacgt 
    10621 gtggtgttta ccaatttacg gtttcaccag ctgagctcaa atacatgact gctaataatt 
    10681 tgtctgcacc taagactgca tatgatgcta tgattcttag ttttaagttg atgggcattg 
    10741 gtggagaacg taatatcaaa atatccactg tgcagtctaa acttacagag atgaagtgta 
    10801 cgaatgttgt cttgcttggc cttttgtcta aaatgcatgt tgaatctaat tcaaaagagt 
    10861 ggaattattg tgttggtttg cataatgaaa tcaatttgtg tgacgaccct gatgtcgtcc 
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    10921 ttgagaagtt acttgcgctc attgcattct ttttgtccaa gcataacaca tgtgacctta 
    10981 gtgatcttat tgagtcttat tttgagaata ccactatttt acagagtgtg gcatctgctt 
    11041 atgcagcctt gcctagctgg attgcctatg aacaagctcg tgcagatcta gaagaggcta 
    11101 agaagaatga tgttagtcct caacttttga aacagcttac aaaggcgtgt aatatcgcta 
    11161 agagtgagtt tgaacgggag gcttcagtgc aaaagaagct tgacaaaatg gcagagcagg 
    11221 ctgcagctgg tatgtacaaa gaggcacgcg ccgtggacag gaagtcgaaa atagtttcag 
    11281 ctatgcatag tttacttttt ggtatgctta agaaactcga catgtccagt gttaatacta 
    11341 ttattgaaca ggctcgtaac ggcgtgttac cattgagtat tataccagct gcctcagcta 
    11401 caagacttat tgttgtaaca cctaatcttg aagtgctttc caaggttaga caggaaaaca 
    11461 atgtgcacta tgcaggtgcc atttggtcaa ttgttgaagt taaggatgct aatggcgctc 
    11521 aagtccactt gaaggaagtt acagctgcca atgaattaaa cataacctgg cccttgagta 
    11581 taacttgtga gagaaccaca aagttgcaga ataatgaaat cttgccaggt aaacttaaag 
    11641 agaaagctgt taaagcatct gctacaattg atggtgatgc ttatggtagc ggtaaagcgc 
    11701 ttatggcttt tgaatgtggt aagagcttta tatatgcatt tatagcatca gacagcaacc 
    11761 ttaagtatgt taaatgggag agcaacaatg atgtaatacc tattgaactt gaggctccat 
    11821 tgcgctttta tgtagatggt gttaatggtc ctgaggttaa atacttgtat tttgtgaaaa 
    11881 gcttgaacac tcttagacgt ggtgctgttc ttggttatat cggtgcaaca gttcgtctgc 
    11941 aagctggtaa acctactgaa cacccatcta atagtggttt gctgacattg tgtgcttttg 
    12001 cacctgaccc tgctaaagca tatgttgatg ctgttaagcg aggtatgcag ccagttacca 
    12061 actgtgtaaa aatgctctca aatggtgccg gtaatggtat ggctatcaca aatggtgtcg 
    12121 aatctaacac acaacagtac tcttatggtg gcgcatctgt atgcatttat tgtagatgtc 
    12181 atgtagaaca tcctgcaatt gatggattgt gccgctttaa aggtaaattc gtccaagtac 
    12241 caaccgggac tcaggatcct attagattct gtattgaaaa tgaagtttgt gtcgtttgcg 
    12301 gttgctggct taataatggt tgtatgtgtg atcgtacttc tatgcaaggc accactattg 
    12361 atcagagtta tttaaacgag tgcggggttc tagtgcagct cgactagaac cctgtaatgg 
    12421 tactgatcca gaccatgtta gtagagcttt tgacatctac aataaagatg ttgcatgtat 
    12481 tggtaaattc cttaagacta attgttcccg ttttaggaat ttagacaaac atgatgccta 
    12541 ctacgtagtc aagcgttgta ctaagagcgt tatggaccat gagcaagtct gttataacga 
    12601 tcttaaagat tcaggtgcag ttgctgaaca tgacttcttt ttgtataagg aaggtcgatg 
    12661 tgaattcggt aatgttgcac gtaaggatct tacaaagtac acaatgatgg atctgtgtta 
    12721 tgctattagg aactttgatg aaaagaactg tgaagttctt aaagaaatac ttgtgacatt 
    12781 aggtgcctgc aatgaatctt tttttgaaaa caaggattgg tttgatccag tagaaaatga 
    12841 agctatacat gaagtgtacg caagacttgg acctatagta gccaacgcta tgcttaaatg 
    12901 tgtagcgttt tgtgatgcta ttgtggaaaa aggttacata ggtattataa ctcttgataa 
    12961 ccaagatctt aatggcaatt tttacgattt cggtgatttt gtaaaaacaa cgccaggttt 
    13021 tggatgtgct tgcgttacat catattattc ttatatgatg cccttaatgg gaatgacttc 
    13081 atgtttagag tccgaaaatt ttgtgaaaag tgatatctat ggtgctgatt ataagcagta 
    13141 tgatttattg gcttatgatt tcacggacca taaggaaaaa cttttccaaa aatactttaa 
    13201 gcactgggat cgaacatacc accctaattg ctctgattgt acaagtgatg agtgcattat 
    13261 tcattgtgcc aattttaaca cgttattttc aatgaccata cctaatactg catttggacc 
    13321 tcttgtacgt aaagtccaca tagatggtgt gccagttgtt gttactgctg gttaccattt 
    13381 caaacagttg ggtattgtgt ggaatcttga tgttaaatta gacactatga agttgactat 
    13441 gacagatctt cttaggtttg tcactgaccc cacattactt gtagcatcaa gccctgcatt 
    13501 gttagatcag cgcactgtct gtttctccat tgcagctttg agtactggtg ttacatacca 
    13561 gacagtgaaa ccaggtcact ttaacaagga tttctacgat tttataacag agcgtggatt 
    13621 ctttgaggag ggatctgagt tgacattgaa acacttcttc tttgcacagg gtggtgaagc 
    13681 tgctatgaca gattttaact attaccgtta caacagagtt actgttttag acatctgtca 
    13741 ggcgcaattt gtttataaaa ttgtgtgtaa gtactttgat tgttacgatg gtggttgcat 
    13801 caatgctaga gaggttgttg tcaccaacta tgataagagt gctggttacc cacttaataa 
    13861 atttggtaag gcaagacttt actatgagac tctatcatat gaggagcagg atgcgctttt 
    13921 tgctttaaca aagagaaatg ttctacccac aatgactcaa atgaatttga aatatgctat 
    13981 atctggcaag gctagagctc gtactgtggg aggagtgtcg cttctttcaa caatgacgac 
    14041 gagacagtac caccagaagc atttgaaatc tattgctgcc acacgtaacg ctaccgtagt 
    14101 tattggaaca actaaattct atggtggctg ggacaacatg ctaaagaatt tgatgcgtga 
    14161 cgtagataat ggttgtttga tgggatggga ctatccaaag tgcgaccgtg ctttgcctaa 
    14221 tatgatacga atggcttccg caatggtatt gggttctaag cacattgggt gttgtacaca 
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    14281 tagtgatagg ttctatcgac tctctaatga gttagctcaa gtactcacag aggttgtaca 
    14341 ttgtacaggt ggtttttata taaaacctgg tggtacaact agtggtgatg gtactacagc 
    14401 gtatgctaac tcggctttta acatctttca agctgtttct gctaatgtta acaagctttt 
    14461 aggagtagat tcaaacacct gtaacaatgt tacagttaag tccatacagc gcaagatata 
    14521 tgataattgt taccgtagta gcagtgtaga tgatgatttt gttgtcgaat actttagtta 
    14581 tttaagaaag cacttctcta tgatgatttt gtctgatgat ggtgttgttt gttacaataa 
    14641 agattatgct gatcttggtt atgtagcaga cattggtgcg tttaaggcca ccttatatta 
    14701 tcagaacaat gtatttatgt ctacagctaa gtgttgggta gaaccagatt ttaatgttgg 
    14761 accacatgaa ttctgttcgc aacacaccct acagattgta ggaccggatg gtgattacta 
    14821 cctaccttat ccagaccctt ctagaatttt gtcagcaggt gtttttgtgg atgatattgt 
    14881 taagacggac aacgtcatta tgcttgaacg ttatgtgtct ttagcaatag atgcatatcc 
    14941 actcacaaaa caccctaaac ctgcatatca aagagtattt tatgctcttc ttgattgggt 
    15001 taaacactta cagaagactc taaatgctgg tatacttgat tcattctctg tcactatgtt 
    15061 ggaggatggt caagataaat tctggagtga agagttctat gccagtcttt atgaaaagtc 
    15121 tactgtcttg caagctgctg gcatgtgtgt tgtttgtggt tcacaaactg tgttacgttg 
    15181 cggagactgt ttaaggagac cccttttgtg cactaagtgc gcctacgacc atgtcatggg 
    15241 tacaaaacat aaattcatta tgtctatcac accgtatgtg tgtagctata atggttgtac 
    15301 tgttaatgat gttacaaaat tgtttttggg cggtcttaac tattactgta ctgaacacaa 
    15361 accacaatta tcattcccgc tctgtgctaa tggtaatgtg tttggcctgt acaagagtag 
    15421 tgcaattggt tctgaagatg ttgatgattt caacaaactt gctgtttcag actggaccaa 
    15481 tgtagaggat tataaacttg ctaacaacgt taaagaatct ctgaaaattt tcgctgctga 
    15541 aaccgtgaaa gcaaaggagg aatctgttaa agctgaatat gcttatgcca tattaaagga 
    15601 ggttgtcgga cctaaggaag ttgtactcca atgggaatcc tctaagatta aacctccact 
    15661 taacagaaat tctgttttca cgtgttttca gataaacaag gatactaaaa ttcagttagg 
    15721 tgaatttgtg tttgagcagt cagaatatgg tagtgattct atttactata aaagtactag 
    15781 cactactaag ctggcaccgg gtatgatttt tgtgttgacg tctcataatg tgagtccact 
    15841 taaagctaac attttagtca accaagagaa gtacaatacc atatccaagc tctatcctac 
    15901 gtttaatata gcggaggcct ataccacatt ggtgccttac tatcaaatga tcggtaagca 
    15961 aaaatttaca actatccaag gtcctcctgg tagtggtaaa tcacattgtg ttataggttt 
    16021 gggtttgtat tatcctcaag ctagaattgt ctatacagca tgttcacatg cagctgtgga 
    16081 tgctttatgt gaaaaggctt ccaagaactt taatgttgat aaatgttcaa ggataatacc 
    16141 tcaaagaatc agagttgatt gctatatggg ttttaaacct aataatacca atgcacaata 
    16201 tttgttttgc acagttaatg ctttgcctga agctaactgt gacattgtgg ttgtggatga 
    16261 agtatcaatg tgtacaaact atgatctcag tgttataaat agtagactga gctacaaaca 
    16321 tattgtttat gtaggtgacc cacaacaact tccagcacct agaaccttga ttaacaaggg 
    16381 cacactccaa cctgaggact acaacgttgt gactcagagg atgtgtaaac taggacccga 
    16441 tgtatttttg cacaaatgtt acagatgccc agctgaaatt gttaaaacag tctctgctct 
    16501 tgtttacgag aataaatttt tacctgtcaa ccctgagtca aagcagtgct ttaagatgtt 
    16561 tgtaaaaggc caagttcaga ttgaatctaa ctcttctata aacaacaagc aactagaggt 
    16621 tgtcaaggca tttttagcac ataatccaaa atggcgtaaa gctgttttta tctcacccta 
    16681 caacagtcaa aattatgtgg cacgacgtct actaggtctg caaacgcaaa ccgtagactc 
    16741 tgcgcaaggt agtgagtatg attatgtcat ttacacacag acatctgata cacagcatgc 
    16801 tattaatgtc aacagattta atgttgccat tactagagca aaggttggca ttctctgtgt 
    16861 catgtgtgac agaaagatgt atgataatct tgatttctat gaactcaaag attcaaagat 
    16921 tggcttgcaa gcaaaacctg aaacttgtgg tttgttcaaa gattgttcaa agaatgacca 
    16981 gtacatacca ccagcatatg ctacgacata tatgagtttg tctgacaatt ttaagacaag 
    17041 tgatggctta gctgttaaca tcggtacaaa ggatgttaaa tatgccaatg ttatctcata 
    17101 tatggggttc aggtttgagg ccaatgtacc aggctaccac acattgtttt gcacacgaga 
    17161 ctttgctatg cgtaatgtta gagcatggct aggttttgat gtcgaaggtg cacatgtttg 
    17221 tggtgataat attggaacta atgtaccact acagctgggc ttttcaaatg gtgtggattt 
    17281 tgtagtacaa actgaaggat gtgttgttac tgaaaaaggt aatagcattg aaattgtaaa 
    17341 agcaagagca ccaccgggtg agcaattcgc gcacttgata ccactcatga ggagaggtca 
    17401 atcgtggcat attgttaggc gtcgtatagt gcagatggtt tgcgactatt tcgacggctt 
    17461 gtcagacatc ttaatttttg tgctatgggc tggtggtctt gagcttacaa ctatgcgata 
    17521 ctttgttaag attggaaaac cacaaaaatg tgagtgtggc aaaatggcaa cttgctatag 
    17581 tagctcacaa tgtgtctatg cttgttttaa acatgcatta ggatgtgatt acttgtacaa 
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    17641 tccttattgc attgacatcc aacaatgggg ctacacaggt tctctgagca tgaatcatca 
    17701 tgaagtttgt aacattcata gaaatgagca tgtggctagt ggtgatgcta tcatgactag 
    17761 gtgccttgct atatatgatt gttttgtcaa acgtgtagat tggtccattg tgtacccttt 
    17821 tattgaaaac gaagaaaaga tcaataaagc tggtcgcatt gtacaatcac atgtcatgag 
    17881 agctgctctt aaggttttca accctgctgc aattcatgat gttggtaatc caaaaggtat 
    17941 tcgttgtgct acgacaccca taccgtggtt ttgttatgat cgtgatccta ttaataacaa 
    18001 tgttagatgt ctggagtatg attacatggt acatggacaa atgaatggtt taatgttgtt 
    18061 ttggaattgt aacgtagaca tgtacccaga gttctcaatt gtctgtagat ttgatactcg 
    18121 aacccgctca aaactgtcat tagaaggttg taatggtggt gcattgtatg ttaataacca 
    18181 tgcatttcac acaccagctt acgatagaag agcatttgct aagcttaaac ctatgccatt 
    18241 cttttattac gatgagagtg actgtgagtt tattgatgga caacctaatt atgtaccact 
    18301 taagtccaat gtttgcataa caaaatgtaa cattggtggt gcagtctgca agaaacatgc 
    18361 tgcactctat agagcgtatg ttgaggacta caatgtgttt gtacaagctg gttttataat 
    18421 ttggtgtcct caaaattttg acacttacat gttgtggcaa ggttttgtta atggcaaagc 
    18481 actccagagc ttggaaaatg tagcttttaa tgttgttaaa aaaggtgcct tcgccgatct 
    18541 aaaaggtgac ttaccaacag cagttgttgc tgataagatc atggtgaggg atggacccat 
    18601 tgataagtgt attttcacaa ataaaactag tttgcctaca aatgtggcct ttgagctgta 
    18661 tgcaaagcgc aaacttggac tcacacctcc cttaacaata cttagaaatc taggtgttgt 
    18721 cgcaacacat aaatttgtgt tgtgggatta tgaagctgaa tgtcctttct caaactttac 
    18781 taagcaagtg tgtgcttaca ctgatcttga tggtgaagtt gtaacatgtt ttgataatag 
    18841 tattagtggt tcttttgaac gctttactac tacgaaagat gcagtgctta tttctaataa 
    18901 tgctgtgaaa ggacttagtg ccattaaatt acaatatggc tttttgaatg atttacctgt 
    18961 aagtactgta ggaaacaaac ctgtcacatg gtacatctat gtgcgcaaga acggtgagta 
    19021 cgttgaacag attgacagtt attatacaca gggacgtact tttgaaacct ttaaacctcg 
    19081 tagtacaatg gaagaagact ttcttagtat ggatactaca ctcttcatcc aaaagtatgg 
    19141 tcttgaggat tatggttttg aacacgttgt atttggagat gtttctaaaa ccaccattgg 
    19201 tggtatgcat cttcttatat cacaagtgcg ccttgcaaaa atgggtttgt tttctgttca 
    19261 agaatttatg aataattctg acagtacact gaaaagttgt tgtataacat atgctgatga 
    19321 tccatcttct aagaatgtgt gcacttatat ggacatactc ttagacgatt ttgtgactat 
    19381 cgttaagagc ttagatctta acgtcgtgtc gaaagttgtg gatgttattg tagattgtaa 
    19441 ggcatggaga tggatgttgt ggtgtgagaa ttcacaaatt aaaaccttct atccacaact 
    19501 ccaatcttcc gagtggaatc caggctatag catgcctaca ctttacaaaa tacagcgtat 
    19561 gtgtctcgaa cggtgtaatc tctacaatta tggtgcacaa gtgaagttac ctgacggcat 
    19621 tactactaat gtcgttaagt atacccagtt gtgtcaatac ctcaatacca ctacactatg 
    19681 tgttccacat aaaatgcgtg ttctgcattt aggagcagca ggtgctaatg gtgttgctcc 
    19741 tggtactacc gtattaaaaa gatggttgcc agatgatgcc atattggttg ataatgatat 
    19801 gagagattat gtttccgacg cagacttcag tgttacaggt gattgtacta acctctatat 
    19861 tgaggataaa tttgatttgc ttatatctga tttgtatgat ggttccacca agtctataga 
    19921 tggtgaaaac acgtctaagg atggcttctt tacatacatt aatggtttca ttaatgagaa 
    19981 gctagcgctt ggaggttctg ttgccatcaa aatcactgaa tttagttgga ataaaagttt 
    20041 atatgaatta attcaaagat ttgagtattg gactgtgttt tgtacaagtg ttaacacctc 
    20101 gtcatcagaa ggtttcctga taggtattaa ctacttggga ccatactgtg acaaggctat 
    20161 agtggatggt aatataatgc atgccaatta tatattttgg agaaactcca caatcatggc 
    20221 attgtcacat aactcagttc tagatactcc caaatttaag tgtcgttgta acaacgcact 
    20281 tgttgttaat ttaaaagaaa gagaattaaa tgacatggtt attggattgc taaggaaggg 
    20341 taaaatactc attagaaata atggtaagtt actaaacttt ggtaatcact ttgttaacac 
    20401 accatgatag tgttaatatt tgcactcctt agcactgcta ggtctgaaga tgcccctcat 
    20461 ggtgttacct tacctcaatt taacacttcc tctaacaatc agaagttcga acttaatttc 
    20521 tataacttct tacaaacttg ggacatacct ccaaatacag aaactattct aggcggttac 
    20581 ctaccctact gtggagacgg cccgaattgt ggatggtata attttgttta tagtcaaaat 
    20641 gtgggacaaa atggtaggca ctcttacata aacactaaaa atctgaacat accgaatgtt 
    20701 cacggtgttt actttgatgt aagagaacat aattctgatg gtttgtggga tgcgcgtgat 
    20761 agagttggct tattgatagc catttatggc acctcgtatt acagtctact aatggtttta 
    20821 caagacaaag tagaggaaaa ccaaccccat gtggctgtta aaatctgtca ttggaaaccg 
    20881 ggtaatataa gttcatacca tcaatttagt gtcaatctag aagatggtgg tcaatgtgtg 
    20941 tttaaccaga gattttcatt agacaccgtg ttgactgcta atgattttta tggtttccag 
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    21001 tggactgaca catatgtcga catctactta ggaggcacta ttactaaggt gtgggttaac 
    21061 aatgactgga gttctgttga agccagtatt tcataccact ggaaccagat taattatgga 
    21121 tattacatac aatttgtcaa cagaaccacg tattatacat acaataatac tggcggttca 
    21181 aattatacgc acttgcagtt agcagagtgc catagtgaat actgtgctgg ttatgctaag 
    21241 aacgtttttg tgccaattga tggcaaaata ccagaaagct tctcttttag taactggttt 
    21301 ctgttatcag ataaatccac tttagtgcaa ggacgtgttc ttagtaggca gcctgtcctt 
    21361 gtacaatgtc ttaggcctgt accaacctgg tccaataata gtgctgtggt atttttcagt 
    21421 aatgacctct attgccctgg tgttacggct gaagttttga ggttcaactt gaactttagt 
    21481 gacagtgatg tttacacaga tttaactaat gatgaccagt tttatttcac atttgaggac 
    21541 aatacaaccg catccatagc ttgttatagc agtgctaatg ttactgattt ccagcctgca 
    21601 aatagtagcg tatctcacat cccacttggc aaaactattt gttttgccaa tttctcacac 
    21661 tctgttgtga gcagacaagt cttgggtata ctgccaccaa ctgtacgaga gtttgcattt 
    21721 ggtagggatg gttccgtttt tgttaatggt tacaaatatt ttagtttacc acctatcaag 
    21781 agtgtcaact tctctattag ttcagttgag cagtatggtt tttggaccat agcttacacc 
    21841 aattatacag atgtaatggt ggatgttaat ggcactggta tcagcaggtt gttctattgc 
    21901 gactcacccc tcaatagaat caagtgtcaa caattgaagc atgtattacc agacgggttt 
    21961 tattctgcta gcatgcttgt taaaaatgat ttacctaaaa catttgtaac tatgccacag 
    22021 ttctacaatt ggatgcatat tacgctacat gtcgtgttga acgacactgc gaagaaagaa 
    22081 gatatcatct tagctgaggc ccctgaacta gcctcacttg ctgatgtaca ctttgaaatt 
    22141 ctccaagcta acggaagtgt cgtgaatgtt accagtctat gtgtccaagc aaaacagttg 
    22201 gctctatttt ataaatatac tagtttacaa ggtttgtata cttattctaa tttggtggag 
    22261 ttacaaaatt atgactgccc tttctcacca cagcatttta ataattattt gcagtttgaa 
    22321 actttgtgtt ttgatgtgaa cccagctgtg gcaggttgta agtggtcgtt agttcatgat 
    22381 gttaattggc gtacacagtt cgccaccatc actgtctctt ataaagatgg tgctatgata 
    22441 acaactatgc caagggcaca gctgggtttc aaagacatct ctaatttagt aaaagatgaa 
    22501 tgcactgatt ataacatata tggatttcaa ggcacaggca ttattagaag caccacctca 
    22561 cgattagtgg ctggccttta ctacacatct attagtggtg atcttctcgc ctttaaaaat 
    22621 agtactactg gggagatttt cactgtagtg ccatgtgatt taacagtgct agcagctgtg 
    22681 attaacgatg agatagtggg agctataaca tctgttaatc aaactgatct gtttgagttt 
    22741 gtcaatcaca cacaagcgaa gagatcacgt aggccgacat cacactcggt aaccacctac 
    22801 aatatgccgc aattttatta cataacatgg tggaacaatg acacctcgac taattgtacg 
    22861 tctgtcatca cttattcctc ctttgctatt tgtaatactg gtgaaatcaa atatgttaat 
    22921 gtcactcatg ttgaaactgt ggacgatata ggtgttatca aacctatttc aacaggtaac 
    22981 atattaatac ctaaaaactt tactgttgca gtgcaagccg aatacattca gattcaagtc 
    23041 aaacctgttg ttgtggattg tgccaagtat gtttgtaatg gcaatacaca ttgccgtagc 
    23101 ttgttaacac aatacacctc agcttgtcaa acaatcgaaa atgcccttaa ccttggtgca 
    23161 cgtcttgaat cgttgatgct taatgatatg atcacagtat cagatcgtag tctggagctt 
    23221 gcaaccattg aaaagtttaa cgccacagcc acaggtggtg taaaactggg tggtctatac 
    23281 tttgatggtc tgagcagtct attaccaccc aaaataggtg cgaggtctgc tgttgaggat 
    23341 ctattgttca ataaggtggt aaccagcggt cttggcactg tggatgatga ttacaaaaag 
    23401 tgctctgctg gtacagatgt agctgatcta gtgtgtgccc aatattacaa tggcattatg 
    23461 gttttacccg gcattgtaga tggtaataag atggccatgt acacagcatc tttaattgga 
    23521 ggtatggctt tgggctctat cacatccgct gtagctgtcc ctttttccat gcaggtgcag 
    23581 gctaggctta attatgttgc attacaaact gatgtcctac aggaaaatca gaaaatactt 
    23641 gctaatgcct ttaacaatgc cattggtaac atcacactag cacttggaaa agtttctaat 
    23701 gctgttacaa ccatttcaga cggctttaac accatggcct cagccttgac taagatccag 
    23761 agtgtggtta atcaacaggg tgaagcgctg agtcaactta ccagtcagtt acagaaaaac 
    23821 ttccaggcta ttagcagttc tattgctgaa atttataata gattggaaaa ggcggaagct 
    23881 gatgcccaag ttgaccgcct cattactggc aggttggcgg cacttaatgc ttacgtgtct 
    23941 caaactttaa ctcagtatgc tgaagtcaag gctagtaggc aactggcaat ggaaaaagta 
    24001 aatgagtgcg tgaaatcaca gtcggatagg tatggtttct gtggcaatgg aacacaccta 
    24061 ttctcacttg tcaattctgc acctgatggt ttgcttttct ttcacacagt tttgcttcct 
    24121 acagaatggg aagaagtgac ggcatggtca ggaatatgtg ttaatcatat ttatgcatat 
    24181 gtgttgaaag atttcgatca ttccattttt agctataaca acacgtatat ggtaactcct 
    24241 cgtaacatgt ttcaacctag aaaacctcag atgagtgatt tcgtgcaaat tacgagttgt 
    24301 gaagtgactt ttttgaacac tacatatacg atgtttcaga atattgtggt tgattatatt 
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    24361 gacattaaca agactatcgc tgatatgctt gaacaatatt attctaatta cacaacgcct 
    24421 gaattagaat tacagctcga aatctttaat cagacaaagt taaacctcac tgcagaaata 
    24481 gaccaattag aacaaagagc tgacaatctt actaccattg cacatgagct acagcagtat 
    24541 atcgacaatc ttaataagac tctcgttgac ctcgaatggc tcaacaggat tgaaacttat 
    24601 gtaaaatggc cttggtatgt gtggctacta attggcttag taatagtctt ctgcatacca 
    24661 ttgttactgt tttgctgttt gagtactggt tgctgtggat gctttggttg tcttggaagt 
    24721 tgttgccact ctctttgtag tagaagacaa tttgaaaatt atgaacctat tgaaaaggtt 
    24781 cacattcact aactaaacga tttatggaca ccgtcaagtc tattggcatc tctgtggacg 
    24841 ctgtacttga cgagttaaac gccattgcat ttgctgtaac acttaaggtg ttatttaatt 
    24901 ctggtagatt acttgtgtgt ataggttttg gtgatacttt tgaggaggct gaacaaaaag 
    24961 cttatgccaa acttcatctg gatattgaag agtcgcctaa tcatacgact tcttaatatc 
    25021 acagtttacg atttttgtgc taaaaactgg tataaattac cttttgcagt cagattgcgt 
    25081 atcataaata atacaaaacc taaaacagca agtactataa aacgtagaag aagggttgtt 
    25141 aacactctaa gttttatagt cactaatcaa catgtgattg ttaataacac accacatgtc 
    25201 gattctatag tacaacaaca acatgttgtt aatgctagta ttaaaagttt tcatttagag 
    25261 ttcagcaccg ctgttctctt tgttttattt ttagctttgt accgtagtac aaactttaaa 
    25321 gtatgtgtcg gcgtcttaat gtttaagata gtttcaatga cacttatagg acctatgctt 
    25381 atagcatttg gttactatat agatggaatt gtgacaacaa ccgtcttagc tttaagattc 
    25441 gtttacttag catacttttg gtatgttaat agtaaatttg aattcatctt atacaataca 
    25501 acgacactaa tgtttgtaca tgacagagct gcaccgttta tgagaagttc tcacggccct 
    25561 atttatgtca cattatatgg aggcataaat tacatgttcg tgaatgatct tacgtagcat 
    25621 tttgtagacc ctatgcttgt aggcatagct atacgtggcc tagtccgtgc tgacctaaca 
    25681 gttgttagag cagttgaact tctcaatggt gtttttattt atatattttc acaggaggcc 
    25741 gtcgtaggag tttacaatgc agccttttct caggcggtta taaacgaaat tgatttgaaa 
    25801 gaagaagaag agcgtgtcta tgatgtttcc tagggcattt accatcatag atgaccatgg 
    25861 catggttatg agcgtcttct tctggctcct gttgataatt atattgatat tgttttcaat 
    25921 agcattgcta aatgttatta aactatgcat ggtatgttgc aatttgggta agactattat 
    25981 agtactacct gcacgccatg catatgatgc ctataagacc tttatgcaaa ttaaggccta 
    26041 taattccgat gaagcatttt tggtttgaac taaacaaaat gaagtacgtt ttgttaatac 
    26101 tcgcgtgcat aattgcatgc gtttttggtg aacgttattg tgccatgaag gatgactcgt 
    26161 ctaatacttg catcaatggc actaattcct catgtcaaac ctgctttgaa cgtggtgatc 
    26221 ttatttggca tcttgctaac tggaacttca gctggtctgt aatattgatt gtttttataa 
    26281 cagtgttaca atatggcaga ccacaattta gctggctcgt ttatggcatt aaaatgctga 
    26341 tcatgtggct attatggcct attgttctag cgcttacgat ttttaatgca tactctgagt 
    26401 accaagtttc cagatatgta atgttcggct ttagtattgc aggtgcagtt gtaacgtttg 
    26461 cactttggat gatgtatttt gtgagatcta ttcagctata tagaaggacc aaatcatggt 
    26521 ggtcttttaa tcctgagacc aacgcaattc tttgtgttaa tgcattgggt agaagttatg 
    26581 ttctaccctt agatggtaca ccaacgggtg tcactctcac tttgctttcg ggaaacctat 
    26641 atgctgaagg ttttaaaatg gctggtggtc ttaccatcga gcatttgcct aaatacgtca 
    26701 tgattgctac acctagtaga accatcgttt acacattggt tggaaaacaa ttaaaagcaa 
    26761 ctactgccac gggatgggct tactatgtaa aatctaaagc tggtgattac tcaacagaag 
    26821 cacgtactga taatttgagt gaacatgaaa aattattaca tatggtgtaa ctaaacttct 
    26881 aaatggccac acagggacaa cgcgtcaact ggggagatga accttccaaa agacgtgatc 
    26941 ggtctaactc tcgtggtcgg aagaatggta atatacctct ttcatacttc aaccccatta 
    27001 ctcttgagtc aggatcaaaa ttttggaaca tatgtccgag agattttgtt cccaagggaa 
    27061 taggtaataa ggatcaacaa attggttatt ggaacagaca ggtgcgttac cgcattgtca 
    27121 gaggccagcg taaggaactt cctgagagat ggttcttcta tttctcaggt acaggacctc 
    27181 atgctgatgc taaattcaaa gataaaattg atggagtctt ctgggttgca agggatggag 
    27241 ccatgaataa gccaacaaca cttggcactc gtggaaccaa caatgaatcc aaacctttaa 
    27301 aatttgatgg taagatacca ccacaattcc agcttgaagt gaaccgttct aggaacaatt 
    27361 caaggtctgg ttcccagcct agatctgttt caagaagcag gtctcaatct agaggaagac 
    27421 aacagtccaa taaccagaat actaatgttg aggatacaat tgtagccgtg cttagtaaat 
    27481 taggtgttac tgacaagcaa aggtcacgtt ctaaatctgg agaacgtaat caatctaagc 
    27541 ccagggatac aacacctaag aatgccaaca aacacacctg gaagaaaact gcaggtaagg 
    27601 gtgatgtgac aaatttctat ggtgctagaa gtagttcagc caactttggt gatagtgatc 
    27661 tcgttgccaa tggtaacgct gccaaatgct accctcagat agctgaatgt gttccatcag 
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    27721 cgtctagcat actctttggc agtcaatggt ctgctgaaga agctggtgat caagtgaaag 
    27781 tcacactcac tcacacctat tacctgccaa aagatgatgc caaaaccagc caattcctag 
    27841 aacagattga tgcttataag caaccttctg aagtggctaa ggatcagagg caaagaaaat 
    27901 cccgttctaa gtctgctgat aagaagcctg aggagttgtc tgtgactctt gtagaggcat 
    27961 acacagatgt gtttgatgac acacaggttg agatgattga tgaggttacg aactaaacgc 
    28021 atgctcgttt tcctacatgc tgtacttgta acagctttaa tcttactact aattggtaga 
    28081 atccaattac tagaaaggtt gttactcagt catctgctta atctcacaac agtcagtaat 
    28141 gttttaggtg tgcctgacag tagtctgcgt gtaaattgtt tgcaactttt gaaaccagac 
    28201 tgtcttgatt ttaacatcct acataaagtt ttagcagaaa tcagattact agtagtagta 
    28261 ctgcgagtga tctttctagt tcttctagga ttttcctgct atacattgtt aggtgcatta 
    28321 ttttaacatc atgattgttg tactccttgt gtgtgttttc ttggctaatg gaattaaagc 
    28381 taccactgtg caacctgaca cccatgaaca tccagtcctc acctgggact tgttgcaaca 
    28441 ttggacacac tctttacatt acaacgtatc agatcttagc actaccgctt ggatctcgtg 
    28501 ttgagtgtga gagtattgaa tgatcatatt gatttttatt tcgatctttc caaccctttc 
    28561 tattcctttg tagatgaatt ttatattgta ggtgaaggaa atcaaagaat taatctcaga 
    28621 ttagttggtg ctgtgccaaa acaaaagaga ttaaatgttg gttgccatac atcatttgct 
    28681 gtagaccttc catttggcac tcagatatac catgacaggg attttcaaca ccctgctagt 
    28741 ggtagacatc tagagtgtac tcacagagtc tactttgtga agtactgccc atacaacttg 
    28801 catggttatt gctttaatga gaagctgaag gtttatgacc tgaagcaact cagaagcaag 
    28861 aaggtcttcg acaaactcaa ccaacatcgt aaaactgagt tataaggcaa cccgatgttt 
    28921 aaaactggtt tttccgagga attactggtc atcgcgctgt ctactcttgt acagaatggt 
    28981 aagcacgtgt aataggaggt acaagcaacc ctattgcata ttaggaagtt tagatttgat 
    29041 ttggcaatgc tagatttagt aatttagaga agtttaaaga tccgctatga cgagccaaca 
    29101 atggaagagc taacgtctgg atctagtgat tgtttaaaat gtaaaattgt ttgaaaattt 
    29161 tccttttgat agtgataaca acaaaaaaaa aaaaaaaa 
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Feline IFNaR Full     1 MLWSQNTSWIRPHDLYPVVYLVVCIGLMVGVVSAWPDLSDESCTLKVTFRSFRLILSWELKNHSIAPTHYTLWYTVMSKP 
CU IFNaR Consensus    1 MLWSQNTSWIRPHDLYPVVY----IGLMVGVVSAWPDLSDESCTLKVTFRSFRLILSWELKNHSIAPTHYTLWYTVMSKP 
IRN IFNaR             1 MLWSQNTSWIRPHDLYPVVY----IGL-IG--MA* 
  
Feline IFNaR Full    81 DDMKIVEHCSNITASFCDLTDVWEVLPETYIPRVDGFRGNTMLVSCISDFFLATHVSLEPPDFDIVGSTNHINVIVKFPP 
CU IFNaR Consensus   77 DDMKIVEHCSNITASFCDLTDVWEVLPETYIPRVDGFRGNTMLVSCISDFFLATHVSLEPPDFDIVGSTNHINVIVKFPP 
IRN IFNaR              
  
Feline IFNaR Full   161 VIPKILNGELLQYYLPLVIEEQSGKIVKKHHPKLNGNIIGNVTYVIDKLIPNTNYCVSVYFKSKDMGAINRSPVKCTFLQ 
CU IFNaR Consensus  157 VIPKILNGELLQYYLPLVIEEQSGKIVKKHHPKLNGNIIGNVTYVIDKLIPNTNYCVSVYFKSKDMGAINRSPVKCTFLQ 
IRN IFNaR              
  
Feline IFNaR Full   241 PGQETESSESAKIGGIIIMFLIAAVFISTILILKRVGYICLRNDFPKVLNFNNLSSWVFLERPPLETVAFVEVIHVNRKK 
CU IFNaR Consensus  237 PGQETESSESAKIGGIIIMFLIAAVFISTILILKRVGYICLRNDFPKVLNFNNLSSWVFLERPPLETVAFVEVIHVNRKK 
IRN IFNaR              
  
Feline IFNaR Full   321 KVWDYNYDDESDSNDEVAPPISGGGYTMHGLTGRLLGPASASSATLEDCNQPDAEEPDQSEPEADTEPLMAAWPSPGQSE 
CU IFNaR Consensus  317 KVWDYNYDDESDSNDEVAPPISGGGYTMHGLTGRLLGPASASSATLEDCNQPDAEEPDQSEPEADTEPLMAAWPSPGQSE 
IRN IFNaR              
  
Feline IFNaR Full   401 CCKSGAYKERGRLPQDPVSEDDDSASEGSGDKITFNVNLNSVFVRIPDDDSEVPPTSPPFLEETANLEDSDETEISFLAA 
CU IFNaR Consensus  397 CCKSGAYKERGRLPQDPVSEDDDSASEESGDKITFNVNLNSVFVRIPDDDSEVPPTSPPFLEETANLEDSDETEISFLAA 
IRN IFNaR              
  
Feline IFNaR Full   481 SGEGTQPPFASPSAECPWPEDALSDKSDSSESDADIRDGYIMR 
CU IFNaR Consensus  477 SGEGTQPPFASPSAECPWPEDALSDKSDSSESDADIRDGYIMR 
IRN IFNaR              
 
Feline IFNαR2 Amino Acid Sequence Alignment. Amino acid sequence alignment 
[CLUSTAL W (1.7)] of feline interferon alpha receptor domain 2 (IFNαR2) comparing a 
published sequence (GenBank #NM_001278859.1) with the sequences determined 
from Fcwf-4 CU and Fcwf-4 CU IRN cells.   
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